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Abstract 
Dissecting the mechanisms of antiplasmodial resistance in Plasmodium falciparum 
James Muriungi Murithi 
The strides made in malaria eradication efforts have been aided by a combination of 
vector control and chemoprevention. However, Plasmodium resistance to first-line 
artemisinin-based combination therapies (ACTs), and mosquito resistance to 
insecticides threatens the progress made. Innovative vector control measures, 
vaccines and antimalarial drugs with novel modes of action are key to disease 
eradication.  
High-throughput phenotypic screening of chemical libraries tested directly against all the 
stages of the Plasmodium lifecycle have been the mainstay of antimalarial drug discovery 
efforts and have identified compounds that are effective in parasite clearance. 
Unfortunately, these screens are handicapped in that they are unable to specify the actual 
compound targets in the Plasmodium parasites. As a result, many candidate hits have 
had to be re-screened in specific assays to determine putative mechanisms of 
antiplasmodial action. Predictably, this has elevated target-specific screens as the next 
frontier in drug discovery. This shift has been aided by a number of factors, including the 
cost effectiveness of these screens and the fact that target-specific screens do not always 
require specialized access to parasites. When combined with knowledge of the target’s 
structure, where known, target-specific screens have the potential to give lead 
compounds with impeccable potency and selectivity. This approach has already been 
successfully put to use, for example, in the identification of P. falciparum p-type ATPase 
4 (PfATP4) and P. falciparum phosphatidylinositol 4-kinase (PfPI(4)K) inhibitors. The new 
challenge now is the identification of quality targets. Here, computational biology ‘omics’ 
tools have proved to be an invaluable resource. Two of the more commonly used of these 
tools are genomics and metabolomics. 
In-vitro evolution assays followed by whole genome sequencing analysis is a popular 
genomics approach and helps unveil novel target genes. Plasmodium parasites are 
exposed to sublethal doses of a compound until an upward shift in the half-maximal 
inhibitory concentration (IC50), indicative of resistant parasites, is observed in the culture. 
Sequenced genomes of the resistant parasite clones are compared to those of the drug-
naive parent to reveal genetic changes, which include both single nucleotide 
polymorphisms (SNPs) and copy number variations (CNVs). While these genomic 
changes may point to genes encoding actual drug targets, they often reveal mediators of 
drug resistance or tolerance. Follow-up assays like SNP validation through gene editing 
are necessary to distinguish between actual targets, resistance mechanisms and random 
background mutations. Expectedly, genetic changes in uncharacterized Plasmodium 
genes are the bottle-necks in the identification of novel druggable targets. Even so, this 
genomics method has uncovered or reconfirmed novel antimalarial drug targets, including 
the proteasome, aminophospholipid-transporting P-type ATPase (PfAT-Pase2) and 
cGMP-dependent protein kinase (PfPKG).    
Metabolomic profiling and transcriptomics narrows down a compound’s mode of action. 
Here, parasites are treated with a compound of interest and the metabolites extracted 
and analyzed using liquid chromatography-mass spectrometry (LC-MS). The 
metabolomics fingerprint or metaprint is then compared to that of untreated parasites. 
While this method rarely provides the exact drug target, it narrows down the compound’s 
mode of action, which is valuable for target validation and characterization. The issue of 
non-specific or non-viable phenotype metabolite signals is easily filtered out by treating 
parasites with various drug concentrations and/or over a period of time. Other areas that 
limit the effectiveness of this tool and need to be addressed include the analysis of 
compounds that do not act through metabolic pathway disruption and potential host 
contamination. Nonetheless, metabolomics are a key player in drug discovery and have 
successfully been used in the study of pantothenamides (MMV689258) where the 
observed CoA analog buildup helped identify their mechanism of action in sequestering 
coenzyme A to block acetyl-CoA anabolism.  
Presented herein is a culmination of my graduate research in antimalarial drug discovery. 
Three independent projects are presented, and they all have either been published or are 
currently under reviewership. Chapter 1 is an introduction to malaria, a disease that has 
and continues to claim hundreds of thousands of lives, especially in my home continent 
of Africa. In chapter 2, I detail the experimental procedures used to generate the data 
presented in chapters 3-5. Chapter 3  is a detailed susceptibility profiling and metabolomic 
fingerprinting of Plasmodium falciparum asexual blood stages (ABS) to clinical and 
experimental antimalarials. This work, published in Cell Chemical Biology (2020), 
presents to the malaria research community a medium-throughput assay that can be 
utilized to identify new antimalarial lead compounds and novel assayable targets. Chapter 
4 presents a detailed analysis of a novel ATP-binding cassette (ABC) transporter that 
confers pleiotropic antimalarial drug resistance in P. falciparum and that was first 
identified through in vitro evolution assays. This work is currently under review in Cell 
Chemical Biology. Chapter 5 presents work on an promising new preclinical compound, 
MMV688533, that provides single-dose cure and that was discovered using an innovative 
orthology-based screen by the Sanofi drug discovery team. In this chapter, I also present 
in detail the assays performed to better understand this compound’s mode of 
antiplasmodial action and the potential drivers of parasite resistance. This work has been 
accepted, pending minor textual revisions, in Science Translational Medicine. Finally in 
chapter 6, I summarize chapters 3-5 and share future follow-up work needed to 
strengthen and contextualize some of the experimental findings presented here. 
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Chapter 1. Introduction 
1.1. Malaria – overview 
 1.1.1. History  
Malaria is estimated to have claimed between 150 million and 300 million lives, thereby 
accounting for  2 to 5 percent of all deaths in the 20th century alone 1. The significant 
progress made in treatment and prevention efforts has saved countless more lives and 
has reduced the number of deaths from well over a million per year in the early 2000s to 
just over 400,000 currently. Still, with the rise and spread of insecticide and antimalarial 
resistance, and with around half of the global population still living in areas where malaria 
is transmitted, these gains can be easily lost 2. By virtue of climate, ecology and poverty, 
sub-Saharan Africa accounted for over 94% of the world’s 229 million malaria cases and 
409,000 deaths in 2019. 
 
The history of this killer disease dates back to ancient times and is a testament to 
malaria’s long reign. The deadly periodic fevers described in clay tablets with cuneiform 
script from Mesopotamia are suggestive of malaria and recently, malaria antigen has 
been detected in Egyptian remains dating from 3200 and 1304 BC 3. However, there is 
perhaps not a better testament to this disease’s ancient hold on society than the evidence 
of the strong selection pressure its exerted on the evolution of the human genome 4,5.  
Some hemoglobin-encoding alleles that in homozygous genotypes cause severe blood 
disorders like thalassemia and sickle cell disease should make these diseases rare as 
affected individuals are unlikely to survive and reproduce. Yet these alleles have been 
positively selected in populations living in malaria-endemic areas because heterozygous 
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genotypes confer strong protection against malaria 6-8. Indeed, up to 38% of the 
population in some parts of Africa carry a single copy of the hemoglobin S gene that is 
associated with sickle cell disease 9. 
 
Genetic polymorphisms that affect red blood cell proteins or cause enzyme deficiencies 
have also been shown to confer protection against severe disease. For example, genetic 
inheritance of mutations in a gene that encodes the red blood cell Duffy antigen, a key 
receptor mediating invasion of the most widespread malaria-causing Plasmodium 
species, Plasmodium vivax, is credited with reducing its spread in Africa, although 
findings of P. vivax infections in Duffy antigen-negative individuals complicate these 
interpretations 10-12. The deficiency of glucose-6-phosphate dehydrogenase (G6PD) in 
hemizygous males also provides protection against severe malaria, albeit through an 
unknown mechanism. Unfortunately, this deficiency also limits the use of primaquine, the 
only antimalarial currently approved for the treatment of  latent (liver-stage) P. vivax 
malaria as it leads to hemolytic anemia in these patients 4,5,13. 
 
Some proposed mechanisms of malaria protection conferred by these varied genetic 
disorders include: increased phagocytosis and elimination of the infected mutant 
erythrocytes by the spleen, which reduces parasitemia; reduced parasite invasion of 
mutant red blood cells; reduced intracellular growth rates; and reduced cytoadherence of 
infected mutant red blood cells 7. These mechanisms, in combination or isolation, 
increase protection against severe malaria, which is the main driver of the aforementioned 
human evolution over what must have been a long period of time.  
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1.1.2. Discovery of the malaria parasite 
Plasmodium, the single-celled protozoan that cause malaria, was discovered in 1880 by 
Charles Louis Alphonse Laveran (1845-1922), a French army doctor who while serving 
in Algeria observed through a microscope crescent-shaped bodies with a small dot of 
pigment (hemozoin) in the blood of a febrile soldier. Through his extensive examination 
of another ~200 patients, Laveran recorded both asexual (schizont and trophozoite) and 
sexual (female and male gametocyte) stages in human blood 14. Laveran was awarded 
the Nobel Prize in 1907 in recognition for this work.  
 
1.1.3. Discovery of malaria’s mosquito stages 
Malaria parasite mosquito stages were discovered by Surgeon-Major Ronald Ross (1857-
1932) of the British Indian Medical Service in 1897 when he observed a clear, circular 
body containing hemozoin in a dapple-winged Anopheles mosquito that had previously 
fed on an infected patient 15. Using the avian parasite P. relictum, Ross observed that 
Plasmodium sporozoites matured in salivary glands leading directly to the proboscis of a 
mosquito that had previously fed on infected birds 16. Ross’ work was in part guided by 
his collaboration with his mentor, Sir Patrick Manson, who in 1877 had demonstrated that 
the filarial worms responsible for lymphatic filariasis were transmitted by mosquitoes 17. 
Later, a group of Italian malariologists (Giovanni Battista Grassi, Amico Bignami, 
Giuseppe Bastianelli, Angelo Celli, Camillo Golgi and Ettore Marchiafava) conclusively 
demonstrated that the human malaria parasites passed through the same developmental 
stages in the mosquito as the avian parasites observed by Ross 17. Like Laveran, Ross 
was also awarded a Nobel Prize in 1902 for his work on malaria. 
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1.1.4. Discovery of malaria parasite in human tissue 
The question of where sporozoites inoculated by mosquitoes undergo early development 
in the human host was not solved until 1948 when Henry Shortt, Cyril Garnham and 
colleagues at the Ross Institute of the London School of Hygiene and Tropical Medicine 
showed that a phase of division in the liver preceded the development of parasites in the 
blood 18. Using the primate malaria species, P. cynomolgi, Shortt and Garnham infected 
rhesus monkeys and were able to detect malaria parasites in their livers a week later 19. 
Shortly afterwards Shortt, Garnham and their co-workers found exoerythrocytic forms of 
P. vivax in human volunteers  and subsequently in volunteers infected with P. falciparum 
in 1949  and P. ovale in 1954 20-22. 
 
1.2. Epidemiology: Malaria vector, the parasite and the disease 
1.2.1. Malaria vector  
There are about 40 species of the mosquito genus Anopheles that exclusively transmit 
human malaria parasites 23. Although malaria-competent Anopheles spp. are abundantly 
distributed all over the globe, their malaria transmission efficacy differs considerably and 
is highly dependent on the species of the vector. Anopheles gambiae, for example, is the 
dominant and most efficient vector in sub-Saharan Africa 23.  
 
Mosquitoes, just like the Plasmodium parasites, have been notoriously hard to eradicate. 
While the large-scale insecticide campaigns that used dichlorodiphenyltrichloroethane 
(DDT) for malaria vector control during the first WHO Global Malaria Eradication Program 
(1955–1969) were effective, their use had to be stopped in part because mosquitoes 
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started developing resistance to the insecticide. Since then, more selective vector control 
approaches, including the use of insecticide-treated bed nets and indoor residual 
spraying, have had their share of success in malaria elimination but mosquito resistance 
to insecticides continues to be a growing concern. This is best exemplified by the fact that 
73 of 82 malaria endemic countries have detected resistance to at least one of the four 
insecticide classes in use since 2010 2.  
 
1.2.2. The parasite 
Plasmodium spp. are single-celled eukaryotic organisms that belong to the phylum 
Apicomplexa, fittingly named for the apical complex that is involved in host cell invasion 
24-26. There are five human-infective Plasmodium spp.; P. falciparum, P. vivax, P. 
malariae, P. ovale and P. knowlesi. Of these, P. falciparum causes the bulk of malaria-
associated morbidity and mortality, especially in sub-Saharan Africa. Outside of this 
region, P. vivax is now often the predominant cause of severe malaria and is found in 
both tropical and temperate areas including Southeast Asia, Ethiopia and South America 
27. P. ovale exists as two sympatric species P.o. curtisi and P.o. wallikeri and is especially 
prevalent in West Africa 28. P. malariae can be found worldwide but is also especially 
prevalent in West Africa and causes the mildest infections. P. knowlesi was initially 
considered as a parasite of non-human primates but is now known to cause malaria in 





1.2.3. The disease  
An estimated 229 million cases of malaria occurred in 2019 and sub-Saharan Africa bore 
the brunt of the burden with 94% of the cases 2. Other affected regions like South-East 
Asia, Eastern Mediterranean region and Western Pacific and the Americas recorded 3%, 
2% and <1% of the cases, respectively 2. Children <5 years of age and fetuses of infected 
pregnant women experience the most morbidity and mortality in areas of continuous 
malaria transmission. Children >6 months of age are particularly susceptible because 
they have lost their maternal antibodies but have yet to develop their own protective 
immunity. Adults and children >5 years of age who live in regions of continuous 
P. falciparum transmission develop a partial protective immunity owing to repeated 
exposure to the parasite. It is therefore unsurprising that of the total 409,000 malaria 
deaths recorded in 2019, 67% were of children <5 years old 2. Expectant women are more 
susceptible to Plasmodium spp. infection because the placenta itself selects for the 
emergence of parasites that express receptors that recognize the placental vasculature;  
these receptors are antigens to which pregnant women have not yet become partially 
immune 31. This vulnerability not only increases the risk of miscarriage but parasitemia in 
the placenta can have adverse effects on the fetus as well 32-34. For disease 
manifestations and diagnosis please refer to section 1.5.1. 
 
Although an estimated 1.5 billion malaria cases and 7.6 million malaria deaths have been 
averted in the period 2000-2019, the rate of malaria case incidence has stalled since 2015 
2. This plateauing can be attributed to the emergence of insecticide-resistant mosquitoes, 
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lack of access to effective medicines and difficulties with achieving higher levels of 
mosquito control 35. 
 
1.3. Plasmodium life cycle 
1.3.1. Liver stage 
Fewer than 100 Plasmodium sporozoites are injected into the dermis during a blood 
meal by the female Anopheles mosquito and can take up to 3 h to exit 36,37. About 70% 
of these sporozoites reach and penetrate a blood vessel to enter the blood-stream by 
gliding motility 38. While the mechanisms of sporozoite exit from the dermis are not clearly 
understood, mutant sporozoites lacking Trap-like protein display normal gliding motility 
but cannot enter the circulation, suggesting an essential role played by this protein in 
sporozoite entry into the circulating system 37. The sporozoites that manage to enter the 
blood stream quickly (within 2 minutes in mice experiments 39) access the liver through 
cell traversal. Here, they cross the sinusoidal barrier by forming a transient vacuole 
(parasitophorous vacuole) using key proteins like the circumsporozoite which bind the 
sporozoites to liver heparan sulphate proteoglycans 40. DNA replication begins on day 2 
post liver invasion and the parasites remain within the parasitophorous vacuole 
membrane through late liver stage development, a process that takes up to 10 days. This 
development culminates in the release of up to 30,000 merozoites per intracellular 
parasite into the bloodstream through budding of parasite-filled vesicles called 
merosomes 41,42. Some parasite species, such as P. vivax and P. ovale, can also enter a 
period of latency by forming a non-replicating hypnozoite instead of a schizont. These 
hypnozoites not only enable long-term survival of the parasite but can also lead to 
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relapses 43. Sporozoite multiplication in the liver is not associated with pathology but 
presents a very appealing target stage for vaccine and prophylaxis because there would 
be no pathology or disease if the infection was blocked at this stage. 
 
1.3.2. Asexual blood stage 
About 105-106 Plasmodium parasites gain entry into the red blood cell through specific 
ligand-receptor interactions mediated by proteins on the surface of the parasite that 
interact with receptors on the host erythrocyte or reticulocyte 10,41. P. falciparum can 
invade and replicate in erythrocytes and reticulocytes but P. vivax and other species 
predominantly invade reticulocytes, which are less abundant 44. Merozoite red blood cell 
invasion is a fast and dynamic process and occurs within minutes 45. The initial interaction 
between the merozoites and the erythrocytes results in parasite actomyosin motor-driven 
deformation of the host cell 45. Little is understood about the molecular details of this 
period but the merozoite surface protein 1 is a major, albeit non-essential, 
glycophosphatidyl-inositol-associated protein on the merozoite surface that forms a 
platform for proteins that bind erythrocytes 46-48. Some of these proteins, like the 
erythrocyte binding-like proteins (EBLs) and P. falciparum reticulocyte-binding protein 
homologs (PfRhs), bind specific receptors, like glycophorin A, B and C, on the red blood 
cell and lay the groundwork for critical signaling activation of subsequent invasion steps 
leading to, among others, the deformation of the erythrocyte 49. Active invasion is 
preceded by the binding of the PfRhs proteins to the essential host receptor basigin, which 
causes the  merozoites to reorientate so that their apical end touches the erythrocyte 
membrane 50. An irreversible attachment of merozoites to erythrocytes is then initiated 
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through the formation of a tight junction between parasite-derived proteins, primarily the 
apical membrane antigen 1 (AMA1) and the rhoptry neck protein RON complex 51. Lipid-
rich rhoptry contents form the parasitophorous vacuole membrane as the merozoite is 
propelled into the erythrocyte using force generated by the parasite actomyosin motor 52. 
Fusion of membranes at the posterior end of the merozoite to seal the parasite within the 
parasitophorous vacuole and erythrocyte concludes the active invasion phase 37. This is 
then followed by echinocytosis, a process that causes the erythrocyte to shrink and form 
spiky protrusions, presumably because of the Ca2+ influx into the host cell resulting from 
the PfRhs-basigin complex 45. The parasites, now inside the red blood cell, export 
hundreds of proteins into the host cell cytoplasm and cell surface. These modulate the 
acquisition of nutrients, cell adhesion and sequestration in tissues and pathogenesis 
37,53,54. 48 h after the establishment of erythrocyte infection, multiple rounds of cell division 
(schizogony) produces as many as 32 merozoites per parasite that egress when fully 
developed. These are released to access new host cells for invasion by exploding from 
the host erythrocytes. Merozoite egress is a tightly regulated process involving multiple 
protein kinases, including the plant-like calcium-dependent protein kinase PfCDPK5 and 
the cGMP-dependent protein kinase (PfPKG) 55-57.  
 
During symptomatic disease the parasites may replicate exponentially up to 1012 
parasites per patient 41. This rapid growth requires sustained pools of amino acids, which 
the parasites, being auxotrophic for all of the amino acids they need, acquire from 
hemoglobin (Hb) digestion in the digestive vacuole (DV). This process supplies all amino 
acids except isoleucine, which is obtained from other host cell components 58. Nutrient 
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uptake by the parasite is coupled to the detrimental accumulation of Na+; however, the 
parasite expresses an essential plasma membrane Na+ export pump (the cation ATPase 
P. falciparum p-type ATPase 4 (PfATP4)) that can maintain Na+ homeostasis 54,59,60. The 
remodeling of the plasma membrane to generate daughter merozoites in the late schizont 
stage requires P. falciparum phosphatidylinositol 4-kinase (PfPI(4)K) 61. 
 
1.3.3. Gametocyte development and mosquito stages 
During schizogony, a proportion of parasites undergo a developmental switch initiating 
commitment to sexual development to form male and female gametocytes. The molecular 
events around this switch are still unclear but the timing of transition occurs at some point 
in the previous schizogony cycle where daughter merozoites from a single schizont-
infected cell are committed to develop into either gametocytes or asexual schizonts 37. 
Environmental stimuli, such as high parasitemia (starvation) and exposure to drugs, are 
associated with increased conversion to gametocyte production. Epigenetic regulation is 
critical for control of sexual differentiation, and the transcription factor AP2-G has been 
shown to be a master regulator of gametocytogenesis 62. While the earliest phases of 
gametocyte development are morphologically indistinguishable from asexual 
development, P. falciparum gametocytes undergo five morphologically discernible stages 
over the course of 9-12 days 63. Stage I gametocytes are morphologically 
indistinguishable from asexual trophozoites. In stage II, the parasite develops a pointed 
end. In stage III, one end of the parasite gets elongated while the other flattens and curves 
so that the parasite resembles the letter ‘D’. In stage IV, the parasite elongates some and 
resembles the shape of a banana with pointed ends. Stage V gametocytes exhibit a 
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characteristic crescent shape with rounded ends 64. Only mature stage V gametocyte 
stages are present in the blood circulation. All the other stages avoid splenic clearance 
by sequestering in host tissues, particularly the bone marrow, and emerge into the 
peripheral circulation only after maturation and for an unknown time until uptake by a 
feeding mosquito 65. Because Plasmodium parasite transmission from humans to 
mosquitoes is an essential part of their developmental process, it provides a great 
intervention point for vaccines or transmission-blocking antimalarials. 
 
Ingestion of gametocytes by a mosquito during a blood meal activates the formation of 
gametes (gametogenesis) in the mosquito midgut lumen. This is thought to be initiated 
by several factors, including the drop of temperature by ~5 °C, the presence of the 
mosquito-derived molecule xanthurenic acid and the increase of extracellular pH from 7.2 
to about 8 66-68. Each male gametocyte undergo three rounds of mitotic division, forming 
eight haploid microgametes. These exflagellate and fuse with the female macrogametes, 
each of which is developed from a single female gametocyte, to form a diploid zygote. 
Multiple rounds of DNA replication and meiosis follow and result in the formation of a 
tetraploid ookinete. Through cell traversal, ookinetes cross the midgut epithelium to form 
oocysts that are lodged under the basal lamina. Finally, oocysts go through multiple 
rounds of cell division and generate thousands of haploid sporozoites which upon 
maturation migrate to the mosquito salivary glands and when injected into a new host 





1.4. Plasmodium biology: Asexual blood-stage parasite genomics and 
hemoglobin catabolism   
1.4.1. Genome 
The P. falciparum genome was sequenced in 2002 and revealed a 23.3 megabase 
nuclear genome partitioned among 14 chromosomes 25,71. About 5700 open reading 
frames have been identified to date. Interestingly, nearly 60% of these lack homologues 
in other organisms in spite of being conserved in other Plasmodium species 71,72. The 
nuclear genome is also notoriously AT-rich; >80% throughout the genome and up to 93% 
in the introns and intergenic regions 71.  
 
Transcriptomic analyses of the asexual and the sexual stages revealed that functionally 
related genes were transcribed at the same stage of the asexual lifecycle and a subset 
of genes were specifically expressed in the sexual stages, suggesting a mechanism of 
coordinated gene regulation and “just-in-time” transcription 73-78. However, because the 
nuclear genome is so AT-rich, 5′-untranslated regions of many genes have not yet been 
accurately defined. It is therefore no wonder that mechanisms of transcriptional regulation 
in Plasmodium are not well understood. Nonetheless, this reduced complexity of the 
noncoding sequences contains large numbers of poly As and Ts that generate an 
abundance of variable microsatellite loci that have been explored as genetic markers 79,80. 
Besides the nuclear genome, P. falciparum also contains a small mitochondrial genome 
of ~6 kilobases containing three protein-coding genes 81,82 and a significantly larger 




But for mitochondria and apicoplast genomes that might be polycistronic 73,74, P. 
falciparum chromosomal gene transcription is thought to be predominantly monocistronic 
and stage-specific 85. That said, bicistronic transcription for merozoite apical erythrocyte-
binding ligand has been reported 86. There is no evidence for transposable elements in 
any Plasmodium species genome 87. In addition, P. falciparum genome also lacks non-
homologous end joining DNA double-strand break machinery. Nucleotide excision and 
homologous recombination repair pathways are largely intact however and make gene-
editing experiments possible, so long as a template is provided 88. 
 
1.4.2. Hemoglobin catabolism and hemozoin production 
Hb degradation in intraerythrocytic malaria parasites is an intense process that occurs in 
the acidic environment of the DV. The process starts with the invagination of the 
parasitophorous membrane to form Hb-containing vesicles known as cytostomes that 
then fuse with the DV membrane and release their cargo therein 89. In the lumen of the 
DV, which is acidified by proton pumps on the membrane to a pH ~5.5, Hb is broken down 
first to oligopeptides and further into dipeptides and amino acids by various aspartic 
proteases and cysteine proteinases 90,91. Hb digestion is most active at the late ring and 
trophozoite stages 92. 
 
In DV’s acidic environment, heme iron, which is a major waste product of Hb digestion, is 
readily oxidized from its Fe2+ (ferrous) form to the Fe3+ (ferric) form, generating reactive 
oxygen species (ROS), which, if not detoxified, can cause widespread damage to DNA, 
lipids, proteins and other biomolecules. Plasmodium parasites deal with this toxic waste 
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by converting it into an insoluble and chemically inert hemozoin crystals, the malaria 
pigment 93. While much still remains to be known about the exact mechanism of heme 
detoxification, histidine-rich proteins 2 and 3 and neutral lipids have been implicated in 
hemozoin formation 94-96. An essential heme detoxification protein has also been 
identified in Plasmodium that has been shown to enhance heme-to-hemozoin 
transformation 97. Although most of the heme, ~95%, ends in hemozoin crystals, some of 
it leaves the DV and is degraded by glutathione in the parasite cytosol 98. Altogether, the 
parasite digests about 70% of the host cell cytosol  but only 16% of the derived amino 
acids are used for protein synthesis 99,100. The major purpose of Hb digestion, as 
determined by model stimulations, is to reduce the colloid-osmotic pressure within the 
host erythrocyte that is essential to preserve the osmotic stability of the infected cell during 
the parasite’s asexual life cycle 101-103. 
 
1.5. Malarial disease 
1.5.1. Clinical presentation and diagnosis 
Fever and parasite presence are two key aspects considered by WHO for disease 
pathology 104. Parasites can be detected using light microscopic examination of a blood 
smear or by a rapid diagnostic test. The patient’s risk of exposure, including their travel 
history or if they live in an endemic region can also assist in making the diagnosis. The 
symptoms of malaria are diverse but belong to one of these four groups: Asymptomatic 
malaria, uncomplicated malaria, severe (complicated) malaria and placental malaria. As 
the name suggests, patients with asymptomatic malaria have circulating parasites but 
lack clinical presentation of an infection. For uncomplicated malaria, the symptoms 
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include fever, moderate-to-severe shaking chills, profuse sweating, headache, nausea, 
vomiting, diarrhea and anemia. Both asymptomatic and uncomplicated malaria can be 
caused by any of the Plasmodium spp. Severe or complicated malaria is usually caused 
by P. falciparum, although recently there’s been increased observation of cases 
associated with the other species 105. Complications include severe anemia and end-
organ damage, including coma from cerebral malaria, pulmonary complications like 
oedema and hyperpnea, and hypoglycemia or acute kidney injury. Severe malaria is often 
associated with high parasitemias and is associated with increased mortality 104. In 
placental malaria, parasites are present in the placenta and this more often than not leads 
to poor outcomes for the fetus and possibly for the mother as was mentioned earlier. 
 
Patient immune systems are responsible for maintaining malaria parasites at equilibrium 
levels in asymptomatic carriers, many of who are children and adults in hyperendemic 
areas. Even so, parasitemia in these carriers can be extremely high, up to 50,000 
parasites per µl in one study of asymptomatic pregnant women 106. Besides the risks 
associated with malaria infections, asymptomatic individuals are a reservoir for infecting 
mosquitoes, which leads to continued transmission. Parasitemias in  patients with 
uncomplicated malaria typically range anywhere from 1,000-50,000 parasites per µl of 
blood although non-immune adults and young children with parasite numbers <1,000 
have been known to present with symptoms 107. Higher parasite numbers are associated 
with severe malaria but this varies with region. As an example, parasitemias averaged 
~4,000 parasites per µl in South America, ~10,000 parasites per µl in Asia and ~20,000 
parasites per µl in Africa in pooled analysis of patient data from 61 studies designed to 
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measure the efficacy of ACTs 107. The complications of severe malaria are mostly caused 
by the blocking of blood vessels by infected red blood cells and the severity and 
symptoms depend on what organ is affected and to what extent. These complications 
also differ by age. While lung and kidney disease are unusual in children for example, 
they are quite common in non-immune adults 104.  
 
The limit of parasite detection by thick-smear microscopy is about 50 per µl 108. WHO-
validated rapid diagnostic tests (RDTs) that are based on the immunological detection of 
parasite antigens like lactate dehydrogenase (LDH) or histidine-rich protein 2 (pfhrp2) in 
the blood can detect 50-1,000 parasites per µl with high specificity but they still lack the 
sensitivity of PCR-based methods 109. Data from controlled human infection models 
where parasite reproduction was monitored by quantitative PCR showed that 
parasitemias can increase 10-20-fold over a 48-h cycle period, highlighting the 
importance of detecting low levels of parasitemia in predicting clinical relapses 110.  
 
In clinical studies, parasitemias of asymptomatic carriers can be monitored using PCR-
based methods, which detect as few as 22 parasites per µl 111. More advanced 
technologies are currently being pursued to detect low-level parasitemia in low-resource 
settings. An example of this is the development of Loop-mediated isothermal amplification 
technology, which is a type of PCR that is fast (109-fold amplification in 1 h) and does not 
require thermal cycling 112,113. RDTs, which have similar sensitivities to light microscopy 
examination have the added advantage that they do not require extensive training of the 
user and that they provide rapid diagnosis at the point-of-care level in resource-limited 
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settings and have consequently greatly improved malaria control. Unfortunately, false-
negative test results, reportedly caused by pfhrp2 gene deletions in P. falciparum strains 
in South America have been reported 114,115. This is dangerous because such results 
could lead to the wrong perception that antimalarial medicines are ineffective, which might 
misleadingly influence policy. In addition, there’s evidence indicating that LDH-targeting 
RDTs are less sensitive for P. vivax than for P. falciparum 116. This is further complicated 
by the limited information on the sensitivity of these tests for the rarer P. ovale, 
P. malariae and P. Knowlesi. 
 
1.5.2. Pathogenesis and immunity 
Malaria’s predominant pathogenic mechanism is the hemolysis of infected red blood cells, 
which releases both the parasites and malaria endotoxin, a complex of hemozoin and 
parasite DNA, into the bloodstream. This combination triggers the Toll-like receptor 9 
(TLR9), a nucleotide-sensing receptor involved in the host immune response against 
pathogens, which leads to  high levels of tumor necrosis factor (TNF) production and to 
clinical symptoms such as fever 117-120. Additionally, membranes of infected red blood 
cells stiffen, lose their deformability and obstruct capillaries, which is life-threatening in 
severe malaria cases when vital organs are affected 121.  
 
Disease severity and pathogenesis are linked to surface proteins expressed by the 
parasite. In P. falciparum, the erythrocyte membrane protein 1 (PfEMP1), a major surface 
antigen encoded by the vast var gene family, is involved in cytoadherence and mediates 
the binding of infected erythrocytes to the endothelial vasculature 31,122-124. Some of the 
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well-studied PfEMP1 host ligands include the ubiquitous CD36 that is associated with 
mild infections, intercellular adhesion molecule 1 (ICAM-1) that is associated with cerebral 
malaria and chondroitin sulfate A (CSA) that allows parasite adhesion to the epithelial 
surface of the placenta 125,126. Disease severity is also predicted by high parasitemia 
levels and more often than not these correlate with poor outcomes 31,127. Predictably, 
circulating levels of P. falciparum histidine-rich protein 2 are used as a biomarker of 
parasitemia to predict the risks for microvascular obstruction and severe disease 128. 
P. vivax does not express the same family of var genes associated with endothelium 
binding and tissue sequestration. Additionally, P. vivax only invades reticulocytes, which 
are fewer than erythrocytes. The two factors may be the cause of decreased disease 
severity and lower parasite levels in P. vivax-infected patients 31. 
 
Malaria parasites first encounter the host immune system when sporozoites, ~15 per 
mosquito bite in one study, are injected into the skin 129. At this stage, the parasites might 
encounter and be vulnerable to antibodies against Plasmodium surface proteins, which 
might be the first line of the host’s acquired immune response against them 130,131. 
Consequently, chances of transmission are increased when the host is bitten by 
mosquitoes carrying larger number of sporozoites, although the diameter of the proximal 
duct limits the number of sporozoites that can be simultaneously injected into the host 132. 
How sporozoites evade all other effectors of the immune system to reach the liver is not 
well understood. However, sporozoite invasion of hepatocytes is believed to be in part 
due to their ability to suppress the function of Kupffer cells, the resident macrophages of 
the liver, and repress the expression of genes that encode MHC class I molecules, which 
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are molecules that sample peptides generated within the cell and signal the cell's 
physiological state to the T lymphocytes and natural killer cells 133. 
 
Parasite burden and risk of complicated malaria is dependent on levels of protective 
immunity acquired by the human host 134-136. This immunity is thought to result from 
circulating IgG antibodies against surface proteins on sporozoites and merozoites, which 
in turn helps block hepatocyte invasion and red blood cell invasion, respectively 134. In 
high-transmission areas, adults develop partially protective immunity from repeated 
infections and young infants (<6 months of age) are also afforded some protection from 
maternal antibodies 135. Children between 6 months and 5 years of age have the lowest 
levels of protective immunity and are therefore the most susceptible to developing life-
threatening complications from high parasitemias 137. In low transmission areas or areas 
that have seasonal malaria, individuals develop lower levels of protective immunity and 
typically have worse symptomatic malaria upon infection 136.   
 
The correlation between protective immunity and malaria severity poses a challenge for 
successful malaria treatment programs because the decrease in the number of infections 
and transmission rates is coupled with increasing numbers of individuals who lose their 
protective immunity and become susceptible to severe disease. Given that malaria has 
been re-introduced in areas that had been malaria-free for many years, this calls for 





1.5.3. Prophylaxis and treatment 
1.5.3.1. Vector control measures  
While eradication of mosquitoes is no longer considered an option to eliminate malaria, 
the use of long-lasting insecticide-treated bed nets and indoor residual spraying are 
estimated to be responsible for two-thirds of the malaria cases averted in Africa between 
2000 and 2015 138. More sophisticated fine-mazed, sturdy, long-lasting and wash-proof 
insecticide-treated bed nets are in use today but their efficacy is threatened by 
inappropriate use and factors like behavioral changes in mosquitoes, which have 
increasingly begun biting during the day 139,140. An even worse problem is the increasing 
emergence of vector resistance to insecticides, which makes it imperative that new 
insecticides with different modes of action be developed 140. Until that happens, 
technology advances in the deployment of indoor spraying chemicals, including timed 
release to coincide with seasonal transmission and slow-release polymer-based wall 
linings will need to play a bigger role in vector control 141-143. 
 
CRISPR-Cas9 gene editing technology has fueled a number of genetic approaches to 
vector control and offer an exciting area of development for novel insect control strategies. 
Mosquito population suppression and population alteration are two of the more well-
known of these initiatives. In the former, mosquitoes are modified so that the progeny are 
sterile while in the latter mosquitoes are modified so that the progeny are refractory to 
Plasmodium spp. infection 144. The initial population suppression approaches that 
involved releasing sterile male insects have been further improved so male insects now 
carry a dominant lethal gene that kills their progeny 145-147. Gene drive systems, which 
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can be used for both suppression and alteration initiatives using homing endonucleases, 
are being re-engineered to recognize mosquito genes and will rapidly increase the 
frequency of desirable traits in a mosquito population 148,149. Feasibility studies are 
currently ongoing to determine efficacy 150,151.  
 
The findings that Aedes aegypti mosquitoes (vector for Dengue, yellow fever and Zika 
viruses) infected with bacteria of the Wolbachia spp. cannot transmit the Dengue virus to 
human hosts has inspired new approaches to malaria vector control as well 152. As a 
result, symbiont Wolbachia spp. that can be modified to make them deleterious to other 
parasites in Anopheles spp. mosquitoes have now been identified 153,154.  
 
While all these approaches are very promising, they are still at very early stages of 
development. As more progress is made in these technologies, the focus will inevitably 
shift to environmental uncertainties associated with their widespread distribution and no 
doubt, there will be complex policy and regulatory requirements that will need to be 
addressed and overcome. 
 
1.5.3.2. Chemoprotection and chemoprevention  
Daily atovaquone-proguanil and daily doxycycline are the WHO-recommended 
chemoprotection medicines (i.e. medication given at prophylactic doses to temporarily 




Chemoprevention is the use of medicines with demonstrated efficacy regularly to large 
populations at full treatment doses. The major upside to doing this is that some of the 
individuals treated will inevitably be asymptomatic carriers, who are key to transmission. 
These campaigns, generally targeting children <5 years of age who are the most 
vulnerable group have had significant success. An example is the Sahel region where 
there are seasonal rains and a recurrent threat of malaria. Seasonal malaria 
chemoprevention with a combination of sulfadoxine-pyrimethamine plus amodiaquine 
resulted in >80% reduction in the number of malaria cases among children and a >50% 
reduction in mortality 156-161. While operationally complex given the required monthly 
treatments, it is estimated that >20 million children have been protected between 2015 
and 2016, at a cost of ~US$1 per treatment. Still, some concern remains about the long-
term success of these campaigns. Disease rebound is always a threat and can be caused 
by among others, interruption by economic difficulties or social unrest and the 
development of drug resistance.  
 
The issue of drug resistance is especially relevant and has indeed led to a different 
approach for the rest of sub-Saharan Africa where seasonal chemoprevention trials are 
monthly 3-day courses of ACTs 160,162. As an example, dihydroartemisinin (DHA)-
piperaquine has been highly efficacious in preventing malaria in high-risk groups 163. 
WHO proposes that drugs used for chemoprevention differ from the front-line treatment 
in use in the same country or region where possible to reduce the potential for the 
emergence of drug resistance 2. This highlights the need for the development of multiple, 
new and diverse antiplasmodial compounds to provide a wider range of options. 
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1.5.3.3. Vaccines  
Natural protective immunity to malaria is lost within 3-5 years in the absence of sustained 
exposure to malaria, presumably due to clearance of circulating antibodies and the failure 
of memory B cells to develop into long-lived plasma B cells 164. That notwithstanding, the 
fact that adults living in high-transmission areas acquire partial protective immunity 
indicates that vaccination is a possibility. Unsurprisingly, parasite proteins targeted by 
natural immunity, like the circumsporozoite protein on sporozoites, proteins expressed by 
merozoites, and parasite antigens exposed on the surface of infected red blood cells, 
have been studied for their potential to be used in vaccine programs 165,166. Unfortunately, 
this surface protein targeted approach, coupled with the species specificity of 
experimental malaria vaccines not only restricts their use but also provides room for the 
emergence of resistance. Still, controlled human infection models have continued to 
provide more precise understanding of the early cytokine and T cell responses in naive 
subjects 167-169. This will inevitably provide a better understanding of the role of regulatory 
T cells in dampening the response against the parasite, which results in the exhaustion 
of T cells  170.  
 
The most advanced vaccine candidate is RTS,S, developed by GlaxoSmithKline and the 
Program for Appropriate Technology in Health Malaria Vaccine Initiative. This vaccine  
contains a recombinant protein with parts of the P. falciparum circumsporozoite protein 
combined with the hepatitis B virus surface antigen and a proprietary adjuvant and aims 
to  trigger the immune system to defend against the first stages of malaria infection by 
preventing sporozoite invasion of the liver 171. RTS,S showed an efficacy of 40% in 
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children who received four vaccine doses over a 4-year period but that fell to 26% when 
only three vaccine doses were administered 172. Furthermore, RTS,S vaccine failed to 
provide long-term protection. At the request of WHO, more studies are currently underway 
in different African countries. The other promising vaccine candidate is the whole 
sporozoite PfSPZ Vaccine made by Sanaria. As the name suggests, this vaccine uses 
irradiated, and therefore non-infectious, sexual forms of the parasites extracted from 
mosquito salivary glands 173,174. In a phase I clinical trial, the efficacy of PfSPZ was highly 
dependent on prior parasite exposure, with naïve individuals being the most protected 175. 
These findings highlight the importance of more extensive clinical testing of both vaccine 
candidates. While promising, they also show the challenge that lays ahead in developing 
a highly efficacious vaccine. 
 
Nonetheless, the success of malaria vaccines should not be measured in efficacy terms 
alone as even with only partial and short-term efficacy they could still be used in the fight 
against malaria in a more targeted approach. An example would be using vaccines as 
additional protective measures for the most at risk individuals like pregnant women. 
Another would be to combined them with chemoprevention to interrupt malaria 
transmission in low-endemic areas 176. In the latter case, vaccines that are unable to 
prevent Plasmodium spp. infection could be repurposed to prevent transmission. That 
said, successful vaccines will inevitably have to include multiple antigens from different 
stages of the Plasmodium life cycle as well as address not only the nature of the immune 




1.5.3.4. Treatment  
The choice of antimalarial drugs used for treatment is heavily influenced by the 
frequencies of drug resistance, with little consideration going into examining the specific 
differences between the five Plasmodium spp. Chloroquine (CQ), with its low cost and 
excellent safety, is used in most cases of non-P. falciparum malaria, where it remains 
effective, whereas P. falciparum malaria requires newer ACT medicines that overcome 
resistance issues 177. The persistence of P. vivax and P. ovale hypnozoites, even after 
clearance of the stages that cause symptoms, necessitates the use of primaquine, and 
recently tafenoquine 2. 
 
The mainstay treatments for uncomplicated P. falciparum malaria are ACTs, which are 
fixed-dose combinations of an artemisinin derivative and a quinine derivative 2. Because 
it is highly lipophilic, artemisinin itself is not the molecule of choice 178. Instead, semi 
synthetic derivatives, namely, DHA (the active metabolite of many artemisinin 
derivatives), artesunate (AS, a succinate prodrug  of DHA that is highly water-soluble) or 
artemether (AT, a  methylether prodrug of DHA) are used in ACTs. The combination 
partners of choice are 4-aminoquinolines like amodiaquine (AQ), piperaquine (PPQ) and 
pyronaridine (PND) or amino-alcohols like mefloquine (MQ) and lumefantrine (LM). 
Currently approved ACTs for clinical use include artemether-lumefantrine (AT-LM), 
artesunate-amodiaquine (AS-AQ), DHA-piperaquine (DHA-PPQ), artesunate-mefloquine 
(AS-MQ), artesunate-sulfadoxine-pyrimethamine (AS-SP) and  artesunate-pyronaridine 
(AS-PND) 41.  These combinations have proven extremely effective, are well-tolerated 
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and are affordable. Importantly, they are stable in tropical climate conditions thanks to 
effective formulations and packaging 179. 
 
CQ or ACTs are WHO-recommended treatments for uncomplicated P. vivax malaria 2. 
Although other ACTs are active against P. vivax, only AS-PND is approved for the 
treatment of blood-stage P. vivax malaria. Relapses of P. vivax malaria are caused by 
dormant hypnozoites in the liver and present a problem in malaria control. Primaquine is 
the only clinical antimalarial drug targeting hypnozoites. Tafenoquine, a next-generation 
8-aminoquinoline currently completing phase III clinical studies is predicted to have 
similar levels of efficacy as primaquine at a single dose 180. As with patients receiving 
primaquine, patients receiving tafenoquine also require an assessment of their G6PD 
enzyme activity to ensure safety.  
 
1.6. Antimalarial drugs 
1.6.1. Antimalarial drug development and resistance 
Along with vector control, chemotherapy has played a big role in the fight against malaria. 
However, the ability of Plasmodium spp. to develop resistance to these treatments has 
continuously compromised the efficacy of clinical antimalarial compounds. This has in 
turn necessitated their use as combinations therapies, a nonstop race to develop new 
compounds and a quest to identify novel parasite targets. This section will mainly focus 
on common clinical antimalarials in use today, briefly touch on those used in the past and 




1.6.2. Artemisinin and its derivatives 
Artemisinin (ART) was first isolated in 1971 by Tu Youyou (winner of the joint Nobel Prize 
in Physiology or Medicine in 2015) from Chinese sweet worm-wood (Artemisia annua) 
181,182. ACTs, which consist of fast-acting semisynthetic derivatives of the endoperoxide 
ART partnered with slower-acting but longer-lasting drugs, are the current WHO-
recommended first-line treatments of uncomplicated malaria 2,183. ART derivatives, 
namely AT, AS or DHA, have improved pharmacological properties and when used 
against ART-sensitive parasites can reduce the parasite biomass by up to 10,000-fold 
every 48 h thereby providing exceptionally rapid clearance rates 184. ART semisynthetic 
derivatives AT and AS are prodrugs which are transformed to the active metabolite DHA. 
Regrettably, ART derivatives are rapidly metabolized and have half-lives in the range of 
1-2 h. As such, they cannot eliminate infections without the added contribution of longer-
lasting, albeit slower-acting, partner drugs, which are responsible for eliminating surviving 
parasites 185. 
 
The exact mode of drug action for ARTs is debated but the most accepted theory is 
compound activation by heme to generate free radicals that cause alkylation of proteins, 
lipids and heme, thereby causing oxidative stress and cellular damage 35,186. Other 
proposed mechanisms include upregulation of the unfolded protein response pathways 
which may be linked to decreased parasite development and inhibition of P. falciparum 




ART and its derivatives are very effective at killing asexual blood stage rings and 
trophozoites 189. The first report of resistance to artemisinin was in western Cambodia in 
2008 and manifested in delayed parasite clearance 190. A decade later, this tolerance 
phenotype was widespread and was reported in 30 independent cases across Southeast 
Asia. Alarmingly, this resistance was to DHA-PPQ combination therapy 191. ART-
resistance is now known to be driven by point mutations in propeller domain of P. 
falciparum Kelch 13 (PfK13) 35,192,193. 
 
1.6.3. Quinolines 
Quinoline antimalarials are divided into the following categories: 4-aminoquinolines, 8-
aminoquinolines and aryl-amino alcohols. The 4-aminoquinolines compounds include 
CQ, AQ, PPQ, PND and ferroquine (FQ). CQ was developed in the 1940s and was used 
to treat all forms of malaria with few side effects. It acts by accumulating inside the 
parasite’s DV where it prevents the biomineralization of toxic free heme into inert 
hemozoin 194. Resistance is driven primarily by mutations in P. falciparum chloroquine 
resistance transporter (PfCRT). These mutations enable the parasites to efflux CQ out of 
the DV, thereby preventing drug accumulation at its primary site of action 195. 
 
AQ was first synthesized in 1948 and in combination with AS, is an integral constituent of 
ACTs as a fixed-dose for the treatment of uncomplicated P. falciparum malaria 196,197. 
Similar to CQ, AQ is thought to inhibit heme detoxification inside the DV 93. Reduced 
parasite sensitivity to AQ has been associated with polymorphisms like N86Y and 
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D1246Y in P. falciparum multidrug resistance transporter 1 (PfMDR1), that have been 
selected for by AQ therapy in different malaria-endemic settings 198. 
 
PPQ is an important ACT partner drug to DHA and was developed in the 1960s as a part 
of the Chinese National Malaria Elimination Program as a replacement for CQ as a 
monotherapy 199. Resistance was first reported in Cambodia in the early 2010s and is 
now known to be primarily driven by PfCRT haplotypes 200-203. PPQ-resistance also 
appears to be augmented via amplifications in plasmepsins 2 and 3 and these have also 
been identified, in genome-wide association studies using PPQ-resistant or PPQ-
sensitive field isolates, as molecular markers of PPQ resistance 204,205. These genes, 
which encode aspartic proteases in the DV, act as hemoglobinases and their amplification 
is proposed to result in faster rates of Hb digestion. This in turn leads to increased globin-
derived peptide and subsequent amino acid availability for protein synthesis, which could 
help counteract the ability of PPQ to inhibit Hb catabolism and heme detoxification 205-207.  
 
Like PPQ, PND, first synthesized in the 1970s at the Institute of Chinese Parasitic 
Disease, was also meant to replace CQ 41,208,209. PND is efficacious against CQ-resistant 
strains and has yet to succumb to widespread resistance in the over 40 years of use. It’s 
mechanism of action is predicted to be inhibition of β-hematin formation and is an 
important ACT partner drug to AS 210. 
 
FQ was designed and synthesized in the 1990s by incorporating a ferrocene unit into the 
basic skeleton of CQ in an effort to develop new antimalarial compounds to counter the 
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spread of ART-resistance in Southeast Asia 211. FQ kills parasites by targeting both 
membrane lipids and inhibiting β-hematin formation in the DV 212. It is currently going 
through clinical trials 213. 
 
The two 8-aminoquinoline drugs, primaquine and tafenoquine, can clear dormant 
hypnozoites in the liver and represent the only likely agents of anti-relapse therapy. 
Indeed, these are the only two compounds approved for radical cures for P. vivax and P. 
ovale malaria 214. Primaquine requires repeated dosing for up to 15 days but tafenoquine, 
which was discovered in 1978 at the Walter Reed Army Institute of Research, is about a 
100-fold more potent, has a longer half-life and can be used a single dose 215,216. While 
thought to be a prodrug, tafenoquine’s mechanism of action is not well understood 217. 
 
The three best known aryl-amino alcohols are quinine (QN), LM and MQ. QN is a former 
frontline antimalarial first isolated from the bark of the cinchona tree in 1820 218. Although 
no longer used as a front-line treatment for malaria, it is currently used to treat 
uncomplicated P. falciparum malaria in pregnant women and provides an alternative to 
AS for severe malaria 219. QN has a complex mode of action that includes the inhibition 
of heme detoxification and parasite mechanism of QN resistance are partially associated 
with polymorphisms in pfcrt and pfmdr1 220.  
 
LM was first synthesized in 1976 as part of the Chinese antimalarial research effort 
“Project 523” which also resulted in the discovery of ART 221. While it’s exact mechanism 
of action is unknown, studies suggest that it inhibits nucleic acid and protein synthesis 
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through the inhibition of β-hematin formation by complexation with heme 93. LM is 
currently used only in combination with AT 41.  
 
MQ was developed in the 1970s by the United States Army as a replacement for CQ 222. 
It has since been used both as a curative and a prophylactic drug and is thought to kill 
parasites through the disruption of Hb digestion. Resistance was first reported in 1986 
and MQ is no longer widely used due to the perception of central nervous system toxicity 
reported to affect a large number of its users 223,224.  
 
Quinoline compounds are commonly used in combination with a complementary drug to 
reduce the chance of resistance development.  
 
1.6.4. Other antimalarials 
Atovaquone and proguanil  
Atovaquone, a naphthoquinone, was first reported in 1991 for the treatment of protozoan 
infections while proguanil was first reported in 1945 as one of the first antifolate 
antimalarial drugs 225,226. The combination of these two (atovaquone-proguanil) since the 
early 2000s has been very effective in treating malaria due to the synergy resulting from 
their individual mechanisms of action. Atovaquone acts as a cytochrome bc1 complex 
inhibitor that blocks mitochondrial electron transport and proguanil, through its metabolite 
cycloguanil, is a dihydrofolate reductase (DHFR) inhibitor that disrupts deoxythymidylate 




Sulfadoxine and pyrimethamine  
Sulfadoxine was developed in the early 1960s and is no longer used as a preventative 
drug due to high levels of resistance 229. Pyrimethamine was developed in the early 1950s 
and was a part of the efforts that won Gertrude Elion and George Hitchings the joint Nobel 
Prize in Physiology or Medicine in 1988 230. The combination of sulfadoxine  and 
pyrimethamine (sulfadoxine-pyrimethamine - SP) was approved for use for the treatment 
of malaria in 1981. Both drugs are known to target the parasite’s folate biosynthesis 
pathway. Pyrimethamine inhibits dihydrofolate reductase (PfDHFR), while sulfadoxine 
inhibits dihydropteroate synthetase (PfDHPS). Together, SP interferes with folate 
biosynthesis, which is essential for DNA synthesis and parasite growth 231. High-grade 
SP resistance occurs in mutant parasites harboring the N51I, C59R, and S108N point 
mutations in PfDHFR and A437G and K540E in PfDHPS 232. 
 
1.6.5. Antimalarial compounds under development 
Given the ability of the Plasmodium spp. to acquire resistance to chemical material, the 
bar for new antimalarials must necessarily be high. As such, the attractiveness of new 
compounds is heavily dependent on a number of factors, including novel modes of action 
with no cross-resistance to current drugs, single-dose cures, activity against both the 
disease-causing asexual blood stages and the gametocytes responsible for transmission, 





Traditionally, antimalarial compounds have been discovered using high-throughput 
phenotypic or whole-cell assays where a large compound library is screened to identify 
molecules that are active against Plasmodium parasites or actual targets in biochemical 
assays 233. This initial screening is then followed by  cheminformatic analysis where 
factors like potency, novelty, ease of synthesis, toxicity and cost are used to help identify 
promising scaffolds. Additional derivatives of the selected scaffolds are often then 
synthesized and tested against the whole parasite or against the specific protein target 
for structure-activity relationship (SAR) analysis, which are in turn used to predict the 
effect of chemical modifications on the properties of the compound. Iterative SAR 
analyses help identify lead compound(s) from which candidates are then picked for 
efficacy testing. The scope and type of assay is usually determined by the number of 
compounds to be screened and the cost of the operation. High-throughput automation 
and related technological advances in liquid handling, image analysis and assembly of 
pure chemical libraries have made it possible to screen millions of compounds 234-237. 
While costly, this drug discovery approach has led to the identification of promising 
compounds like KAE609 and KAF156 that are currently in clinical trials and have the 
potential to be the next generation antimalarials 238,239. High-throughput screens have 
also been developed to identify compounds that act exclusively on the nonreplicating 
mature gametocytes to prevent their transmission, without exerting selective pressure on 
asexual blood stage parasites that could generate resistance 240-244. 
 
While the traditional high-throughput screening of compounds is still relevant today, 
newer and innovative ways are also currently being pursued. There is now a push to 
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further leverage heme detoxification, to focus on drugs with a pleiotropic array of cellular 
targets or target processes like parasite-mediated endocytosis of Hb, that involve host 
proteins.  
 
Towards this end, CQ-like compounds that couple targeting heme with a 
chemosensitizing component that counteracts mutant PfCRT-mediated CQ resistance 
are now being designed 245,246. Our detailed knowledge about drivers of resistance, like 
PfCRT and PfMDR1, where mutations conferring resistance to one drug can sensitize 
parasites to other agents has also been harnessed to lay the groundwork for clinical trials 
(NCT02612545 and NCT02453308) with the triple ACTs AL plus AQ or DHA-PPQ plus 
MQ to test whether these combinations can successfully eliminate resistant and sensitive 
infections, and, potentially, block the emergence of parasites resistant to all three agents. 
Lastly, some potential target host factors required for intraerythrocytic parasite growth 
have been identified. These include the human ferrochelatase which is imported into 
parasites and seems to contribute to heme biosynthesis and a host tyrosine kinase that 
seems to be co-opted to assist with erythrocyte membrane destabilization and parasite 
egress 247-250.  
 
Another promising strategy is the repurposing of existing drugs that are used to treat other 
diseases but are efficacious against malaria parasites. The advantage of this method is 
that the said compounds may already have good biological properties and hence require 
less optimization and may also reveal novel antiplasmodial mechanisms of action. Some 
examples of repurposed compounds include: methylene blue, which is a drug for the 
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treatment of methaemoglobinemia in clinical trials (NCT02851108) as a combination with 
primaquine; fosmidomycin, an antibiotic in clinical trials (NCT02198807) as a combination 
with PPQ; rosiglitazone, an antidiabetic drug that in clinical trials as an adjunctive therapy 
for severe malaria (NCT02694874); imatinib, a cancer therapy drug currently in clinical 
trials (NCT03697668) as a triple combination with DHA-PPQ; and sevuparin, a drug for 
the treatment of sickle cell disease in clinical trials (NCT01442168) as a combination with 
atovaquone-proguanil.  
 

















Table 1. 1. | Select antiplasmodial compounds identified by recent drug discovery efforts. 
Compound Compound class Stage in development Target/MoA Reference 
M5717 quinoline-4-carboxamide Phase I (NCT03261401) PfeEF2 251,252 
DM1157 “reversed chloroquine” Phase I (NCT03490162) inhibition of β-hemozoin 253,254 
P218 2,4-diaminopyrimidine Phase I (NCT02885506) PfDHFR 255 
(+)-SJ733 tetrahydroisoquinolone carboxanilide Phase I (NCT02661373) PfATP4 238,256 
ACT-451840 Piperazine Phase I (NCT02223871) Unknown 257,258 
OZ439 trioxolane Phase IIb (NCT02497612) Oxidative stress 259,260 
KAF156 imidazolopiperazine Phase IIb (NCT03167242) PfCARL, UDP-galactose Acetyl-CoA 261,262 
KAE609 spiroazepineindole Phase IIb (NCT03334747) PfATP4 263,264 
DSM265 triazolopyrimidine Phase IIa (NCT02123290) PfDHODH 265,266 
MMV048 3,5-dia-ryl-2-aminopyridine Phase IIa PfPI4K 61,267 
Bortezomib peptidyl boronic acid Pre-clinical β5 P. falciparum 20S proteasome 268 
WLL, WLW peptide vinyl sulfones Pre-clinical β2, β5 (WLL), β2 (WLW) P. falciparum 20S proteasome 269,270 
GNF-Pf-5640 Hexahydroquinoline Pre-clinical -- 271 
MB14 4-cyano-3-methylisoquinoline Pre-clinical PfATP4 272 
MMV030084 trisubstituted imidazole Pre-clinical PfPKG 57 
AN13762 benzoxaborole Preclinical PfCPSF3 273,274 
MMV253 triaminopyrimidine Lead development PfATP4 inhibition 275 
SC83288 amicarbalide -- PfATP6 and PfMDR2 276,277 
UCT943 2-aminopyrazine -- PfPI4K 278,279 
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MoA: Mechanism of Action; PfeEF2: P. falciparum elongation factor 2; PfDHFR: P. 
falciparum dihydrofolate reductase; PfATP4: P. falciparum P-type cation-transporter 
ATPase; PfCARL: P. falciparum cyclic amine resistance locus; UDP: Uridine diphosphate 
galactose; PfDHODH: P. falciparum dihydroorotate dehydrogenase; PfPI4K: P. 
falciparum phosphatidylinositol 4-kinase; PfPKG: P. falciparum cGMP-dependent protein 
kinase; PfCPSF3: P. falciparum cleavage and polyadenylation specificity factor; PfATP6: 
P. falciparum Ca2+-ATPase; PfMDR2: P. falciparum multidrug resistance protein 2; --:
unknown.
1.6.6. Antimalarial drug targets 
This section briefly describes some of the targets listed in Table 1.1. above. 
Translational elongation factor 2 (PfeEF2): PfeEF2 is an essential factor for eukaryotic 
protein synthesis and catalyzes the translocation of tRNA and mRNA 280. It is currently a 
target by the antiplasmodial compound M5717 281. 
P-type ATPase 4 (PfATP4): The malaria parasite must maintain a low intracellular Na+
concentration to survive, especially in the presence of the high concentration of 
extracellular sodium ions. The parasite’s influx of Na+ is regulated by using PfATP4 that 
shuttles sodium ions out of the cell. Inhibition of this transporter by compounds like (+)-
SJ733, KAE609 and MB14 results in a buildup of Na+ inside the parasite and leads to cell 
death 238,263,272.  
V-type H+-ATPase: H+ are imported through the same pathway regulating its Na+
concentration. To maintain an intracellular pH of ~7.3, the parasite effluxes H+ using a 
complementary V-type ATPase transporter 282. Inhibition of this transporter by 
compounds like bafilomycin A and concanamycin A leads to cell death 283. 
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Phosphatidylinositol 4-kinase (PfPI4K): PfPI4K phosphorylates lipids, allowing them to 
regulate intracellular signaling and trafficking 61. Inhibition of the ATP-binding pocket of 
PI4K by compounds like MMV048 and UCT943 leads to disruption of the intracellular 
distribution of PI4-phosphate (PI4P), which in turn results in decreased late-stage parasite 
development.  
Dihydroorotate dehydrogenase (PfDHODH): Plasmodium parasites are unable to use 
endogenous host pyrimidines and must synthesize them de novo. A key step in the 
biosynthesis of pyrimidines is the oxidation of dihydroorotate to produce orotate, a 
reaction that is catalyzed by the enzyme dihydroorotate dehydrogenase (DHODH) 284. 
Compounds like DSM265 inhibit this enzyme so that the malaria parasite can no longer 
obtain the required metabolites to survive, and is killed 285. 
Dihydrofolate reductase (PfDHFR): Malaria parasites also require folates in order to 
maintain their high rate of replication. Unlike the pyrimidines, the parasites are able to 
scavenge folates or synthesize them de novo. Dihydrofolate reductase (DHFR) catalyzes 
a step required for folate recycling, which in turn are used in the synthesis of thymidylate, 
purines and methionine. The inhibition of this enzyme by compounds like P218 kills the 
parasites by depriving them of these essential molecules 286. 
1.7. The rise and spread of multidrug resistance 
The prior combination of AS-MQ has been largely replaced by DHA-PPQ in Asia as a 
consequence of P. falciparum multidrug resistance-1 transporter (pfmdr1) amplifications 
in Southeast Asian parasites. pfmdr1 encodes a DV membrane-bound ATP-binding 
cassette (ABC) transporter whose amplifications or polymorphisms constitute a major 
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determinant of parasite resistance to MQ and LM 287,288. PPQ is generally effective against 
parasites that evolved resistance to CQ through specific sets of point mutations in PfCRT, 
which is also present on the DV membrane 289,290. However, the rapid increase in mutant 
K13 parasite strains in Southeast Asia has resulted in greater numbers of parasites being 
exposed to the ACT partner drugs as monotherapy agents, once the short-lived ART 
component has dropped to sub-therapeutic levels. As a consequence of this increased 
selection pressure, resistance to the partner drug PPQ has now emerged, is spreading 
quickly in Southeast Asia and is rendering DHA-PPQ treatment increasingly inefficacious 
291-293. PPQ resistance is also driven by gain of individual PfCRT mutations, including the
H97Y, M343L, G353V and F145I, which confer varying levels of fitness costs that 
ultimately influences their relative abundance within parasite populations 207,294. 
Alarmingly, novel mutant K13 parasite strains have recently been identified in Africa 295.  
As has been mentioned, MQ or LM treatment in Southeast Asia selects for parasites 
with increased pfmdr1 copy number 288,296,297. Luckily, pfmdr1 copy-number variants 
are exceedingly rare in Africa and LM continues to be an important ACT partner drug to 
AT 41,298. Why the aryl-amino alcohols select for gene amplifications in the parasites of 
one continent and not another is not quite clear but a possible explanation is that Africa’s 
combination of lower drug pressure coupled with more frequent mixed infections 
exacerbates the fitness cost resulting from pfmdr1 overexpression, which in turn results 
in the predominance of single-copy pfmdr1 parasites. 
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Distinct PfMDR1 haplotypes can modulate the efficacy of several antimalarials. A good 
example is the N86Y mutation that has been shown to confer partial resistance to the 
active metabolite of AQ (monodesethyl-AQ) as well as augment the level of CQ resistance 
imparted by mutations in PfCRT. Surprisingly, this mutation is counter-selected by LM, 
ARTs and MQ, which shows the interconnectedness of many of the clinical antimalarials 
and/or the parasite’s mechanisms of resistance 297,299. Disturbingly, multiple new 
mutations in PfMDR1 and PfCRT have been documented across Asia and Africa, 
suggesting that the widespread use of ACTs is selecting for novel variants of these multi-
drug resistance transporters 300. 
The fear of imminent spread of multidrug resistance to Africa is merited and is backed by 
history. Southeast Asia is the original source of parasite resistance to the former first-line 
drugs CQ and SP 301. From there, resistance spread to Africa where it caused a dramatic 
worsening of the malaria situation until ACTs were deployed. In Senegal for example, the 
emergence of CQ resistance was estimated to have caused up to a six-fold increase in 
mortality rates in children with malaria 302. There is therefore a valid concern that 
resistance mechanisms originating in Southeast Asia could once again spread into Africa, 
with potentially devastating consequences 303.  
Why Southeast Asia in general, Cambodia in particular, is P. falciparum’s favored region 
for the emergence of multi-drug resistance is still debated but could be as a result of any 
or a combination of the following: 1) the frequent choice to ACTs and issues of incomplete 
patient compliance coupled with substandard drugs 304; 2) Asian parasites, being in a low 
41 
transmission region, are largely monoclonal and this might lessen any resistance-
associated fitness cost, thereby allowing parasites to optimize resistance mechanisms 
and enable their successful dissemination. In contrast, parasite infections in high 
transmission Africa are frequently polyclonal and any resistance-associated fitness cost 
would compromise the parasite’s ability to compete 183; 3) host immunity, which plays an 
important role in the clearance of resistant P. falciparum infections, is typically lower in 
Asian settings because of the reduced frequency of human exposure to malaria parasites. 
Consequently, little if any, natural clearance of drug-resistant infections in Asia allows 
these parasites to thrive 305.  
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Chapter 2. Experimental Procedures 
2.1. Experimental Procedures for Chapter 3 
2.1.1. Experimental model and subject details. 
The P. falciparum parasites used in this study were cultured in human O+ blood (sex of 
donor unknown) at 3% hematocrit in RPMI-1640 media supplemented with 50 μM 
hypoxanthine, 2 g L-1 sodium bicarbonate, 2 mM L-glutamine, 25 mM HEPES, 0.5% 
AlbuMAXII (Invitrogen) and 10 μg mL-1 gentamycin in 5% O2, 5% CO2 and 90% N2 at 37 
°C. The 3D7-A10 P. falciparum line is a clone of the 3D7 line received from the Goldberg 
lab at Washington State University in St. Louis. The 3D7-MR4 line was obtained from the 
Malaria Research and Reference Reagent Resource Center (MR4, Cat#MRA-102). The 
Dd2-B2 P. falciparum line is a clone obtained by limited dilution from the Dd2 line provided 
by Dr. Thomas Wellems (NIAID, NIH). 
2.1.2. Stage specificity assay. 
Standard asexual blood stage susceptibility results were collected by exposing 
asynchronous 3D7-A10 parasite cultures to 10 different concentrations plus no-
compound controls for 72 h. To determine the specific asexual blood stage at which the 
compounds are active, schizonts were magnetically purified using MACS LD columns 
(Miltenyi Biotec) from cultures that had been repeatedly synchronized with 5% sorbitol. 
After a 3h incubation at 2% hematocrit to allow re-invasion, cultures were again sorbitol-
synchronized to obtain a pure ring-stage culture (time = 0 h). These parasites were then 
plated in five 96-well plates and exposed to compounds as early rings (0-8 h), late rings 
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(8-16 h), early trophozoites (16-24 h), late trophozoites (24-32 h) or schizonts (32-40 h). 
Incubation times were adjusted to the 40 h asexual blood stage cycle of the 3D7-A10 
parasite line. Synchronicity of the cultures was confirmed by imaging on average 83 
parasites per time point in control conditions. Compounds were removed through three 
rounds of washing including two plate changes in 37°C prewarmed culture media after 
each exposure. All pipetting steps to expose and wash parasites were performed using a 
Tecan Freedom Evo 100 for increased throughput and accuracy. Each group of plates 
per timepoint were placed in a separate humidified chamber to avoid any delay in growth 
rate due to temperature variations. For the stage specificity assay, growth inhibition was 
assessed at the 60 h time point at which parasites had expanded, reinvaded new RBCs, 
and developed into the trophozoite stage that allows straight-forward quantification by 
flow cytometry. This is very similar to the standard 72 h assay in which parasites are not 
synchronized, but also allowed to reinvade and develop further for another half life cycle. 
Parasite survival for both the 72 h and stage-specific 8 h exposures was assessed by 
SYBR Green and MitoTracker Deep Red FM staining (Life Technologies) and subsequent 
flow-cytometric analysis (Accuri C6, BD Biosciences) 306. IC50 values were derived from 
growth inhibition data using nonlinear regression (Prism 7, GraphPad). All asexual blood 
stage assays were repeated on at least three independent occasions with two technical 
replicates. 
2.1.3. Culturing for Metabolomics. 
3D7-MR4 parasites were cultured at 50 ml volumes and 2% hematocrit as described 
elsewhere 260. Cultures were kept at the appropriate temperature and gas mixture in 
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incubators between media exchange, culture division, and synchronization. 
Synchronization was achieved via 5% sorbitol. All reagents and experimental spaces 
were mycoplasma-free, and reagents passed through 0.2 µm liquid filters when possible 
prior to use. 
2.1.4. Metabolomics. 
Hydrophilic metabolite changes in response to compound exposure were profiled as 
previously described 260. Treatments were performed on 1×108 MACS-purified, 
synchronized trophozoite parasite-infected RBCs (24-36 h post invasion) in 5 mL RPMI. 
Compounds were added at a concentration of 10×IC5072h and incubated for 2.5 h. All 
treatment conditions were performed as technical triplicates and included an untreated 
control. Subsequently, PBS washes were performed, and infected RBCs were extracted 
with 90% methanol containing 0.5 µM 13C15N-labelled aspartate as an internal standard, 
then dried under nitrogen and stored at -80°C. Process blanks were generated at the time 
of extraction in technical triplicates. Samples were then resuspended in high-performance 
liquid chromatography (HPLC) grade water containing 1 µM chlorpropamide as an 
additional internal standard and analyzed by ultra-high-performance liquid 
chromatography mass spectrometry UHPLC-MS as described 260. 
2.1.5. Targeted Analysis. 
Following negative ionization analysis of hydrophilic extracts on a Thermo Exactive Plus 
Orbitrap, sample data were converted and transferred for analysis. Targeted peak picking 
from a curated list of 298 metabolites was achieved using el-MAVEN software 
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(https://elucidatainc.github.io/ElMaven/ 307), followed by normalization and analysis via 
RStudio (http://www.rstudio.com/) and Metaboanalyst (https://www.metaboanalyst.ca/ 
308). Data were visualized using the Hyperspec (http://hyperspec.r-forge.r-project.org) and 
Suprahex R (Fang et al., 2014) scripting packages in RStudio. Hierarchical clustering of 
the metabolic profiles to identify related metabolic signatures was performed using the 
Ward method, based on the Pearson correlation coefficients, by the Hyperspec R 
integrated heatmap function. 
2.1.6. Resistance selections. 
Attempts to obtain parasites resistant to MMV030666, MMV000787 and MMV021735 
were performed using either single step (continuous) or ramping selection protocols as 
described elsewhere 233. For single step selections, parasites are continuously exposed 
to relatively high concentrations of the compound of interest (usually 3×IC50) with culture 
media and RBCs being regularly refreshed until actively growing parasites are again 
observed. Cultures were monitored for minimum 70 days after start of exposure. For 
ramping selections, parasites are exposed at low compound concentrations (usually 
1×IC50 or lower) and parasite growth is continuously monitored. When parasites seem to 
have adapted to the pressure, compound concentrations are gradually increased to adapt 
parasites to even higher levels of compound. Standard IC5072h assays were performed on 
recrudesced parasites from single step selections, if any, and on parasites resulting from 
ramping selections. 
46 
2.1.7. Solubility assay. 
The aqueous solubility of MMV007181, MMV000442 and MMV006455 was determined 
at a single concentration of 500 µM because of compound scarcity. The protocol used 
was adapted from Millipore Corporation’s “MultiScreen® Solubility Filter Plate” application 
note. Dihydroartemisinin, chloroquine and piperaquine were used as controls. Briefly, 
compounds were first dissolved in DMSO at 10 mM. They were then added to 1× PBS 
(pH 7.4) at a 1:20 ratio in 1.5 ml tubes and mixed on a shaker (100 rpm) at room 
temperature for 1.5 h. They were then filtered using Target2 regenerated cellulose 0.2 
μM filters (Thermal Scientific, part number F2500-8) to remove any precipitate. 160 µl of 
the filtrate was dispensed into flat-bottomed 96-well culture plates and diluted with 40 
µl/well acetonitrile. The plate was then placed on a shaker (100 rpm) at room temperature 
for 10 min. After mixing, the filtrate was analyzed using a Spectramax 340PC (Molecular 
Devices) at 280, 300, 320, 340, 360 and 800 nm. Standards were made by adding 
compounds into standards buffer (80:20 1× PBS: acetonitrile, pH 7.4) at a 1:25 ratio. The 
mixtures were allowed to mix on a shaker (100 rpm) for 10 min at room temperature and 
analyzed at the same six wavelengths as mentioned above. The aqueous solubility of 
compounds was then determined by calculating the ratio of absorbances between the 
filtrate and the standard using the formula below:    
(∑AU	at	280, 300, 320, 340, 360	nm) − (AU	at	800	nm)	Filtrate
(∑AU	at	280, 300, 320, 340, 360	nm) − (AU	at	800	nm)	Standard 
If the ratio is ≈ 1, a compound’s aqueous solubility is ≥ 500 µM. Ratios < 1.0 and > 0.5 
indicate a solubility between 100 µM and 500 µM, while ratios ≤ 0.5 indicate a solubility 
≤ 100 µM. 
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2.2. Experimental Procedures for Chapter 4 
2.2.1. Experimental model and subject details. 
Asexual blood stage P. falciparum parasites used in this study were cultured at 3% 
hematocrit in O+ human erythrocytes in RPMI-1640 medium supplemented with 50 μM 
hypoxanthine, 2.1 g/L NaHCO3, 2 mM L-glutamine, 25 mM HEPES, 0.5% (w/v) AlbuMAXII 
(Invitrogen) and 10 μg/mL gentamycin at 37°C in flasks gassed with 5% CO2/5% O2/90% 
N2. The 3D7-A10 Dd2-B2 and NF54 P. falciparum parasites lines used here have been 
previously reported 189,309. Dd2 Dd2 and Dd2 3D7 isogenic pfcrt-edited lines were reported in 
310. The human biological samples were sourced ethically and their research use was in
accordance with terms of informed consent under an IRB/EC approved protocol. 
2.2.2. Compounds, resistance selections and in vitro drug susceptibility assays. 
Compounds 2-5 were kindly provided by the Medicines for Malaria Venture (Geneva, 
Switzerland), and 1 and 6 were synthesized at the Drug Discovery and Development Centre 
(H3D) at the University of Cape Town in South Africa as part of the SoftFocusKinase 59 
(SFK59) library 311,312. Parasites resistant to compound 1 were obtained from single-step 
selections where 107 3D7-A10 parasites in triplicate were cultured continuous at 3 IC50 
drug pressure. For the SNP-selecting 3 and 4, single-step selections were run on 109 3D7-
A10 parasites. The same numbers of parasites and selection methods were used on Dd2-
B2 selections using compound 5. Resistant clones were obtained from bulk cultures by 
limiting dilution. For the susceptibility experiments, compounds were assayed using 2-fold 
dilutions with inhibition measured after 72 h. Parasite viability was determined by staining 
the parasites with SYBR Green and MitoTracker Deep Red (Life Technologies) followed by 
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flow cytometry (Accuri C6, BD Biosciences or iQue Plus, Sartorius) 306. IC50 values were 
derived by nonlinear regression (Prism 7, GraphPad).  
2.2.3. Whole-genome sequencing analysis. 
Sequencing of P. falciparum clones resistant to compounds 2-4 was performed by the 
Winzeler lab, using methodology reported in 313. For 1 and 5, resistant clones were 
sequenced by the Fidock lab, using methods reported in 57,314. Paired-end libraries were 
sequenced on Illumina HiSeq or MiSeq instruments.  
In the Winzeler lab, the Nextera XT kit (Illumina) was used to prepare DNA libraries from 
samples for whole-genome sequencing using the dual index protocol 313. The libraries were 
run on the Illumina HiSeq 2500 in rapid run mode with 100-bp paired-end reads. The reads 
were aligned to the P. falciparum 3D7 reference genome (PlasmoDB v. 13.0) as described 
previously 315. Single nucleotide polymorphisms (SNPs) and indels were called with the 
Genome Analysis Toolkit’s (GATK) HaplotypeCaller. Variants were filtered by quality scores 
and sequencing bias statistics based on GATK’s default filtering parameters. SNPs were 
filtered out if they met any of the following criteria: quality depth (QD), <2.0; mapping quality 
(MQ), <50.0, Phred-scaled P value using Fisher’s exact test to detect strand bias (FS), 
>60.0; symmetric odds ratio (SOR), >4.0; Z-score from Wilcoxon rank sum test of
alternative versus reference read mapping qualities (MQRankSum), less than 12.5; 
ReadPosRankSum (RPRS) parameter, less than 8.0. Indels were filtered out if they met 
any of the following criteria: QD, <2.0; RPRS, less than 20.0; FS, >200.0. Variants were 
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annotated using snpeff (version 4.2). Custom scripts were used to compare the variants 
between the parent sequence and the resistant clones. 
In the Fidock lab, whole-genome sequencing of genomic DNA from parental and resistant 
clones employed an Illumina TruSeq DNA PCR-Free library preparation protocol and a 
MiSeq sequencing platform. Briefly, 2 mg of genomic DNA were sheared to a mean length 
of 550bp, end-repaired, adenylated on their 3’ ends and ligated to indexed adaptors. 
Samples were pooled and sequenced on Illumina MiSeq flow cells to obtain 300 bp 
paired-end reads. Sequence data were aligned to the P. falciparum 3D7 genome 
(PlasmoDB version 48) using BWA (Burrow-Wheeler Alignment). We used Samtools and 
Picard to remove PCR duplicates and reads that did not map to the reference genome. 
Reads were realigned around indels using GATK RealignerTargetCreator and base 
quality scores were recalibrated using GATK Table-Recalibration. GATK HaplotypeCaller 
(version 4.1.8; Min Base quality score ≥ 18) was used with the clones to identify all 
possible variants, which were filtered based on quality scores (variant quality as function 
of depth QD > 1.5, mapping quality > 40) and read depth (depth of read > 5) to obtain 
high-quality SNPs. These SNPs were annotated using snpEFF. The list of variants from 
the resistant clones were compared against the 3D7-A10 parent to obtain homozygous 
SNPs that were present exclusively in the resistant clones. IGV was used to confirm the 
SNPs present in the resistant clones. BicSeq was used to discover copy number variants 
(CNVs) against the 3D7-A10. 
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2.2.4. Genome editing.  
L690I mutation in ABCI3 was validated by engineering it into 3D7-A10 parent using a two-
plasmid CRISPR/Cas9 system. The Cas9 was derived from Streptococcus pyogenes and 
was fused to the selection marker yDHODH that confers resistance to DSM1 316. Both 
Cas9 and the selection marker were expressed from the P. falciparum calmodulin 
promoter. The Cas9 plasmid also contained a guide RNA that was expressed from the 
U6 promoter. Guide RNA sequences were selected using ChopChop, an online gRNA 
design tool, and were based on their proximity to the mutation of interest, GC content, 
and absence of poly A/T tracks (http://chopchop.cbu.uib.no). The donor plasmid 
contained the abci3 fragment with the L690I mutation and blasticidin-S deaminase (bsd), 
a selection marker that protects against blasticidin (Sigma-Aldrich). Plasmid transfections 
were conducted using an Amaxa nucleofector 317. Briefly, a cell pellet of 7×108 highly 
synchronized and magnet-purified 3D7-A10 mature schizonts were first re-suspended in 
100 µl of Nucleofector Solution 2 (with the supplement added) that had been pre-warmed 
to room temperature. This was then mixed with 10 µg of plasmid DNA in a volume of 5 µl 
deionized water. The sample was then transferred into an Amaxa certified cuvette and 
electroporation done using the Amaxa U-033 program. The parasite were allowed to re-
invade fresh red blood cells in complete media that had been pre-warmed to 37oC. 
Parasite uptake of the donor plasmid was selected with 2 mg/ml BSD for six days starting 
one day after the transfections, and parasites were maintained thereafter in complete 
media until recrudescence. Gene editing was assessed via Sanger sequencing of PCR 
products amplified from bulk cultures. Edited parasite clones were obtained by limiting 
dilution. Parasites were assayed for drug susceptibility by flow cytometry 306. 
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3´Flag and 3´HA tagging of ABCI3 was achieved by transfecting highly sorbitol-
synchronized 3D7-A10 ring-stage parasites with an all-in-one CRISPR/Cas9 plasmid. 
The P. falciparum codon-optimized Cas9 endonuclease was derived from Streptococcus 
pyogenes and was expressed under a calmodulin promoter. The plasmid also carried a 
human DHFR (hDHFR) selectable marker (that confers resistance to WR99210) under a 
P. chabaudi dhft-ts promoter and the guide RNA (gRNA) sequence under a U6 promoter.
Guide RNAs were selected using the online tool ChopChop 9 
https://chopchop.cbu.uib.no). 108 parasites were electroporated with purified circular 
plasmid DNA as described 318. Briefly, a 5 mL culture of 3D7-A10 (³ 10% rings) was 
washed and resuspended in 220  µL 1× Cytomix. This mixture was then added to 50 μg 
of plasmid DNA and electroporated at a voltage of 0.31 kV and capacitance of 950 µF 
using a Gene-Pulser (Bio-Rad) 319. Starting on the day after the transfections, the cultures 
were maintained in 2.5 nM WR99210 until recrudescence 320. Successful gene editing 
was assessed via Sanger sequencing of products PCR amplified from bulk cultures. 
Edited parasite clones were obtained by limiting dilution. Successful gene tagging was 
confirmed via PCR, Sanger sequencing immunofluorescence and immune-EM assays. 
Oligonucleotide primers used in this study are listed in Table 2.1 below.
52
 
Table 2. 1. | Oligonucleotides used in this study. 
--: No oligonucleotides
Experiment Nucleotide Sequence (5' to 3') Description Lab name
GGGAAATAACTATGGAATATAAAAAAACAG ABCI3 L690I donor fragment fwd p6417
GTTGTGTCGAAGAGGTATCATGGG ABCI3 L690I donor fragment rev p6418
GTTTCGATATAAATAAAGAG ABCI3 L690I guide RNA p6387/p6388 
GACAAACAAAATGACGAATG ABCI3 F689C guide RNA (1) p8159/p8160
GTTTCGATATAAATAAAGAG ABCI3 F689C guide RNA (2) p8165/p8166
GAGGTACCGAGCTCGaattcCAGATGAAAAGGAGTATCAGG ABCI3 F689C/S696Y donor 
fragment fwd (In-Fusion)
p8161





ABCI3 RHR forward --
GGGTATTAGACCTAGGGATAACAGGGTAATGGAAAAATATAAAAAAT
GAAACTACACC
ABCI3 RHR reverse --
GTTTAACGACAAAGATATCG sgRNA target site --
ATTGCTTTAATGAGTTACAT ABCI3 3' tagging guide RNA p7421/p7422
AGAGGTACCGAGCTCGaattcCTCATCTCACCAGAAGATATG ABCI3 3' donor fragment fwd p7423
CGAAAAGTGCCACCTGacgtcTCTACAACTATATAAGAAACTCC ABCI3 3' donor fragment rev p7424
GCAGAAAATTTATATTTTCAAAGTGGAGATTATAAAGATCATGATGGA
GATTATAAAGATCATGATATAGATTATAAAGATGATGATGATAAAtaa
TEV + 3×Flag tag fragment --
TACCCATACGATGTTCCTGACTATGCTGGTTATCCTTATGACGTGCCTG
ACTATGCAGGATCCTATCCATATGACGTTCCAGATTACGCT
3×HA tag fragment --
--: No oligonucleotides
Table S3. Oligonucleotides used in this study.
L690I validation 
in 3D7-A10 












A10 (related to 
Fig. S5) 
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2.2.5. Generation of cKD parasite lines. 
We utilized CRISPR-Cas9 to modify the native PfABCI3 (PF3D7_0319700) locus and 
install the linearized pSN054 donor vector 321, which incorporates a 10× aptamer array 
and the TetR-DOZI expression cassette containing the blasticidin S-deaminase gene, the 
reporter gene Renilla luciferase (RLuc), and the fusion proteins TetR-DOZI 322. The right 
homology region (RHR; 264 bp) was PCR amplified and inserted into the pSN054 vector 
using the I-SceI restriction site. Fragments corresponding to the left homology region 
(LHR; 426 bp) fused to the re-codonized 3'-end of the gene (bp 9991-10092) without the 
stop codon as well as the target-specifying guide RNA sequence were synthesized using 
the BioXP™ 3200 System (SGI-DNA) and cloned into the pSN054 vector using restriction 
sites FseI/AsisI and AflII, respectively. Donor vector generation was carried out via 
Gibson assembly, and the final construct was confirmed by restriction digests and Sanger 
sequencing. Transfection into Cas9- and T7 RNA polymerase-expressing NF54 parasites 
was carried out by preloading erythrocytes with the donor vector as described previously 
323. Cultures were maintained in 500 nM anhydrotetracycline (aTc; Sigma-Aldrich 37919)
and the selectable drug 2.5 mg/mL of Blasticidin (RPI Corp B12150-0.1), and recovered 
parasites were monitored via Giemsa smears and RLuc measurements.  
2.2.6. Parasite growth assays. 
To assess the effect of knocking down the expression of the ABCI3 protein on the viability 
of parasites, synchronous ring-stage parasites were cultured in the presence (50 nM) and 
absence of aTc and set up in triplicate in a 96-well U-bottom plate (Corning 62406-121). 
Luminescence was measured at 0, 72, and 120 h post-invasion using the Renilla-Glo(R) 
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Luciferase Assay System (Promega, E2750) and the GloMax Discover Multimode 
Microplate Reader (Promega). The luminescence values were normalized to CQ-treated 
(200 nM) samples and results were visualized on a scatter plot using GraphPad Prism 
(version 8; GraphPad Software).  
 
2.2.7. Compound susceptibility assays.  
Compound susceptibility of the cKD parasites was assessed as described above. 
Compounds were assayed using 2-fold dilutions with inhibition measured after 56 h. 
Parasite viability was determined by staining the parasites with SYBR Green and 
MitoTracker Deep Red (Life Technologies) followed by flow cytometry (Accuri C6, BD 
Biosciences) 306. IC50 values were derived by nonlinear regression (Prism 7, GraphPad). 
 
2.2.8. Immunofluorescence assays.  
Indirect Immunofluorescence assays (IFAs) were performed in suspension as described 
193. Briefly, parasites were fixed in 4% (v/v) formaldehyde (Thermo Fisher Scientific) for 1 
h at room temperature. This was followed by a second fixation step that supplemented 
the 4% formaldehyde solution with 1 mM cysteine and CaCl2 followed by an overnight 
incubation at 4°C. Cells were then permeabilized on ice using 0.05% Triton X-100 in 
1´PBS for 5 min. Autofluorescence was quenched using a 50 mM glycine treatment for 
10 min. After two washes in 1´ PBS the cells were resuspended in 1% (w/v) bovine serum 
albumin (BSA) in 1´PBS blocking buffer and incubated with the appropriate dilution for 
each primary antibody used: 1:200 for rabbit or mouse anti-Flag (Genscript), rabbit anti-
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ERD2 (BEI Recourses), rabbit anti-BiP (kindly provided by Min Zhang), 1:50 for rat anti-
Rab5B and Rab7 (kindly provided by Gordon Langsley) and 1:200 for anti-PfCRT 
antibodies. This was followed by incubation with the corresponding species-specific 
secondary antibodies (Alexa Fluor 488-, 594- or 647- conjugated goat anti mouse or 
rabbit antibodies; Thermo Fisher) diluted 1:2000 in 1% BSA in 1´ PBS. Thin blood smears 
of stained RBCs were prepared on microscope slides and mounted with cover slips using 
Prolong Diamond Antifade Mount with DAPI (Thermo Fisher). Parasites were imaged 
using a Nikon Eclipse Ti-E wide-field microscope equipped with a sCMOS camera 
(Andor) and a Plan-apochromate oil immersion objective with 100× magnification (1.4 
numerical aperture). A minimum of 27 Z stacks (0.2 μm step size) were photographed for 
each parasitized RBC. NIS-Elements imaging software (Version 5.02, Nikon) was used 
to control the microscope and camera as well as to deconvolve the images (using 25 
iterations of the Richardson-Lucy algorithm for each image). ImageJ (Fiji) (version 2.0.0-
rc-68/1.52 h) was used to crop the images, adjust brightness and intensity, overlay 
channels and prepare montages. 
2.2.9. Measurement of drug cellular accumulation using the inoculum effect 
analysis.  
In the absence of radioactively labelled compounds, we measured the drug cellular 
accumulation using the inoculum effect 324. Briefly, highly synchronized 3D7-A10, ABCI3 
3 copies (resistant to 1) and ABCI3 L690I ed. (resistant to 4) parasite lines were exposed to 
serially diluted MMV compounds or CQ at parasitemia ranging from 0.25% - 4%. The 
inoculum size, which ranged from 0.75 - 6 was calculated as the parasitemia ´ hematocrit 
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324. The measure of absolute drug potency was achieved by extrapolating the linear 
relationship between the increasing inoculum size and IC50 to an inoculum size of zero 
from the following equation: IC50 measured = IC50 absolute + (IC50 absolute ´ 
accumulation ratio ´ fractional volume of parasitized erythrocytes, PRBCs) 324. The 
mathematical relationship for the determination of the cellular drug accumulation ratio 
(CAR): CAR = (IC50 measured − IC50 absolute)/(IC50 absolute ´ fractional volume of 
PRBCs) has been previously reported 325. This ratio represents the amount of drug in the 
infected cell pellet to the amount of drug in a similar volume of medium.  
 
2.2.10. Immuno-electron microscopy.  
To immunolocalize HA-tagged ABCI3, P. falciparum cultures were fixed in 4% 
paraformaldehyde (Polysciences Inc., Warrington, PA) in 100 mM PIPES/0.5 mM MgCl2, 
pH 7.2 for 1 h at 4°C. Samples were then embedded in 10% gelatin and infiltrated 
overnight with 2.3 M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C. Samples 
were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut UCT7 cryo-
ultramicrotome (Leica Microsystems Inc., Bannockburn, IL). 50 nm sections were blocked 
with 5% fetal bovine serum (FBS)/5% normal goat serum (NGS) for 30 min and 
subsequently incubated with rabbit anti-HA antibody (Sigma, St. Louis, MO) at 1:100 for 
1 h, followed by secondary anti-rabbit IgG antibody conjugated to 18 nm colloidal gold 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 1 h. Sections were 
stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission 
electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel 
digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy 
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Techniques, Woburn, MA). All labeling experiments were conducted in parallel with 
controls omitting the primary antibody. These controls were consistently negative at the 
concentration of colloidal gold conjugated secondary antibodies used in these studies. 
 
 2.2.11. Detergent-based β-hematin Inhibition Assay (βHIA). 
A solution containing water + 305.5 µM Nonidet P-40 (NP-40) + DMSO at a v/v ratio of 
70% + 20% + 10%, respectively, was prepared and 100 μL added to all wells in columns 
1-11 in a flat-bottomed 96-well plate. Working stocks of test compounds and controls were 
constituted to 10 mM from which 20 μL of each was added to wells in the final column 
(column 12) together with distilled water (140 μL) and 305.5 µM NP-40 detergent (40 μL). 
This effectively lowered the final drug concentration to 1mM. Serial dilution of each 
compound (100 μL) from column 12 to column 2 was carried out (column 1 served as a 
blank). A 25 mM hematin stock solution was prepared by sonicating hemin in DMSO for 
3 mins and 178.8 μL of this suspended in 20 mL acetate buffer (1 M, pH 4.8) and 
thoroughly mixed. The homogenous suspension (100 μL) was then added to all wells to 
give final hematin concentrations of 100 mM and final drug concentration of 0.5 mM in 
column 12. Plates were covered and incubated at 37 °C for 5 h after which 32 µL of 50% 
pyridine solution (20% (v/v) H2O, 20% (v/v) acetone and 2 M HEPES buffer (pH 7.4) and 
50% pyridine) was added to each well to give a final pyridine concentration of 5% (v/v). 
Acetone (60 µL) was then added to assist with hematin dispersion. The UV-vis 
absorbance of the plate wells was read at 405 nm on a SpectraMax P340 plate reader. 
The βH inhibitory IC50 values for each compound were computed from the blank-
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corrected absorbance values at 405 nm using a sigmoidal dose-response curve fitting 
analysis on GraphPad Prism software (GraphPad Prism 9, La Jolla, USA). 
 
2.2.12. Cellular heme fractionation assays.  
Baseline NF54 parasite sensitivity to compounds 1, 3, 4, 5, CQ and pyrimethamine was 
determined using a standard 72 h SYBR Green chemosensitivity assay. The IC50 values 
were used to set up the heme fractionation experiment as described elsewhere 93,326. 
Briefly, ring-stage NF54 parasites were synchronized by treating them for two cycles 
using 5% sorbitol. The ~3-5 h old parasites were then incubated in a gradient of IC50 
concentrations (based on the 72 h chemosensitivity assay) ranging from 0.5-4× at 5% 
parasitemia and 2% hematocrit. A no-drug control was included. After 28 h, late 
trophozoites were harvested by lysis of the red blood cells with 0.05% saponin followed 
by multiple washes with 1× PBS (pH 7.5) to remove traces of RBC Hb. Pellets were then 
resuspended in 1× PBS (pH 7.5) and an aliquot of the trophozoite suspension used to 
quantify the total number of trophozoites isolated using flow cytometry with parasites 
stained with 1´ SYBR Green and 100 nM MitoTracker Deep Red. Contents of the 
remaining trophozoite pellet were then released by hypotonic lysis and sonication. The 
fractions corresponding to digested Hb, free heme and Hz were then carefully recovered 
through centrifugation and treatment with HEPES buffer (pH 7.4), 4% SDS, 25% pyridine 
solution, 0.3M HCl and 0.3M NaOH. The UV−visible spectrum of each heme fraction as 
an Fe(III)heme−pyridine complex was measured using a multi-well SpectraMax P340 
plate reader. The total amount of each heme species was quantified using a heme 
standard curve where the mass of each heme-Fe species per trophozoite (fg/cell) was 
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calculated by dividing the total amount of each heme species by the corresponding 
number of parasites in that fraction, as determined by flow cytometry. Statistical 
comparisons and analyses for trends were made using prism (Prism 9, GraphPad) using 
Students’ t-test with Welch correction. 
2.3. Experimental Procedures for Chapter 5 
2.3.1. Synthesis of MMV688533. 
Step 1. Pd(PPh3)2Cl2 (4.96 g, 7.07 mmol) and cuprous iodide (1.34 g, 7.06 mmol) were 
added to a degassed solution of methyl 3-bromo-5-(trifluoromethyl)benzoate (20.0 g, 70.67 
mmol) and trimethylsilylacetylene (17.4 g, 176.67 mmol) in 100 mL of acetonitrile in a sealed 
tube. The tube was degassed again and heated at 70 °C for 2 h.  The reaction mixture was 
cooled and filtered through a celite bed. The filtrate was concentrated in vacuum and the 
residue purified through silica gel (60-120 mesh) column chromatography using petroleum 
ether to generate a 3-Trifluoromethyl-5-trimethylsilanylethynyl-benzoic acid methyl ester (14 
g, yield 66 %) as yellow liquid. 
Step 2.  Potassium carbonate (0.58 g 4.2 mmol) was added to a solution of 3-
Trifluoromethyl-5-trimethylsilanylethynyl-benzoic acid 2-methyl ester (14.0 g, 46.60 mmol) 
in 50 mL methanol and stirred at room temperature for 20 minutes. The reaction mixture 
was concentrated under reduced pressure.  The residue was diluted with 100 mL ethyl 
acetate, washed with water and brine and dried over anhydrous sodium sulphate and 
concentrated to yield 3-Ethynyl-5-trifluoromethyl-benzoic acid methyl ester (11 g, yield 61%) 
as a brown liquid. 
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Step 3. Lithium hydroxide (6.0 g, 144.10 mmol) was added to an ice cooled solution of 3-
Ethynyl-5-trifluoromethyl-benzoic acid methyl ester (11.0 g, 48.03 mmol) in 50 mL 
tetrahydrofuran and 25 mL water and stirred at room temperature for 3 h. The reaction 
mixture was concentrated and acidified with aqueous citric acid solution. The precipitated 
solid was filtered, washed with water and dried to generate 3-Ethynyl-5-trifluoromethyl-
benzoic acid (9.2 g, yield 78%) as pale brown solid. 
Step 4. Dicyclohexylcarbodiimide (13.28 g, 64.48 mmol) and pentafluorophenol (11.8 g, 
64.48 mmol) in 50 mL tetrahydrofuran was added to a solution of 3-Ethynyl-5-trifluoromethyl-
benzoic acid (9.2 g, 42.99 mmol) and stirred at room temperature for 3 h. Upon the 
completion of the reaction, the mixture was cooled in an ice bath and the precipitated 
dicyclohexylurea removed by filtration. The filtrate was concentrated and purified using a 
silica gel (60-120 mesh) column chromatography using ethyl acetate in petroleum ether, 
producing 3-Ethynyl-5-trifluoromethyl-benzoic acid pentafluorophenyl ester (13.6 g, yield 
83%) as an off-white solid. 
Step 5.  Monobocguanidine (6.82 g, 42.94 mmol) was added to a solution of 3-Ethynyl-5-
trifluoromethyl-benzoic acid pentafluorophenyl ester (13.6 g, 35.78 mmol) in 50 mL 
tetrahydrofuran and stirred at room temperature for 4 h. After the completion of the reaction, 
the mixture was evaporated and purified through silica gel (60-120 mesh) column 
chromatography using ethyl acetate in petroleum ether to generate tert-butylN-[N-[3-ethynyl-
5-(trifluoromethyl)benzoyl] carbami-midoyl]carbamate (8.2 g, yield 64 %) as an off white 
solid. 
Step 6:  10 mL of concentrated H2SO4 was added dropwise to a solution of 5-bromo-2-
iodobenzoic acid (100 g, 305.89 mmol) in 800 mL MeOH. The mixture was refluxed for 16 
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h and then concentrated. The residue was dissolved in 1 L ethyl acetate. The organic layer 
was washed with saturated NaHCO3 and 3 ´ 200 mL brine, dried over Na2SO4, filtered and 
concentrated to generate 5-Bromo-2-iodo-benzoic acid methyl ester (101.4 g, yield 90%) as 
yellow solid.  
Step 7. Copper (I) bromide (1.21g, 8.45 mmol) was added to a solution of 5-Bromo-2-iodo-
benzoic acid methyl ester (24 g, 70.4 mmol) and methyl 2,2-difluoro-2-
(fluorosulfonyl)acetate (13.5 mL, 105.6 mmol) in 80 mL N-methyl-2-pyrrolidinone. The 
reaction mixture was stirred at 100 °C for 5 h. The reaction was filtered and partitioned 
between ethyl acetate and brine. The aqueous layer was extracted with ethyl acetate, and 
the organic layers were combined and dried over Na2SO4. After filtration, the solvent was 
removed in vacuo. The residue was purified by silica gel column (0-4% Ethyl acetate in 
Petroleum ether) to give the 5-Bromo-2-trifluoromethyl-benzoic acid methyl ester (119.2 g, 
yield 96%) as yellow oil.  
Step 8.  Lithium hydroxide (4.4 g, 104.76 mmol) was added to an ice cooled solution of 5-
Bromo-2-trifluoromethyl-benzoic acid methyl ester (9.1 g, 35.68 mmol) in 20 mL 
tetrahydrofuran and 10 mL water and stirred at room temperature for 3 h.  The reaction 
mixture was concentrated and acidified with aqueous citric acid solution. The precipitated 
solid was filtered, washed with water and dried to produce 5-Bromo-2-trifluoromethyl-
benzoic acid (8 g, yield 95%) as pale yellow solid. 
Step 9. 5-Bromo-2-trifluoromethyl-benzoic acid (8.0 g, 29.74 mmol) in 40 mL thionyl chloride 
solution was heated to reflux for 3 h. The completion of reaction (conversion of acid chloride 
to methyl ester) was observed by thin layer chromatography (TLC). Thionyl chloride was 
evaporated and the residue added to the reaction mixture containing 2-amino pyridine (3.2 
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g, 32.71 mmol), triethyl amine (12.44 mL, 89.21 mmol) in dry 80 mL ethyl acetate at 0 ºC.  
The reaction mixture was stirred at room temperature for 12h. Reaction completion was 
observed by TLC.  The reaction mixture was then added to 200 mL water and extracted with 
2 × 200 mL ethyl acetate. The combined organic layer was washed with 2 × 100 mL water, 
brine, dried over sodium sulphate and evaporated. The crude material was purified by 
column chromatography using ethyl acetate in petroleum ether to generate 5-Bromo-N-
pyridin-2-yl-2-trifluoromethyl-benzamide (5.1 g, yield 49%) as off white solid. 
Step 10. 5-Bromo-N-pyridin-2-yl-2-trifluoromethyl-benzamide intermediate (0.690 kg, 2 
mol.), CuI (0.019 kg, 0.1 mol.), Pd(PPh3)2Cl2 (0.140 kg, 0.2 mol.) and acetonitrile  were 
mixed in a 6 L reactor under nitrogen. Tert-butyl N-[N-[3-ethynyl-5-
(trifluoromethyl)benzoyl]carbamimidoyl]carbamate intermediate (0.924 kg, 2.6 mol) was 
added in 5 min on the suspension while stirring at 25 °C. The mixture was degassed under 
nitrogen bubbling for an additional 30 min while still stirring. Triethylamine (0.605 kg, 5.98 
mol) was added in 17 min at 25 °C. An exotherm of  + 6 °C was observed. The dropping 
funnel was washed with 0.5 L acetonitrile. The reaction mixture was heated at 45 °C and 
maintained for 2 h until tert-butyl N-[N-[3-ethynyl-5-(trifluoromethyl)benzoyl]-
carbamimidoyl]carbamate was < 1%. The suspension was then cooled to 10 °C at the rate 
of – 20 °C/h and maintained for 1 h. The expected intermediate tert-butyl N-[N-[3-[2-[3-(2-
pyridyl-carbamoyl)-4-(trifluoromethyl)phenyl]ethynyl]-5-(trifluoromethyl)benzoyl]-carba-
mimidoyl] carbamate was filtered and the cake was washed with 1.4 L acetonitrile followed 
by 0.7 L water. After drying by nitrogen flux overnight at 0.3 bar, tert-butyl N-[N-[3-[2-[3-(2-
pyridylcarbamoyl)-4-(trifluoromethyl)phenyl]ethynyl]-5-
(trifluoromethyl)benzoyl]carbamimidoyl]-carbamate was isolated (0.745 kg, yield 60%). 
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Step 11. A suspension of tert-butyl N-[N-[3-[2-[3-(2-pyridylcarbamoyl)-4-(trifluoromethyl) 
phenyl]-ethynyl]-5-trifluoromethyl)benzoyl]carbamimidoyl]carbamate (1.5 kg, 2.42 mol)  in 
14.5 L  ethyl acetate  was heated at 70 °C while stirring. Trifluoroacetic acid (2.2 kg, 19.30 
mol) was added in 30 min at 70 °C. The dropping funnel was washed with 0.75 L ethyl. The 
reaction mixture was maintained for 22 h at 70 °C until tert-butyl N-[N-[3-[2-[3-(2-
pyridylcarbamoyl)-4-(trifluoromethyl)-phenyl]ethynyl]-5-
(trifluoromethyl)benzoyl]carbamimidoyl]carbamate was < 1%. After cooling at 20 °C the 
mixture was basified by addition of a solution of 28% NH4OH in 1 h until pH was between 9-
10. After an additional 15 min stirring, 11.3 L water were added and the phases separated. 
The organic layer was diluted with 45 L, 30 vol ethyl acetate and washed successively with 
an aqueous solution of sodium metabisulfite (Na2S2O5 0.15 kg in 15 L water) and 15 L water. 
An additional treatment with charcoal (Darco S51) was done. 56.37 kg of ethyl acetate 
solution was used for the next salification step. 
Step 12. A part of the previous acetate solution of 5-((3-(carbamimidoylcarbamoyl)-5-
(trifluoro-methyl)phenyl)ethynyl)-N-(pyridin-2-yl)-2-(trifluoromethyl)benzamide (0.958 kg, 
1.844 mol,), which was estimated to be pure, was concentrated under a reduced pressure 
of 100 mbars and at 50 °C into 10 vol of ethyl acetate. An additional azeotropic drying was 
realized with 15 vol ethyl acetate. The obtained 10 vol solution was heated at 50 °C, and 
then a seeding with 2% of 5-((3-(carbamimidoylcarbamoyl)-5-
(trifluoromethyl)phenyl)ethynyl)-N-(pyridin-2-yl)-2-(trifluorom-ethyl)-benzamide malonic acid  
was done. A solution of malonic acid (0.192 kg, 1.144 mol.) in 2.8 L ethyl acetate was added 
in 30 min at 50 °C. The dropping funnel was washed with 0.4 L ethyl acetate and 
crystallization was observed during the addition of the acid. Stirring was maintained for 1 h 
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at 50 °C and cooled to 10 °C at the rate of -20 °C/h. 5-((3-(carbamimidoylcarbamoyl)-5-
(trifluoromethyl) phenyl)ethynyl)-N-(pyridin-2-yl)-2-(trifluoromethyl) benzamide malonic acid 
was isolated by a fast filtration and the cake was washed twice with 1 L ethyl acetate. The 
product was dried under nitrogen flux overnight to generate 5-((3-
(carbamimidoylcarbamoyl)-5-(trifluoromethyl) phenyl)ethynyl)-N-(pyridin-2-yl)-2-
(trifluoromethyl)benzamide malonic acid compound (1.096 kg,  yield of 95.3%). 
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2.3.1.1. Nuclear magnetic resonance (NMR) and mass spectrometry (MS) analysis. 
1H NMR and 13C NMR data were recorded on a Bruker 400MHz AVANCE series or 
Bruker300 MHz DPX Spectrometer with CDCl3 or DMSO-d6 or CD3OD as solvent. 1H 
chemical shifts were referenced at 7.26 ppm for CDCl3, 2.5 ppm for DMSO-d6 and 3.3 ppm 
for CD3OD. 13C chemical shifts were referenced at 77 ppm for CDCl3, 39 ppm for DMSO-
d6 and 44 ppm for CD3OD, and obtained with 1H decoupling. Multiplicities are abbreviated 
as follows: singlet (s), doublet (d), triplet (t), quartet (q), doublet-doublet (dd), quintet (quint), 
sextet (sextet), septet (septet), multiplet (m), and broad (br). 
 
MS data were measured on Agilent 1200/1260 Series LC/MSD mass spectrometer with the 
following settings. Column: Zorbax XDB C18 (50 × 4.6) mm, 5µm or Acquity BEH C18 (50 
× 2,1 mm; 1.7 µm). Mobile phase: Solvent A: 0.1% Formic Acid in Milli-Q water (or) 0.1% 
Trifluoroacetic acid in Milli-Q-water. Solvent B: Acetonitrile. Flow rate: 1.5 mL/min. Injection 
Volume: 2 µL. Wavelength: Maximum chromatogram (210-400nm). Run time: 6.0 
min.  Ionization source: Multi-mode (ESI and APCI). Purity was measured on an Agilent 
1200/1260 Series HPLC spectrometer. Column: C18 (250 × 4.6) mm, 5µm (or) C18 (150 × 
4.6) mm, 5µm. Mobile phase: Solvent A: 10 mM ammonium acetate in Milli-Q water (or) 
0.1% Trifluoroacetic acid in Milli-Q-water; Solvent B: Acetonitrile. Flow rate: 1.0mL/min. 
Injection Volume: 2 µL. Wavelength: Maximum chromatogram (210-400 nm). Run time: 30 
min.    
 
For compound 1c, MS data were measured with UPLC-SQD (Simple Quad, from Waters). 
Column: Acquity BEH C18 (50 × 2,1 mm; 1.7 µm). Mobile phase: Solvent A: H2O+0.05% 
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TFA; Solvent B: CH3CN+0.035% TFA. Flow rate; 1 mL/min. UV Detection: l = 220 nm. MS 
detection (Simple Quad) ionization: ESI + Electrospray First / Last Mass (uma) FS: 160 / 
1200 uma. Capillary voltage (KV): 3.5.Cone. (V): 20. Source Temperature: 150°C. 
Desolvation temperature: 500°C. Desolvation gas flow (L/h): 1200. Cone gas flow (L/h): 100. 
LM 1 resolution: 13.00. HM1 resolution: 13.00. Ion energy1: 0.20.  
For the intermediate 5-Bromo-2-iodo-benzoic acid methyl ester (step 6), LC-MS was 
measured as follows: Column: XBridge C18,4.6*50mm, 3.5 µm Mobile phase: 10 mM 
NH4HCO3 (A) / acetonitrile (B). Elution program: Gradient from 5 to 95% of B in 1.6 min 
at 1.8 mL/min. Temperature: 50ºC. Detection: UV (214, 4 nm). MS: ESI, Positve mode, 
110 to 1000 amu. 
 
2.3.2. Compound potency against P. falciparum and P. vivax parasites. 
Antimalarial activity against resistant culture-adapted strains of P. falciparum and clinical 
field isolates was performed with the modified [3H]-hypoxanthine incorporation assay, as 
previously reported 327. MMV688533 (Sanofi, Toulouse, France) and the reference 
antimalarial drugs chloroquine, piperaquine, mefloquine, and artesunate (provided by the 
WWARN QA/QC Reference Material Programme), were prepared as 1 mg/mL stock 
solutions in dimethyl sulfoxide (DMSO) or H2O according to the manufacturers’ instructions. 
Drug plates were pre-dosed by diluting the compounds in 50% methanol followed by 




2.3.2.1. Field location and sample collection.  
In Papua Indonesia, Plasmodium isolates were collected from patients attending malaria 
clinics in Timika, a region endemic for multidrug-resistant strains of P. vivax and P. 
falciparum 328,329. Patients with symptomatic malaria were recruited into the study if singly 
infected with P. falciparum or P. vivax, with a parasitemia of between 2,000 and 80,000 
parasites per μL, and a majority (>60%) of parasites present as rings. Venous blood (5 mL) 
was collected by venipuncture and host white blood cells were removed with Plasmodipur 
filters (EuroProxima B.V., The Netherlands). Packed infected RBCs were then used for ex 
vivo drug susceptibility assays. In Uganda, Plasmodium isolates were collected from 
patients aged 6 months or older presenting to the Tororo District Hospital, Tororo District, 
or Masafu Hospital in the Busia District, with a clinical syndrome suggestive of malaria and 
Plasmodium falciparum parasites identified in blood by microscopy. Informed consent was 
obtained from patients and/or primary care givers (depending on age). 
 
2.3.2.2. Ex vivo drug susceptibility assays.  
In Papua Indonesia, drug susceptibility was measured in P. vivax and P. falciparum isolates 
using a protocol modified from the WHO microtest 254,329,330. In brief, 200 μL of a 2% 
hematocrit of blood media mixture, consisting of RPMI 1640 medium plus 10% AB+ human 
serum for P. falciparum or McCoy’s 5A medium plus 20% AB+ human serum for P. vivax 
was added to each well of pre-dosed drug plates containing 11 serial concentrations (2-fold 
dilutions) of the test antimalarials (maximum concentration shown in brackets) chloroquine 
(2,993 nM), piperaquine (1,029 nM), mefloquine (338 nM), artesunate (49 nM), and 
MMV688533 (237 nM). A candle jar was used to mature the parasites at 37 °C for 35-56 h. 
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Incubations were stopped when >40% of the ring-stage parasites had reached the mature 
schizont stage in the drug-free control wells, as determined by light microscopy. Parasite 
growth was quantified by nucleic acid staining and parasitemias were measured using flow 
cytometry. Parasite growth was quantified for each drug concentration and normalized to 
the control well. The dose-response data were analyzed using nonlinear regression 
analysis and the half-maximal inhibition of growth (IC50) values derived using an inhibitory 
sigmoid Emax model (In Vitro Analysis and Reporting Tool; IVART7). Ex vivo IC50 data were 
only used from predicted curves where the Emax and E0 were within 15% of 100 and 1, 
respectively. The drug plate quality was assured by running schizont maturation assays 
with the P. falciparum chloroquine-resistant strain K1 and the chloroquine-sensitive strain 
FC27. For data quality control, raw flow cytometry values were analyzed by two 
independent operators and compared. If the raw dose-response data derived by the two 
operators led to a dramatic shift in IC50 estimates for any of the drugs, they were reviewed 
and adjusted by a third operator. Ethical approval for this study was obtained from the 
Eijkman Institute Research Ethics Commission of the Eijkman Institute for Molecular 
Biology, Jakarta, Indonesia; the Human Research Ethics Committee of the Northern 
Territory Department of Health & Families; and the Menzies School of Health Research, 
Darwin, Australia. 
 
In Africa, drug susceptibility was measured in P. vivax and P. falciparum isolates using a 
protocol summarized as follows: All MMV compounds were dissolved in DMSO to a final 
concentration of 0.5-10 mM and stored at -20°C. On the day of assay, 2 µL of DMSO 
stocks drug were diluted in 498 µL complete RPMI media (RPMI 1640 medium 
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supplemented with 25 mM HEPES, 0.2% NaHCO3, 0.1 mM hypoxanthine, 100 µg/mL 
gentamicin, and 0.5% Albumax I [Invitrogen]). Diluted drugs were not stored for longer 
than 24 h. Drugs were serially diluted 3-fold in 96-well assay plates in complete media 
containing 0.4% DMSO, to a final volume of 50 µL, in columns 1-10. Column 11 contained 
drug-free controls while column 12 contained uninfected RBC controls. Parasitized whole 
blood samples were washed 3 times with RPMI (w/o Albumax) media at 37 °C and then 
resuspended in fresh RPMI media to a final hematocrit of 2%. 150 µL of the parasite 
culture was added to each well into the assay plate for final parameters of 0.2% 
parasitemia and 2% hematocrit. Plates were incubated for 72 h in a humidified modular 
incubator under a tri-gas mixture (5% O2, 5% CO2, 90% N2) at 37 °C. Plates were then 
stained with SYBR Green I and fluorescence determined using a BMG Fluostar Optima 
plate reader at excitation 485 nm / emission 530 nm 331. Fluorescence data were curve 
fitted to estimate IC50 values (GraphPad Prism 7). For each isolate, a Z’ factor was 
calculated from drug-free positive and negative controls (8 parasitized RBC wells and 8 
uninfected RBC wells, respectively). 
 
2.3.3. Determination of the in vitro rate of killing (parasite reduction ratio, PRR).  
As described in 332, the compound IC50 was determined via [3H]-hypoxanthine incorporation. 
For PRR assays, 105 3D7A parasites cultures were exposed to MMV688533 at 10×IC50 for 
120 h. Drug treatment was renewed every 24 h over the entire period. Parasite aliquots 
were taken from the treated cultures every 24 h, with drug washout, throughout the 5-day 
treatment period. Fresh RBC and new media were then added to the drug-free parasites, 
which were serially diluted in quadruplicate into 96 well plates. Growth in individual wells 
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was detected after 3 and 4 weeks using [3H]-hypoxanthine incorporation. The number of 
viable parasites was determined by the dilution down to which growth was observed. The 
rate of killing was represented by the log of viable parasites as a function of treatment 
duration. PRR was defined as the log-linear reduction of viable parasites over 48 h. 
 
2.3.4. Determination of efficacy and pharmacokinetic profiles in the P. falciparum 
SCID mouse model.  
Immunodeficient female NSG or NOG mice were engrafted with a minimum of 40% human 
erythrocytes circulating in peripheral blood during the entire experiment. Each mouse was 
inoculated with a 50%-75% hematocrit erythrocyte suspension (Basque Center of 
Transfusion and Human Tissues, Galdakao, Spain and Bank of Blood and Tissues, 
Barcelona, Spain) in RPMI1640 medium, 25% (vol/vol) decomplemented human serum, 
3.1 mM hypoxanthine. Intraperitoneal (i.p.) and/or intravenous (i.v., via tail lateral vein) 
injections were done once daily until the end of the drug administration period. Humanized 
NSG or NOG mice were infected with peripheral blood from CO2-euthanized donor mice 
harboring 5-10% parasitemia. The humanized mice of the efficacy study were infected by 
inoculation of 0.3 mL of the infected-erythrocyte suspension by the lateral vein of the tail. 
For treatment, drug was administered at Day 1 (~1% patent parasitemia) (P0) by oral 
gavage (volume p.o. is 10 mL/kg body weight). To measure the therapeutic response, 2 μL 
peripheral tail blood from P. falciparum-infected mice were stained with TER-119-
Phycoerythrine (marker of murine erythrocytes) and SYTO-16 (nucleic acid dye) and 
analyzed by flow cytometry (Attune NxT Acoustic Focusing Flow Cytometer, Invitrogen). 
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Drug effect on circulating P. falciparum Pf3D70087/N9 parasites was assessed by 
microscopy (Giemsa-stained blood smears; 2 μL blood samples taken at 48 h and 96 h).  
 
To assess the drug concentrations in mice, 25 μL samples of peripheral blood were taken 
at different times (usually 0.5, 1, 2, 4, 6 or 8 h and 23 h after the first dosing), mixed with 25 
μL of MilliQ H2O and immediately frozen on a thermal block at -80º C. The treated mice that 
reached the limit of detection by standard flow cytometry (<0.01% from total circulating 
erythrocytes) were maintained until day 60 of the assay with a chimerism >50% of total 
circulating erythrocytes by regular injection of human erythrocytes every 3 or 4 days. During 
the follow up period, 2 μL blood samples were taken every 2 or 3 days and analyzed by 
flow cytometry with a limit of quantification of 0.1%. The first day of parasitemia detection 
was recorded. The mice were deemed cured (free of detectable parasite) if no 
recrudescence was detected by day 60. 
 
As biological controls; a) parasite growth in untreated and/or vehicle-treated individuals was 
evaluated from day 1 to 5; b) the parasite burden was measured from day 1 to 5 of the 
assay in individuals treated with a fixed dose of a standard antimalarial; and c) the 
distribution of parasitemia at day 1 of the assay for all individual mice tested in the assay 
was compared to parasitemia distributions in previous experiments. 
 
For data analysis, ED90 and AUCED90 were defined and calculated according to 333. ED90 is 
the effective dose in mg/kg that reduced parasitemia by 90% at day 5 compared to vehicle-
treated mice. AUCED90 is the average estimated daily exposure that reduced parasitemia 
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from peripheral blood at day 5 of the assay by 90% compared to vehicle-treated mice. The 
ED90 was calculated by fitting the variable Y= log10 [parasitemia at day 5 of the assay] and 
the variable X= log10 [dose level in mg/kg] defined as an ordered pair for every individual of 
the study. The AUCED90 was calculated by fitting the variable Y= log10 [parasitemia at day 5 
of the assay] and the variable X= log10 [AUC of compound during the first 23 h after the first 
drug administration, in ng·h/mL] defined as an ordered pair for every individual of the study. 
The equation used to fit the data is Y=Bottom + (Top-Bottom)/(1+10((LogED50-X)×Hill 
Slope)). The ED90 and AUCED90 were calculated by interpolation of the X value that 
corresponded to antilog10 [Y= “Top”-1] in each respective best fitted curve 333.  
 
The time in days (te) and the average concentration in blood (C, in ng/mL) for killing all P. 
falciparum parasites in mice were interpolated from a multivariate logistic regression. The 
fitted function links the dichotomic response variable Therapeutic response (Tr), which 
takes Tri=0 if an individual shows recrudescence and Tri=1 if no recrudescence was 
detected at day 60 of the assay, and the explanatory variables te and C. These parameters 
offered direct empirical estimates of the time of exposure and concentration in blood to at 
least kill a defined number of circulating parasites, which was typically 108 per mouse. The 
regression formular is as follows: (!"=1|#$,)= 11+ $−(%+&1#$+&2'). 
 
Data analysis was performed using GraphPad Prism 7.0 (GraphPad Software), Excel 
2016 (Microsoft) and R free software (https://www.r-project.org). Phoenix WinNonlin 
vers.7.0 (Certara) was used for PK Non-Compartmental Analysis. Animal experiments 
performed at TAD were approved by The Art of Discovery Institutional Animal Care and 
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Use Committee (TAD-IACUC). The Committee is certified by the Biscay County 
Government (Bizkaiko Foru Aldundia, Basque Country, Spain) to evaluate animal 
research projects from Spanish institutions according to point 43.3 from Royal Decree 
53/2013, from the 1st of February (BOE-A-2013-1337). All experiments were carried out 
in accordance with European Directive 2010/63/EU. The results from the animal 
experiments are reported following ARRIVE guidelines. (https://www.nc3rs.org.uk/arrive-
guidelines) except for disclosure of business trade confidential information. 
 
2.3.4.1. Prediction of the efficacious dose in humans based on P. falciparum SCID 
mouse PK/PD.  
The prediction of the first efficacious dose in human was based on: 1) minimum 
parasiticidal concentration (MPC) as evaluated from a population-based PK/PD modeling 
of experimental data from SCID mouse studies. At team at MMV used a NonMem 
software and another at Sanofi used a Monolix software to build a PK/PD model. Both 
teams reached a similar median estimate value of 20 ng/mL as the MPC; 2) Kkill of the 
compound as deduced from in vitro logPRR (5 in 48 h). However, a conservative 
approach was recommended by MMV to use a capped value of 3 based on values 
observed for endoperoxides when tested in human; 3) predicted human PK parameters 
as determined by an allometric approach. For the allometric scaling of clearance from 
animal data, two methods, Mahmood rules and Fixed exponent method, were used. 
These led to the prediction of a low to a very low MMV688533 clearance in humans 3.6 
and 1.4 L/h respectively, that corresponded to a total clearance of < 5% of hepatic blood 
flow. This in turn corresponded to a predicted half-life of 103 h and 277 h respectively in 
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humans. The volume of distribution (Vdss) relying on allometry method with an exponent 
of 1, was predicted to be as large as 540 L for 70 kg human; 4) biopharmaceutical model 
(GastroPlus) used to estimate Fa% vs dose in human and verified on Rat & Dog PK data. 
 
2.3.5. P. falciparum lines used for selections, drug assays and transfections.  
Asexual blood-stage parasites were cultured at 3% hematocrit in O+ human erythrocytes 
in RPMI-1640 medium supplemented with 50 μM hypoxanthine, 2.25 g/L NaHCO3, 2 mM 
L-glutamine, 25 mM HEPES, 0.5% (w/v) AlbuMAXII (Invitrogen) and 10 μg/mL 
gentamycin at 37 °C in flasks gassed with 5% O2/5% CO2/90% N2. The P. falciparum 
3D7-A10 and Dd2-B2 clones used for the selections and drug assays, and the NF54attB 
line used to express pfacg1-eGFP and pfehd-3×HA, have been previously reported 
189,271,334.  
 
2.3.5.1. Parasite stage-specificity assays.  
In vitro IC50 values were determined by incubating parasites for 72 h across a range of 10 
different concentrations of antimalarial compounds plus two no-compound controls. Stage-
specificity assays used a modified protocol with tightly-synchronized parasites tested at 
different starting stages of the ABS cycle 189.  
 
2.3.5.2. P. falciparum resistance selections. 
Single-step selections for MMV688533 resistance employed triplicate flasks of 2×109 Dd2-
B2 parasites exposed to 5-14× the IC50 (25–80 nM) of MMV688533. Selections were 
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terminated after 60 days as resistant parasites had not emerged. Ramping selections used 
triplicate flasks of 2×108 3D7-A10 parasites exposed to MMV688533 at concentrations that 
increased gradually from 1-10× the IC50 (5.5–60 nM) over a six-month period. Resistant 
clones were obtained from the bulk cultures of the ramping selections by limiting dilution, 
and four clones were selected for whole-genome sequencing. MMV688533 growth 
inhibition was determined by staining the parasites with SYBR Green and MitoTracker Deep 
Red (Life Technologies) followed by flow cytometry (Accuri C6, BD Biosciences) 306. IC50 
values were derived from growth inhibition data using nonlinear regression (Prism 7, 
GraphPad). Unless stated otherwise, all drug assays were performed on at least four 
separate occasions (as biological repeats) with two technical replicates.  
 
2.3.5.3. Genome editing.  
Mutations in PfACG1 and PfEHD that were identified from the in vitro selections were 
validated by engineering them into the parental 3D7-A10 line using an “all-in-one” pDC2-
based CRISPR/Cas9 plasmid (335). The Cas9 in this plasmid is derived from 
Streptococcus pyogenes, has been codon optimized for P. falciparum, and is under the 
expression of a calmodulin promoter. The plasmid also contains a human dhfr (hdhfr) 
selectable marker (that confers resistance to WR99210) under a PcDT promoter, and the 
sequence encoding the guide RNA (gRNA) under a U6 promoter. Guide RNAs were 
selected using the online tool ChopChop based on their proximity to the mutation of 
interest, GC content, and absence of poly A/T tracks (http://chopchop.cbu.uib.no). The 
gRNA primers were annealed with BbsI overhangs using PCR and cloned into a BbsI-
linearized pDC2 CRISPR/Cas9 vector. The donor templates, also supplied on the same 
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plasmid, had >300bp of homology flanking the mutation of interest. These fragments were 
first amplified by PCR and cloned into pGEM-T vectors to introduce shield mutations by 
site-directed mutagenesis. Shielded donor fragments were then amplified by PCR and 
cloned into the EcoRI/AatII-linearized pDC2 CRISPR/Cas9 vector by In-Fusion cloning 
(Takara). Finally, the plasmids were midi-prepped for transfections. 
Parasites were electroporated with purified circular plasmid DNA as described 318. Briefly, 
a 2.5 mL culture of 3D7-A10 or sel. 533-CL1 (³ 5% rings) was washed and resuspended 
in 220  µL 1× Cytomix. This mixture was then added to 50 μg of plasmid DNA and 
electroporated at a voltage of 0.31 kV and capacitance of 950 µF inside 2 mm gap 
cuvettes (Bio-Rad) using a Gene-Pulser (Bio-Rad) 319. Starting one day after the 
transfections, the cultures were selected for six days with 2.5 nM WR99210 320 and 
maintained thereafter in complete media until recrudescence. Gene editing was assessed 
via Sanger sequencing of blood PCR (Bioline) from bulk cultures. Edited parasite clones 
were obtained by limiting dilution. The parasites were then assayed for resistance to 
MMV688533 using flow cytometry.  
 
Both the mycobacteriophage Bxb1 serine integrase system 319 and CRISPR/Cas9 gene 
editing tools were used to generate the doubly-tagged parasite line expressing PfACG1-
eGFP and PfEHD-3×HA fusion proteins. Briefly, NF54attB parasites 334 were first co-
transfected with an integrase-expressing plasmid pINT and a donor attP-containing 
plasmid pDC2-pfacg1-eGFP. This donor plasmid also contained a blasticidin S-
deaminase (BSD) selectable marker that confers resistance to blasticidin hydrochloride 
336. The integrase plasmid pINT contained a Neomycin selectable marker that confers 
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resistance to geneticin (G418; 337. Transfections were done as described above and the 
cultures maintained in 250 µg/mL G418 + 2 µg/mL BSD media for six days post-
transfection, followed by 2µg/mL BSD media until recrudescence. Sorbitol-synchronized 
eGFP-tagged ring-stage clonal parasites obtained by limiting dilution were then 
transfected with the codon-optimized all-in-one plasmid containing a 1.1kb pfehd donor 
fragment consisting of two 3’ homology sequences flanking the 3×HA tag. These 
transfections were selected with 2.5 nM WR99210 until recrudescence. Successful gene 
tagging was confirmed via PCR, Sanger sequencing and immunofluorescence assays. 
 
2.3.6. Conditional knock-down (cKD) parasite studies. 
2.3.6.1. Generation of cKD parasite lines.  
To investigate the interaction between MMV688533 and PfACG1 and PfEHD genes, we 
utilized CRISPR/Cas9 to generate parasite cell lines stably expressing the TetR-DOZI-
RNA aptamer module for conditional regulation of target gene expression. These 
transgenic lines also contained the reporter construct Renilla luciferase (RLuc), the 
selection marker Blasticidin-S deaminase, and a C-terminal 2×HA epitope tag 322. To 
construct the donor plasmids, PCR-amplified right homology regions (RHR) and 
BioXP3200 System-synthesized DNA fragments corresponding to the left homology 
regions (LHR) fused to the re-codonized 3'-end of each target genes, as well as the target 
specifying guide RNA sequences, were cloned via Gibson assembly into the pSN054 
linear vector 321. The final constructs were confirmed by restriction digests and Sanger 
sequencing. Transfections into Cas9- and T7 RNA polymerase-expressing NF54 
parasites were carried out by preloading erythrocytes with the donor plasmids as 
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described previously 323. Cultures were maintained in 500 nM anhydrotetracycline (aTc; 
Sigma-Aldrich 37919) and 2.5  µg/mL of Blasticidin-S (RPI Corp B12150-0.1). Parasite 
cell lines stably integrating the donor plasmids were monitored via Giemsa smears and 
RLuc measurements. 
 
2.3.6.2. Western blotting of cKD parasite lines.  
PfACG1 and PfEHD cKD parasites were cultured with 50 nM aTc or without aTc to 
maintain and downregulated protein expression, respectively. Proteins were then 
extracted after 72 h via saponin lysis and resuspended in lysis buffer that consists of 
4% SDS and 0.5% Triton X-114 in 1×PBS. Proteins were separated on Mini-
PROTEAN TGX precast gels (4-15% gradient) in tris-glycine buffer, transferred to a 
polyvinylidene fluoride (PVDF) membrane using the Mini Trans-Blot Electrophoretic 
Transfer Cell system, and blocked with 100 mg/mL skim milk in TBS/Tween. Membrane-
bound proteins were probed with mouse anti-HA (1:3000; Sigma H3663) and rabbit anti-
GAPDH (1:5000; Abcam AB9485) primary antibodies, and anti-mouse (1:5000; Thermo 
Fisher Scientific 62-6520) and anti-rabbit (1:5000; Cell signaling 7074S) horseradish 
peroxidase (HRP)-conjugated secondary antibodies. Following incubation in SuperSignal 
West Pico Chemiluminescent substrate (Thermo Fisher Scientific PI34080), protein blots 





2.3.6.3. cKD proliferation assays.  
To assess the effect of conditionally perturbing PfACG1 and PfEHD expression on 
parasite growth, synchronous ring-stage parasites cultured in the presence (50 and 3 nM) 
or absence of aTc were cultured in triplicate in a 96-well U-bottom plate (Corning 62406-
121). Luminescence signals were taken at 0, 72, and 120 h post-invasion using the 
Renilla-Glo(R) Luciferase Assay System (Promega E2750) and the GloMax Discover 
Multimode Microplate Reader (Promega). The luminescence values in the knockdown 
conditions were normalized to aTc-treated (100% growth) and chloroquine-treated 
(200 nM) samples (no growth) as controls and results were analyzed using GraphPad 
Prism (version 8; GraphPad Software). 
 
2.3.6.4. Compound susceptibility assays with cKD parasite lines.  
A stock solution of MMV688533 was dispensed into 96-well U-bottom plates and serially 
diluted in complete medium to yield final concentrations ranging from 0.3-160 nM. 
Synchronous ring-stage PfACG1 and PfEHD cKD parasite lines as well as a control cell 
line expressing an aptamer-regulatable fluorescent protein were maintained in the 
presence (500 nM) or absence of aTc and were distributed into the drug plates. DMSO- 
and chloroquine-treated samples (200 nM) served as reference controls. Luminescence 
was measured after 72 h as described above and EC50 values were obtained from 




2.3.7. Whole-genome sequencing analysis.  
The 3D7-A10 parent and MMV688533-resistant clones were subjected to whole-genome 
sequencing using an Illumina TruSeq DNA PCR-Free library preparation protocol and a 
MiSeq sequencing platform, as described 57.  
 
2.3.8. Immunofluorescence assays.  
Indirect IFA studies were performed in suspension. Cells were fixed in 4% (v/v) 
formaldehyde (Thermo Fisher Scientific) for 1 h at room temperature. followed by a 
second fixation step supplementing the 4% formaldehyde solution with 1 mM cysteine 
and CaCl2 and subsequent incubation overnight at 4 °C. Cells were then permeabilized 
on ice using 0.05% Triton X-100 in 1×PBS for 5 min. Autofluorescence was quenched 
using a 50 mM glycine treatment for 10 min. After two washes in 1× PBS the cells were 
resuspended in 1% (w/v) bovine serum albumin (BSA) in 1×PBS blocking buffer and were 
then incubated with the appropriate dilution for each primary antibody used (1:200 for 
rabbit anti-ERD2 (BEI Recourses), anti-PMT (kindly provided by Choukri Ben Mamoun), 
anti-PDI (mouse anti-PDI (1D3), Enzo Life Sciences), rabbit or mouse anti-GFP (Takara 
(Clontech), Roche),  rabbit anti-HA antibodies (Sigma), 1:50 for rabbit anti-Rab5A, 
Rab5C, or Rab11A, rat anti-Rab5B or Rab7 (kindly provided by Gordon Langsley), 1:200 
for anti-coronin (kindly provided by Jake Baum), 1:200 for anti-ACP (kindly provided by 
Geoffrey McFadden), 1:200 for anti-K13 193, 1:200 for anti-PfCRT antibodies 41 followed 
by incubation with corresponding species-specific secondary antibodies (Alexa Fluor 488-
, 594- or 647- conjugated goat anti mouse or rabbit antibodies; Thermo Fisher) diluted 
1:2000 in 1% BSA in 1× PBS. MitoTracker Red CMXRos (Thermo Fisher) was used to 
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stain mitochondria. HCS LipidTOX Deep Red Neutral Lipid Stain and Nile Red 
(Invitrogen) were used to stain neutral lipid bodies according to the protocol provided by 
the manufacturer. Thin blood smears of stained RBCs were prepared on microscope 
slides and mounted with cover slips using Prolong Diamond Antifade Mountant with DAPI 
(Thermo Fisher). Parasites were imaged using a Nikon Eclipse Ti-E wide-field microscope 
equipped with a sCMOS camera (Andor) and a Plan-apochromate oil immersion objective 
with 100× magnification (1.4 numerical aperture). A minimum of 27 Z stacks (0.2 μm step 
size) were photographed for each parasitized RBC. NIS-Elements imaging software 
(Version 5.02, Nikon) was used to control the microscope and camera as well as to 
deconvolve the images (using 25 iterations of the Richardson-Lucy algorithm for each 
image) and perform 3D reconstructions 193. ImageJ (Fiji) (version 2.0.0-rc-68/1.52 h) was 
used to crop the images, adjust brightness and intensity, overlay channels and prepare 
montages. 
 
2.3.9. Evaluation of genotoxicity. 
 Salmonella typhimurium test strains including the mixed strains TA7001 and TA7006 for 
detection of base-pair substitutions and TA98 strain for detection of frameshift mutations 
were used for genotoxicity testing (Ames test). MMV688533 was cytotoxic starting at 300 
µg/mL in mixed and TA98 strains in the absence of metabolic activation. Cytotoxicity was 
also noted in the presence of metabolic activation starting from 100 µg/mL in TA98 strain 
and from 1000 µg/mL in mixed strains. Under the conditions of the test, MMV688533 was 
classified as non-mutagenic. 
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L5178Y and TK6 cells were used for in vitro micronucleus test to investigate the 
clastogenicity/aneugenicity potential of MMV688533. There was no statistically significant 
increase in the number of micronuclei as compared to the solvent control with or without 
metabolic activation. MMV688533 was therefore deemed non-clastogenic/aneugenic. 
 
2.3.10. Pharmacokinetic studies in mice, rats and dogs.  
Pharmacokinetic studies in mice were performed following a single intravenous (3 mg/kg) 
or oral (3.5, 10 and 30 mg/kg) administration of MMV688533 to male Swiss mice (3 dosed 
intravenous (i.v.) and 3 per os (p.o.)). Feeding was performed ad libitum. Vehicles / 
Formulations were at 0.6 mg/mL in PEG200/Solutol/G5% (20%/5%/75%) for i.v. solution 
and at 0.3, 1 and 3 mg/mL in Methylcellulose /Tween 80 (0.6%/0.5%) for p.o. suspensions 
in water. Administration modes were i.v. 3 mg/kg, 5 mL/kg and p.o. 3.5, 10 and 30 
mg/kg,10 mL/kg. Matrix and Sampling times were for i.v. plasma and lung / 0.083, 0.5, 1, 
2, 4, 6, 8 and 24 h and for p.o plasma (only at 10 mg/kg), blood, liver and lung / 0.25, 0.5, 
1, 2, 4, 6, 8 and 24 h. The analytical method was LC-MS/MS with a lower limit(s) of 
quantification 2 ng/mL for plasma, 5 ng/mL for blood and 6 ng/g for tissues. PK analysis 
were performed using non-compartmental models (Plasma, IV bolus and Plasma, 
Extravascular) Phoenix (WinNonLin version 6.4) 
 
In rats, the PK studies were performed following a single intravenous (3 mg/kg) or oral 
(10 mg/kg) administration to male Sprague-Dawley rats. The procedure was as described 
above but for the following exception: The rats were not fasted and the oral volume of 
administration of 10 mg/kg was 10 mL/kg Matrix. The sampling times for i.v. blood were 
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0.083, 0.25, 0.5, 1, 2, 4, 7, 24 and 48 h and for p.o. blood 0.5, 1, 2, 4, 7, 24 and 48 h. PK 
analysis was performed using a the 200-202, IV bolus and Extravascular non-
compartmental models. 
 
In dogs, the PK of MMV688533 was performed following a single 2 mg/kg intravenous 
administration of the compound to female Beagle dogs that were fasted overnight. The 
vehicle / formulation solution was at 2 mg/mL PEG400/Ethanol/Solutol HS15/G5 % 
(20/5/5/70) pH 3. For administration, i.v. was the preferred route (2 mg/kg, 1 mL/kg). 
Matrix and sampling times were blood at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24, 30, 48 and 72 
h. The limit of quantification was 1 ng/mL. MMV688533 following a single oral dose of 0.5 
mg/kg was also administered as malonate salt in a capsule or oral solution to male Beagle 
pentagastrin-dogs weighing 8.6 to 10.8 kg. 3 males per dose were dosed p.o, and serial 
sampling was applied. Feeding conditions were fasted overnight and fed 4 h post dosing. 
Vehicles / Formulations were capsule (MMV688533/microcrystalline cellulose/ 
croscarmellose sodium (5/91.67/3.33) followed by 50 mL of water. Solution at 0.25 mg/mL 
in PEG400/Ethanol/Solutol/G5% (20/5/7.5/67.5). Administration mode was p.o. 0.5 mg/kg 
(active compound), 2 mL/kg for solution. Matrix and sampling times were blood at 0.25, 





2.3.11. Safety pharmacology profiling. 
2.3.11.1. Preliminary non-clinical toxicology studies in rats.  
Two-week toxicity studies in rats were conducted to evaluate the potential toxicity of 
MMV688533 (malonate form) when administered once daily for 15 days to Sprague Dawley 
rats by the oral route (gavage). Four study groups, each composed of 5 male and 5 female 
Sprague Dawley rats, were given MMV688533 at 12.5, 25 or 50 mg/kg/day or vehicle alone 
[0.5% (w/w) Polysorbate 80 and 0.6% (w/w) methylcellulose in water], once daily for 15 
consecutive days, under a dose-volume of 5 mL/kg. In addition, 3 satellite rats/sex/group 
were included in the study. These rats received the test item in the same conditions as 
principal animals and were used for toxicokinetic studies. Parameters evaluated included 
mortality, clinical signs, body weight, and food consumption. Blood samples for hematology, 
coagulation and clinical chemistry were collected from all principal animals on day 3 and at 
necropsy. Blood samples for toxicokinetic determinations were obtained from satellite 
animals at 1, 2, 4, 7 and 24 h after dosing on day 1, as well as 1, 2, 4, 7, 24, 48 and 96 h 
after dosing on day 14. Control animals were sampled at 4 and 24 h after dosing on both 
days. At necropsy, all study animals were observed for any macroscopic post-mortem 
examinations, and weights of selected organs were recorded. Representative tissue 
samples at 50 mg/kg/day and in controls were histologically examined. Tissues with 
suspected compound-related microscopic findings were also evaluated microscopically for 




2.3.11.2. Preliminary non-clinical toxicology studies in dogs.  
Two male and two female beagle dogs were given MMV688533 (malonate form) at 10, 30 
or 100 mg/kg/day, or the vehicle alone [0.5% (w/w) Polysorbate 80 and 0.6% (w/w) 
methylcellulose in water], once a day for 15 consecutive days, under a dose-volume of 5 
mL/kg. Animals of all groups were treated for 15 days, except for those at 100 mg/kg/day, 
which were euthanized prematurely after 11 and 10 administrations, respectively for males 
and females, for ethical reasons. Parameters evaluated included mortality, clinical signs, 
body weights and food consumption. Blood samples for hematology, coagulation and 
clinical chemistry analyses were collected once during the pretest period and on Days 3 
and 8 (all animals), and on Day 14 (groups 1, 2 and 3). Urine samples for chemistry 
analyses were collected once during the pretest period (all animals) and on Day 14 (groups 
1, 2 and 3). At necropsy [Day 10 (group 4 females) or 11 (group 4 males), or Day 16 for 
group 1, 2 and 3 animals], all study animals were observed for any macroscopic post-
mortem examinations, and weights of selected organs were recorded and representative 
tissue samples were examined. In addition, the toxicokinetic profiles of MMV688533 and its 
main metabolite MMV893023 were determined from blood samples collected on Day 1 (all 
animals) and on Day 15 (groups 1, 2 and 3) at 1, 2, 4, 7 and 24 hours post-dosing. For 
group 4 animals, blood samples for TK determinations were collected on Day 11 for the 
males or on Day 10 for the females, before dosing, and 1 and 2 hours post-dosing. 
 
2.3.11.3. Ex vivo rabbit Purkinje fibers cardiovascular study.  
This study was designed to evaluate the cardiac cellular electrophysiological effects of 
MMV688533 on the action potential parameters in isolated rabbit Purkinje fibers. 
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MMV688533 was tested at 0.1, 1.4, 4.9 and 6.4 μmol/L corresponding to 0.05, 0.7, 2.5 and 
3.3 μg/mL of active ingredient, respectively. The effects of the active MMV688533 
metabolite RA11263363A on resting membrane potential and action potential parameters 
recorded from isolated rabbit Purkinje fibers (male, New Zealand rabbits; 1.3 to 1.5 kg; 7-
10 weeks of age) were evaluated through a microelectrode technique. The following 
parameters were measured: resting potential (RP in mV), amplitude (APA in mV), maximal 
rate of rise of action potential (Vmax in V/s) and the action potential duration at 50 and 90% 
of repolarization (APD50 and APD90 in ms). The fibers were superfused with an 
oxygenated physiological solution containing 120 mM NaCl; 4 mM KCl; 1 mM MgCl2; 1.8 
mM NaH2PO4; 25 mM NaHCO3; 11 mM glucose; 1.8 mM CaCl2; pH = 7.4, at 36±1°C. 
RA11263363A (592.3 g/mol, salt form and 519.4 g/mol, base form, batch CLT.CBN1.039.1) 
was first dissolved into DMSO to obtain a 12 mM stock solution. This solution was further 
diluted with 100% DMSO to obtain solutions at 4, 1.2 and 0.12 mM. These four solutions 
(0.12, 1.2, 4 and 12 mM) were added into the physiological solution to obtain the appropriate 
nominal concentrations of 0.3, 3, 10 and 30 μM, which corresponded to 0.2, 1.6, 5.2 and 
15.6 μg/mL of active ingredient respectively. The final concentration of DMSO in the test 
formulation was kept constant at 0.25% (v/v) in the physiological solution. Purkinje fibers 
(n=3) were first superfused by the physiological solution. After a 30-minute control period, 
test compound was evaluated at increasing concentrations sequentially applied, every 30 
minutes. For each tested concentration, the fibers were stimulated at the basal rate of 1 
pulse per second (1 Hz). In addition, stimulation rate was decreased from 1 pulse per 
second (1 Hz) to 1 pulse every 4 seconds (0.25 Hz) for 3 minutes, increased again to 1 
pulse per second for 1 minute and finally increased to 3 pulses per second (3 Hz) for 2 
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additional minutes (between the 19th and the 25th minute). The low stimulation rate was 
used to favor the occurrence of abnormal electrical events during the repolarization phase 
of the action potential and to facilitate the development of Early After Depolarization’s 
(EADs). The high stimulation rate was used to evaluate the use-dependent sodium channel 
blockade. After the highest concentration, the physiological solution was superfused again 
to evaluate the reversibility of the drug effect (washout). 
 
2.3.11.4. In vivo anaesthetized guinea pig cardiovascular study.  
The purpose of this study was to assess the potential effects on cardiovascular parameters 
of continuous intravenous (IV) administration of MMV688533 chlorhydrate to anesthetized 
guinea pigs, when tested at cumulative doses of 10, 20 and 30 mg/kg. Each dose was 
successively administered as a 15-min infusion/dose. Blood concentrations of MMV688533 
were also assessed. An aqueous solution of ethanol/solutol/NaCl (10% / 5% / 85%, v/v/v) 
was used for the study. Cardiovascular functions were evaluated by measuring 
hemodynamic parameters like arterial blood pressure (BP) and heart rate (HR), and 
electrocardiographic (ECG) parameters. 
 
Animals were premedicated with buprenorphine (0.05 mg/kg intramuscular) ~30 min prior 
to surgery and anesthesia maintained under isoflurane (2-5%) and constant O2 flux (0.7 – 
1.3 mL/min). Under deep anesthesia, lidocaine was injected subcutaneously at sites of the 
tracheotomy and insertion of electrocardiogram needles, and a tracheotomy performed to 
allow mechanical ventilation followed by carotid (arterial measurements) and jugular 
(infusion of control article or test article) catheterizations. Administration of Ringer lactate 
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solution (5 mL/ kg intraperitoneal), heated to body temperature to compensate for the hydric 
loss inherent to anesthesia, was performed at the discretion of the study director according 
to major bleeding surgery or signal instability (information documented in study records). 
BP and ECG parameters were recorded in anesthetized guinea pigs placed on a heating 
pad. Systemic BP was recorded using an independent catheter pressure transducer 
(MillarTM equipment) introduced into the carotid artery. The standard ECG (one lead 
derivation among L1 or L2 or L3) was recorded using four subcutaneously-placed needle 
electrodes to provide an optimal separation of T wave from P wave of the next complex. 
Once satisfactory in terms of their quality and stability, the signals were recorded for 15 
minutes (corresponding to the stability period). Thereafter a set of animals (group T2) 
received a NaCl infusion (starting at T0 min) followed by RA11263363A at cumulative doses 
of 10, 20 and 30 mg/kg. Each infusion was delivered every 15 minutes at a rate of 0.3 
mL/kg/min, with the last infusion followed by a period of recovery. 
 
At the end of the recovery period (T75 min) one single arterial blood sample (~0.2 mL) was 
collected from the abdominal artery. A second set of animals (group T1) was infused with 
the control article in the same experimental conditions without the terminal blood sampling. 
A last set (group T3) was dedicated to evaluating pharmacokinetic (PK) parameters in which 
animals fitted with a jugular catheter (for RA11263363A infusion) and a carotid catheter 
(arterial blood sampling) were treated in the same experimental conditions as those 
described for the group T2. At the end of each 15-min period of infusion a blood sample 
(~0.2 mL) was collected. This was also done during the recovery period at 5, 10 and 75 
min. Each volume of blood collected was immediately replaced by an equivalent volume of 
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Ringer lactate solution. Of note, in group T3, at the end of the recovery period (T75 min) 
arterial blood (~0.2 mL) was sampled and was compared to the corresponding sample in 
group T2. All blood samples (0.2 mL) were collected with sodium heparinate as 
anticoagulant and placed on wet ice immediately after collection. Then all samples were 
stored at -20°C until analysis. Thereafter the animals were euthanized by IV or intra-cardiac 
overdose of sodium pentobarbital. 
 
2.3.12. Patch Clamp electrophysiological hERG assay. 
2.3.12.1. Cell culture procedure.  
HEK293 cells were stably transfected with hERG cDNA. Stable transfectants were selected 
by co-expression with the Geneticin (G418)-resistance gene incorporated into the 
expression plasmid. Selection pressure was maintained by including G418 in the culture 
medium. Cells were cultured in Dulbecco’s Modified Eagle Medium / Nutrient Mixture F-12 
(D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 
100 μg/mL streptomycin sulfate and 500 µg/mL G418.  
 
2.3.12.2. Electrophysiological Procedures.  
Cells were transferred to the recording chamber and superfused with vehicle control 
solution. Micropipette solution for whole cell patch clamp recordings was composed of: 130 
mM potassium aspartate; 5mM MgCl2; 5mM EGTA; 4mM ATP; 10mM HEPES. The pH was 
adjusted to 7.2 with KOH. Micropipette solution was prepared in batches, aliquoted, frozen 
for storage and a fresh aliquot thawed each day. The recording was performed at a 
temperature of 33-35 ºC using a combination of in-line solution pre-heater, chamber heater 
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and feedback temperature controller. Temperature was measured using a thermistor probe 
in the recording chamber. Micropipettes for patch clamp recording were made from glass 
capillary tubing using a P-97 (Sutter Instruments, Novato, CA) or PC-10 (Narshige, 
Amityville, NY) micropipette puller. A commercial patch clamp amplifier (PC-505B from 
Warner Instruments, Hamden CT) was used for whole cell recordings. Before digitization, 
current records were low-pass filtered at one-fifth of the sampling frequency. 
 
2.3.12.3. Experimental Procedures.  
Cells stably expressing hERG were held at -80 mV. Onset and steady state inhibition of 
hERG potassium current due to MMV688533 were measured using a pulse pattern with 
fixed amplitudes (conditioning prepulse +20 mV for 1 s; repolarizing test ramp to -80 mV (-
0.5 V/s) repeated at 5 s intervals). Each recording ended with a final application of a 
supramaximal concentration of the reference substance (E-4031, 500 nM) to assess the 
contribution of endogenous currents. The remaining uninhibited current was subtracted off-
line digitally from the data to determine the potency of the test substance for hERG 
inhibition. MMV688533 was tested at 1 μM in three cells (n = 3). Inhibitory effects on hERG 
potassium current amplitude of 17.9, 11.5 and 12.4% were observed. Based on these 
results and the solubility limit of the test article in the vehicle, additional nominal 
concentrations (0.3 and 3 μM; Protocol Amendment No. 1) were selected to evaluate the 
concentration-response relationship. One or more test article concentrations were applied 
sequentially (without washout between test substance concentrations) in ascending order, 
to each cell (n ≥ 3). Peak current was measured during the test ramp. A steady state was 
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maintained for at least 20 s before applying test article or positive control. Peak current was 
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We report detailed susceptibility profiling of asexual blood stages of the malaria parasite 
Plasmodium falciparum to clinical and experimental antimalarials, combined with 
metabolomic fingerprinting. Results revealed a variety of stage-specific and metabolic 
profiles that differentiated the modes of action of clinical antimalarials including 
chloroquine, piperaquine, lumefantrine and mefloquine, and identified late trophozoite-
specific peak activity and stage-specific biphasic dose-responses for the mitochondrial 
inhibitors DSM265 and atovaquone. We also identified experimental antimalarials hitting 
previously unexplored druggable pathways as reflected by their unique stage-specificity 
and/or metabolic profiles. These included several ring-active compounds, ones affecting 
hemoglobin catabolism through distinct pathways, and mitochondrial inhibitors with lower 
propensities for resistance than either DSM265 or atovaquone. This approach, also 
applicable to other microbes that undergo multiple differentiation steps, provides an 




Malaria caused by the protozoan parasite Plasmodium falciparum remains a major public 
health menace, especially in young children in sub-Saharan Africa 338. When an individual 
is bitten by a Plasmodium-infected mosquito, the parasite first replicates in hepatocytes 
and then initiates ~48 h cycles of red blood cell (RBC) infection. In these RBCs, the 
parasite develops inside a parasitophorous vacuole, progressing from a ring into a highly 
metabolically active trophozoite and then a multinucleated schizont that yields 8-24 
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merozoites generated through asexual replication. Upon egress from the lysed host RBC, 
these merozoites infect new RBCs, with parasites capable of infecting up to 10-20% of 
RBCs in an immunologically naïve host 339. 
 
Chemotherapy remains a major pillar in the fight against malaria, alongside vector control, 
diagnosis and access to treatment. The former first-line antimalarials chloroquine and 
sulfadoxine-pyrimethamine mainly affected trophozoites by inhibiting the hemoglobin 
catabolism pathway that provides nutrients for the parasite and the folate biosynthesis 
pathway that delivers the building blocks for DNA synthesis, respectively 41. KAI407, a 
phosphatidylinositol 4-kinase (PI4K) inhibitor, is one of the more recent candidate 
antimalarials that specifically inhibit schizont development 61. These drugs mostly target 
trophozoites and schizonts, which sequester in the microvasculature 340. Compounds 
targeting ring stages, which circulate throughout the blood stream, are desirable to 
prevent further vasculature blockage. Artemisinins were the first clinical antimalarials with 
ring-stage activity and artemisinin-based combination therapies have proven effective in 
reducing the malaria death and case load 338. However, parasites resistant to artemisinins 
and their partner drugs have emerged and are now undermining malaria control 294,341. 
The discovery of antimalarials that hit novel targets and are active against multiple 
asexual blood stages, including rings, is thus of paramount importance. 
 
Thousands of antimalarials with submicromolar potency have been identified in high-
throughput whole-cell screens 234-236,342-345, but target identification forms a major 
bottleneck for their further development into leads with increased target binding, 
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selectivity, and whole-cell activity 346. Metabolomic analysis of biochemical pathways 
affected upon compound exposure recently identified the mode of action of various 
candidate antimalarials from the Medicines for Malaria Venture Malaria Box 260, and is a 
valuable tool to interrogate new screening hits. Combining this approach with other 
phenotypic assays can help explore the activity profile and therapeutic potential of 
candidate antimalarials. 
 
The Malaria Drug Accelerator (MalDA) consortium aims to identify new antimalarial leads 
through in vitro phenotypic screens and the identification of novel assayable targets 233,343. 
Within this context, we developed an assay that compares the stage-specific susceptibility 




We designed a medium-throughput in vitro assay to quantitatively assess the 
susceptibility of the distinct stages of P. falciparum intra-erythrocytic development. Highly-
synchronized 3D7-A10 parasites (that have an accelerated 40 h asexual blood stage 
cycle) were exposed to a range of compound concentrations for 8 h during the early ring, 
late ring, early trophozoite, late trophozoite, and schizont stages (Fig. 3.1A). Assays were 
performed in 96 well plates, with a maximum in-well DMSO concentration of 0.35%. 
Cultures were continued to allow parasites to further develop in the absence of 
compound, extending through to invasion of new RBCs and development until the 
trophozoite stage. The total assay duration was 60 h. Parasites were stained with SYBR 
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Green and Mitotracker Deep Red and quantified by flow cytometry. Half-maximal 
inhibitory concentrations (IC50) were derived by non-linear regression analyses of the 
dose-response data. The IC50 value based on these 8 h exposures at specific asexual 
blood stages is referred to as the IC508h, while the IC50 calculated from the standard 72 h 
exposure assay is the IC5072h. 
 
Light microscopy confirmed that the different periods of exposure corresponded to the 
different developmental stages and showed that the 32-40 h timepoint spanned schizont 
development, parasite egress and reinvasion (Fig. 3.1A), indicating that all asexual blood 
stages were profiled. The assay was further validated by the stage-specific susceptibility 
profiles of dihydroartemisinin, chloroquine and KAI407 that showed the expected peak 
activity on early rings, rings and trophozoites, and schizonts, respectively 41,347 (Fig. 
3.1B). The 35-fold difference in IC508h between schizonts and late trophozoites for KAI407 




Fig. 3. 1. | Experimental design for asexual blood stage specificity profiling of antimalarials 
and profiles of reference drugs.  
Sorbitol-sync
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(A) Synchronized parasites were exposed for 8 h at the stages indicated. Survival at 60 
h post-invasion was assessed by flow cytometry. (B) Unique stage-specificity profiles of 
chloroquine, dihydroartemisinin and KAI407. Bar plots indicate the IC508h when parasites 
were exposed only during the early ring, late ring, early trophozoite, late trophozoite or 
schizont stage, with error bars showing the standard error of the mean based on at least 
three independent repeats. All data are available in Table 3.1. 
 
The asexual blood stage susceptibility profile was determined for a set of 36 compounds 
that included licensed drugs, candidate antimalarials, compounds with a known target, 
and various screening hits (profiles of compounds are shown in Fig. 3.2-3.5, simplified 
molecular input line entry system (SMILES) for compounds are listed in Table 3.2, and 
structures of compounds are displayed in Fig. 3.1-3.2). Hits were selected from screens 
previously performed by the MalDA consortium (see Table 3.2 references) and prioritized 
based on their potency, chemical diversity and unknown mode of action. Licensed 
antimalarial drugs and additional previously published preclinical compounds were 
included to provide more insights into their mode of action or to serve as a reference. 
 
First, compounds were classified based on their timing of peak activity, defined as the 
asexual blood stage at which the compounds showed the lowest IC508h values. This 
identified compounds with peak activity during (i) all rings and trophozoites, (ii) all rings, 
(iii) all trophozoites, (iv) all trophozoites and schizonts, (v) late trophozoites, and (vi) 
schizonts (Fig. 3.6). When compounds were classified by their overall activity profile 
based on identifying the specific stages that showed IC508h values < 1 μM (Fig. 3.10; 
Table 3.1), seven active classes were identified: compounds active on (i) all asexual 
blood stages, (ii) all rings and trophozoites, (iii) late rings and all trophozoites, (iv) all 
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trophozoites and schizonts, (v) late trophozoites and schizonts, (vi) only late trophozoites, 
and (vii) only schizonts. Fosmidomycin, a moderately potent inhibitor of P. falciparum 
isoprenoid biosynthesis 348, as well as the hit compounds MMV000787, MMV019017, 
MMV020746, MMV022478 and MMV665939 showed IC508h values > 1 μM at all tested 
stages and therefore did not match any of these groups (Table 3.1).  
 
The clinical antimalarials dihydroartemisinin, chloroquine, piperaquine and lumefantrine 
showed little variation in IC508h values throughout the ring and trophozoite stages, and 
were consequently classified in the group with peak activity at ring and trophozoite stages. 
While chloroquine, piperaquine and lumefantrine IC508h values were similar for ring and 
trophozoite stages, survival curves for early rings were less steep than those for late rings 
and trophozoites (Fig. 3.1, Fig. 3.2). DSM265 and atovaquone, which are inhibitors of 
pyrimidine synthesis and the mitochondrial electron transport chain, respectively (Fig. 
3.5A), showed peak activity specifically during late trophozoite stages (Fig. 3.5B, Fig. 
3.6). These mitochondrial inhibitors also displayed a biphasic survival curve at the early 
trophozoite and schizont stages that was not observed at other stages (Fig. 3.5B; Table 
3.1). 
 
MMV000442, MMV006455, MMV007181 and MMV665971 showed incomplete killing at 
all asexual blood stages, with evidence of initial growth inhibition at lower concentrations 
followed by demonstrably better growth at higher concentrations in the early and late ring 
stages (Fig. 3.3, Fig. 3.4). This incomplete killing was not observed in the 72 h exposure 
survival curves for these compounds (Fig. 3.3, Fig. 3.4). Aqueous solubility experiments 
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for MMV000442, MMV006455 and MMV007181 indicated a solubility >100 μΜ (Table 




















































































































































































































































































































































































































































































































































































































































Peak activity on all rings
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Fig. 3. 2. | Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak 
Activity on All Rings or All Rings and Trophozoites.  
Data for chloroquine and dihydroartemisinin can be found in Fig. 3.1. Bar graphs indicate 
mean IC508h values, whereas survival graphs show the most representative curves from 
independent repeats. Error bars indicate the standard error of the mean based on >3 
independent repeats. Data are summarized in Table 3.1. 
Fig. 3. 3. | Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak 

































































































































































































































































































































































































































































































































































































































Bar graphs indicate mean IC508h values, whereas survival graphs show the most 
representative curves from independent repeats. Error bars indicate the standard error of 
the mean based on >3 independent repeats. Data are summarized in Table 3.1. 
Fig. 3. 4. | Detailed Asexual Blood Stage Susceptibility Profiles for Antimalarials with Peak 
Activity on Late Trophozoites, or on All Trophozoites and Schizonts. 
Data for DSM265 and atovaquone, both compounds with peak activity at the late 





















































































































































































































































































































































































































































































































































































































Peak activity on late trophozoites
104 
whereas survival graphs show the most representative curves from independent repeats. 
Error bars indicate the standard error of the mean based on >3 independent repeats. Data 
are summarized in Table 3.1. 
Fig. 3. 5. | Late trophozoites are the most susceptible stage to DSM265 and atovaquone 
that inhibit pyrimidine biosynthesis and the mitochondrial electron transport chain, 
respectively. 
(A) Overview of the pyrimidine biosynthesis and the mitochondrial electron transport
chain pathways. DSM265 inhibits DHODH, whereas atovaquone inhibits cytochrome bc1
(Goodman et al., 2017). (B) Stage specificity profiles for DSM265 and atovaquone. IC508h
values for (B) are available in Table 3.1.
10
5 
Fig. 3. 6. | Stage of peak activity for clinical and experimental antimalarials. 
Peak activity illustrates the period when the parasite was most susceptible to the tested compounds. MMV020746 and 
MMV665939 were omitted as their IC508h values were >10 mM. All data are available in Table 3.1 and Fig. 3.1-3.5. ATQ, 
atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; FQ, ferroquine; LMF, lumefantrine; MB, methylene blue; MQ, 
mefloquine; NQ, naphthoquine; PPQ, piperaquine. 
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To further examine whether the compound stage-specificity profiles that we identified 
correlated with their mode of action, we examined the metabolic profile of 33 compounds 
(Fig. 3.7). These consisted of 27 newly assayed compounds, plus another six 
(chloroquine, DSM265, MMV000248, MMV006455, MMV019017 and KAE609) for which 
data were already available 260. In these experiments, we exposed trophozoite-infected 
RBCs to 10×IC5072h concentrations and then subjected parasite extracts to mass 
spectrometry-based metabolomic profiling 260. 
Across all 33 compounds, we obtained quantitative data for 195 metabolites that 
represent major metabolic pathways, including but not limited to pyrimidine and purine 
synthesis, hemoglobin catabolism, folate biosynthesis, central carbon metabolism, 
glycolysis, and redox metabolism. Based on these metabolic profiles, compounds were 
hierarchically clustered via Ward clustering based on Pearson correlation coefficients to 
identify related metabolic signatures (Fig. 3.7).  
Several established metabolic signatures were observed among the analyzed 
compounds. Mitochondrial electron transport chain disruption is linked to inhibition of 
dihydroorotate dehydrogenase (DHODH) and cytochrome bc1 (CytBC1), leading to 
increases in the pyrimidine precursors dihydroorotate and N-carbamoyl-L-aspartate 260. 
This metabolic signature was observed for DSM265 and ATQ, which respectively inhibit 
DHODH and CytBC1, as well as MMV000787, MMV021735, and MMV030666 for which 
the mode of action was previously unknown (Fig. 3.7). 
107 
We performed resistance selections with MMV021735, MMV030666 and MMV000787 to 
compare their propensity for resistance to that of DSM265 and atovaquone, which have 
a relatively low minimum inoculum for resistance of 2×106 and 2×107parasites, 
respectively, when using 3×IC5072h drug concentrations 339. Selections involving 
continuous exposure of 1×109 Dd2-B2 parasites to a 3.5×IC5072h concentration of 
MMV000787, or intermittent drug pulsing in which parasites were exposed for several 
days at a time to 6×IC5072h concentrations of MMV000787 for 5 months, did not result in 
MMV000787-resistant parasites. For MMV021735, exposing 5×108 3D7-A10 parasites to 
3×IC5072h concentrations in triplicate failed to yield resistant parasites. Exposing 5×108 
3D7-A10 or Dd2-B2 parasites to 3×IC5072h concentrations of MMV030666 also failed to 
yield resistance. A ramping selection with 3D7-A10 parasites starting at 1×IC5072h and 
gradually increasing to 1.8×IC5072h over the course of 3 months also did not produce 
resistance. These data indicate that MMV000787, MMV21735 and MMV030666 have 
minimum inocula of resistance well above 5×108 parasites. 
Peptide decreases commonly linked with inhibition of hemoglobin endocytosis and/or 
catabolism within the digestive vacuole were also observed across multiple antimalarial 
compounds (Fig. 3.7). This metabolic signature of decreased peptide levels (HVDD, 
PVNF, PEEK, PEE, DLS, SDL, SID, DLH, LD, PE, PD, SD, VD, and EV) was particularly 
pronounced for the compounds MMV022478, MMV019555, MMV667491, MMV030666, 
MMV000248, MMV006455, MMV007181, MMV020746, MMV000442, GNF-Pf-5660, 
KAE609 and MMV019017. Of these, MMV006455, MMV019017 and KAE609 also 
possessed increased levels of the deoxyribonucleotides dAMP and dTMP and decreased 
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levels of cAMP. KAE609 and MMV019017 additionally showed decreased nucleoside di- 
and triphosphates levels (GDP, UDP, GTP, dATP, dGTP/ATP, dUTP), which have 
previously been identified as a signature of inhibiting the Na+/H+-dependent ATPase 
PfATP4 260. The hemozoin inhibitor chloroquine did not show the expected strong 
hemoglobin catabolism signature, but instead showed a more modest decrease in peptide 
levels and clustered with the PFATP4-inhibitor KAE609.  
Interestingly, the metabolic profile for MMV030666 indicated perturbation of both the 
mitochondrial electron transport chain and Hb catabolism. MMV022224 induced 
increased levels of peptides, a profile that has not been observed before. Due to the 
peculiar profiles of these compounds, they were selected for an additional study in which 
synchronized parasites were exposed to 3× the IC508h of the most sensitive life stage at 
8 h intervals, similar to the stage specificity assay, and cell morphology was assessed by 
microscopy at the end of each interval (Fig. 3.11). This showed MMV030666-exposed 
parasites to be most susceptible during the late trophozoite stage, as evidenced by their 
bloated digestive vacuoles. This phenotype is characteristic of Hb catabolism perturbation 
201, and is consistent with the metabolomics data. MMV022224-exposed parasites proved 
to be affected mostly during early and late trophozoite stages, without displaying swollen 
vacuoles. The health of ring-stage parasites, which showed similar IC508h values as 
trophozoites for MMV022224, was harder to microscopically evaluate due to their smaller 
size. 
109 
Mefloquine, naphthoquine, piperaquine, methylene blue, MMV675939, 
dihydroartemisinin, WLL-vs, MMV668311, ferroquine, MMV085071 did not induce major 
changes within the set of metabolites detected in our study and therefore clustered in the 


























































































































































































































































































































Fig. 3. 7. | Metabolic profiling of compounds identified cellular processes targeted by compounds. 
Compounds were clustered based on hydrophilic metabolite response to all measured metabolites. Compounds are listed 
only if they showed a >2-fold change (log2 > 1) in metabolite levels compared with untreated controls in at least one of the 
treated samples. Compounds are color-coded based on peak activity as shown in Fig. 3.6. Metabolite data for chloroquine, 
DSM265, MMV000248, MMV006455, MMV019017, and KAE609 were sourced from (Allman et al., 2016). Data for all other 
27 compounds were generated in this study. ATQ, atovaquone; Cmpd, compound; CQ, chloroquine; DHA, 
dihydroartemisinin; FQ, ferroquine; LMF, lumefantrine; MB, methylene blue; mETC, mitochondrial electron transport chain; 
MQ, mefloquine; NQ, naphthoquine; PPQ, piperaquine. 
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Table 3. 1. | Asexual blood stage-specific IC508h data in nM for the tested antimalarials. Table S1 (related to Figures 1-3). Asexual blood stage-specific IC50 data in nM for the tested antimalarials.
Dihydroartemisinin 1.5 0.1 3 2.4 0.1 3 2.4 0.4 3 3.9 0.2 3 11.6 1.3 3 1.0 0.1 4 Rings + Trophs 1.5
Chloroquine 17.8 5.5 4 18.6 2.5 3 17.4 3.5 3 30.1 6.3 3 60.3 13.4 3 5.9 0.8 3 Rings + Trophs 2.9
Mefloquine 258 106 3 147 74 3 28.8 7.0 3 29.5 6.9 3 138 39 3 9.8 1.0 3 Trophs 3.0
Lumefantrine 15.4 4.0 3 15.8 3.5 3 19.54 1.6 3 22.3 2.0 3 81.0 32.5 3 1.3 0.0 3 Rings + Trophs 11.6
Piperaquine 26.2 1.1 3 46.3 13.1 3 27.4 3.3 3 32.9 1.1 3 67.0 9.6 3 15.4 2.3 4 Rings + Trophs 1.7
Ferroquine 4.9 0.3 3 10.9 1.7 3 23.2 2.4 3 36.8 3.3 3 49.3 6.2 3 3.5 0.4 4 Rings 1.4
Methylene blue 3.2 0.3 3 13.3 2.7 3 5.9 0.4 3 8.3 2.0 3 64.8 17.8 3 1.8 0.1 4 Rings + Trophs 1.8
KAI407 - shift 1 - - - - - - - - - 161 44.0 3 - - - - - - - 3.9
KAI407 - shift 2 16263 904 2 14021 923 3 5139 1727 3 13386 354 2 46.2 0.6 3 11.8 1.0 3 Schizonts -
AN3661 > 1.25 μM - 3 > 1.25 μM - 3 > 1.25 μM - 3 138 39 3 400 34 3 35.6 3.6 3 Late Trophs 3.9
KAE609 > 1.25 μM - 3 > 1.25 μM - 3 3.2 0.6 3 1.1 0.2 3 1.2 0.1 3 0.73 0.05 4 Trophs + Schizonts 1.5
WLL-vs 23.7 2.6 3 29.4 4.4 3 57.6 3.1 3 47.1 3.1 3 50.1 5.7 3 7.2 0.8 3 Rings 3.3
DSM265 - shift 1 - - - - - - 10.2 2.2 3 7.7 0.9 3 19.2 2.3 3 3.8 0.1 3 Late Trophs 2.0
DSM265 - shift 2 4821 1605 3 1493 308 3 1481 240 3 - - - > 25 μM - - - - - - -
Atovaquone - shift 1 - - - - - - 0.68 0.06 3 3.7 0.2 3 7.4 1.3 3 1.1 0.1 3 Late Trophs 3.3
Atovaquone - shift 2 553 228 3 324 45 3 619 132 3 - - 3 > 25 μM - 3 - - - - -
Fosmidomycin > 10 μM - 3 > 10 μM - 3 1983 665 3 1993 117 3 > 10 μM - 3 405 8 3 Trophs 4.9
GNF-Pf-5660 119 30 3 238 57 3 108 6 3 79.3 10.8 3 290 50 3 4.4 0.2 3 Rings + Trophs 18.0
MMV665794 369 101 3 590 177 3 210 20 3 165 10 3 203 8 3 91.3 5.2 4 Trophs + Schizonts 1.8
Naphtoquine 4.2 1.8 3 8.1 0.4 3 19.5 2.9 3 29.2 3.1 3 42.8 8.4 3 3.2 0.4 4 Rings 1.3
MMV000442 > 8 μΜ - 3 > 8 μΜ - 3 176 11 3 197 22 3 503 48 3 37.2 3.1 3 Trophs 4.7
MMV675939 1170 277 3 268 84 3 62.9 29.9 3 146 54 3 1647 45 3 30.8 4.4 5 Trophs 2.0
MMV085071 893 78 3 492 122 3 61.1 0.1 3 81.4 2.8 3 254 47 3 105 11 3 Trophs 0.6
MMV668311 140 39 3 97.7 4.3 3 68.9 11.9 3 122 26 3 382 79 3 63.5 1.7 3 Rings + Trophs 1.1
MMV020746 > 25 μM - 2 > 25 μM - 2 12587 1681 2 > 25 μM - 2 > 25 μM - 2 56.8 6.6 4 All stages > 10 μM 221.5
MMV667491 2264 349 3 1270 92 3 521 28 3 731 50 3 842 108 3 243 35 4 Trophs + Schizonts 2.1
MMV006455 > 12.5 μM - 3 > 12.5 μM - 3 441 10 3 450 46 3 933 142 3 439 46 4 Trophs 1.0
MMV022478 7628 202 2 4870 353 2 2132 252 2 2529 353 2 3370 269 2 11.1 0.8 3 Trophs + Schizonts 192.4
MMV007181 > 25 μM - 3 > 25 μM - 3 253 27 3 274 16 3 570 107 3 84.9 8.9 3 Trophs 3.0
MMV665971 > 25 μM - 3 > 25 μM - 3 496 51 3 485 26 3 523 29 3 185 9 3 Trophs + Schizonts 2.6
MMV665939 17011 2420 3 22853 5330 3 13476 4752 3 39017 13066 3 54384 14265 3 478 49 4 All stages > 10 μM 28.2
MMV019017 8418 1862 2 8663 2298 3 1338 133 3 1708 116 3 3060 229 3 306 12 3 Trophs + Schizonts 4.4
MMV000248 n.d. n.d. 0 6744 - 1 411 - 1 376 - 1 754 - 1 103 14 4 Trophs 3.7
MMV021735 > 25 μM - 3 > 25 μM - 3 5422 1392 3 234 12 3 5281 622 3 232 11 4 Late Trophs 1.0
MMV022224 838 123 3 845 152 3 542 39 3 752 58 3 2486 472 3 199 31 5 Rings + Trophs 2.7
MMV027496 2760 529 3 878 130 3 168 26 3 199 9 3 4339 545 3 89.7 7.9 3 Trophs 1.9
MMV019555 755 159 3 788 221 3 81.4 1.6 3 110 20 3 349 66 3 33.3 1.8 3 Trophs 2.4
MMV030666 10264 3053 3 11440 861 3 5124 506 3 858 29 3 4191 307 3 462 18 4 Late Trophs 1.9
MMV000787 5737 1215 3 7870 731 3 3312 629 3 1354 57 3 5912 617 3 1960 83 3 Late Trophs 0.7
Shift 1 and shift 2 indicate the two half-maximal inhibitory concentrations for biphasic dose response curves (curves shown in Figure S1).  SEM: standard error of the mean; n: number of biological repeats; - : no data; IC508hr: IC50 
based on 8 hr exposure; IC50
72hr: IC50 based on 72 hr exposure.






















Shift 1 and shift 2 indicate the two half-maximal inhibitory concentrations for biphasic dose response curves.  SEM: standard 
error of the mean; n: number of biological repeats; - : no data; IC508h: IC50 based on 8-h exposure; IC5072h: IC50 based on 
72-h exposure.
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Table 3. 2. | SMILES and suspected mode of action (if known) of the tested antimalarials. 
Dihydroartemisinin (DHA) C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CCC(O3)(OO4)C)O)C - - -
Chloroquine (CQ) CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl β-hematina - -
Mefloquine (MFQ) c1cc2c(cc(nc2c(c1)C(F)(F)F)C(F)(F)F)[C@@H]([C@H]3CCCCN3)O - - -
Lumefantrine (LMF) CCCCN(CCCC)CC(C1=C2C3=C(C=C(C=C3)Cl)C(=CC4=CC=C(C=C4)Cl)C2=CC(=C1)Cl)O - - -
Piperaquine (PPQ) c1cc2c(ccnc2cc1Cl)N3CCN(CC3)CCCN4CCN(CC4)c5ccnc6c5ccc(c6)Cl β-hematinb - -
Ferroquine (FQ) CN(C)CC1=C(C=[C-]C1)CNC2=C3C=CC(=CC3=NC=C2)Cl.C1C=CC=[C-]1.[Fe+2] β-hematinc,d - -
Methylene blue (MB) CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] β-hematine - -
KAI407 O=C(N(C)C1=CC=C(C=C1)C#N)C2=CN3C(C=N2)=NC=C3C4=CC=C(C=C4)C(F)(F)F PI4Kf - -
AN3661 OB1C2=C(CCC(O)=O)C=CC=C2CO1 CPSFg - -
KAE609 ClC1=C(F)C=C2C(NC3=C2C[C@H](C)N[C@@]34C(CC5=C4C=C(Cl)C=C5)=O)=C1 ATP4h - -
WLL-vs CC(C)C[C@@H](/C=C/S(=O)(=O)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN3CCOCC3 Proteasomei,j - -
DSM265 FS(F)(F)(F)(C1=CC=C(NC2=CC(C)=NC3=NC(C(F)(F)C)=NN23)C=C1)F DHODHk - -
Atovaquone (ATQ) O=C1C([C@@H]2CC[C@@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=CC=CC=C41)=O CYTBl - -
Fosmidomycin C(CN(C=O)O)CP(=O)(O)O DXRm - -
GNF-Pf-5660 CCOC(=O)C1=C(C)NC2=C(C1C3=CC=CC=C3Cl)C(=O)CC(C2)C4=CC=C(OC)C(OC)=C4 *n - -
Naphthoquine (NQ) CC(C)(C)NCc1cc(c2c(c1O)CCCC2)Nc3ccnc4c3ccc(c4)Cl - - MMV000017
MMV665794 FC(F)(F)C1=CC(NC2=C(NC3=CC(=CC=C3)C(F)(F)F)N=C3C=CC=CC3=N2)=CC=C1 - MMV Malaria Box -
MMV000442 CC(C)(C)c1ccc2OCN(Cc3ccc(Cl)cc3)Cc2c1 - MMV Malaria Box -
MMV675939 FC(F)(F)C1=CC=C(NC2=CC(NC(C3=CC(C(F)(F)F)=CC=C3)=N4)=C4C=N2)N=C1 - Literatureo -
MMV085071 COc1cncc(c1)-c1cncc(n1)N1CCN(CC1)c1ccncc1 - MMV Pathogen Box -
MMV668311 CNc1nc(NCCCN(C)C)c2sc(cc2n1)c3cccc(c3)C(F)(F)F - Literaturep -
MMV020746 Cc1ccc(Oc2ncccc2C(=O)Nc2cccc3cccnc23)c(C)c1 - Literaturep TCMDC-125499
MMV667491 CN(C)CCCn1cnc2c(c1=N)C(c3ccc4ccccc4c3O2)c5ccc(cc5)OC - MMV Malaria Box -
MMV006455 CCCN(CCC)CC(O)COC1=C(C=CC=C1)C(=O)NC1=CC=CC=C1 - MMV Malaria Box -
MMV022478 Clc1cccc(c1)-c1cnn2ccc(nc12)C(=O)Nc1ccc(cc1)N1CCNCC1.OC(C(F)(F)F)=O - MMV Pathogen Box -
MMV007181 CC1=C2C=CC(O)=CC2=NC(NC2=CC=C(OCC3=CC=CC=C3)C=C2)=C1 - MMV Malaria Box -
MMV665971 CCOC(=O)C1=C(C)N=c2s\c(=C/c3cc(Cl)ccc3O)c(=O)n2C1c1ccc(OC)cc1 - MMV Malaria Box -
MMV665939 FC1=CC=C(C=C1)C(=O)NC1=C(SC=C1)C(=O)NC1CCCCC1 - MMV Malaria Box -
MMV019017 COCCNCC(O)CN1C2=CC=C(Cl)C=C2C2=C1C=CC(Cl)=C2 - MMV Malaria Box -
MMV000248 Cl.CCN(CC)CCn1c2ccccc2n(CC(O)c2ccc(Cl)c(Cl)c2)c1=N - MMV Malaria Box -
MMV021735 CCCCCCCN(CC1=CC=C(OC(C)(C)C(=O)OCC)C=C1)C(=O)NC1=CC=C(Cl)C=C1OCC - Literaturep TCMDC-131919
MMV022224 [O-]C(=O)C(F)(F)F.CN(C)CC1=CC=C(C=C1)C1=CC2=C(N1)N=CC=C2C1=CC=C(CN(C)C)C=C1 - Literaturep TCMDC-132409
MMV027496 COC1=C(OCCN(C)C)C=CC(=C1)C1=NC(=C(N1)C1=CC=CC=C1)C1=CC=CC=C1 - Literaturep TCMDC-137716
MMV019555 Cl.C(CCCNc1c2CCCCc2nc2ccccc12)CCNc1c2CCCCc2nc2ccccc12 - MMV Malaria Box TCMDC-124183
MMV030666 CC(C)(C)OC(=O)N1CCN(CC1)C1=CC=CC=C1NC(=O)C1=C(OC2=CC=C(F)C=C2)C(=CC=C1)C(F)(F)F - Literaturep TCMDC-140951
MMV000787 CCCOCC1=C2C=CC=NC2=C(O)C(CN2CCN(CC2)C2=CC(Cl)=CC=C2)=C1 - MMV Malaria Box -
aSlater, A.F., and Cerami, A. (1992). Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 355 , 167-169.







PI4K: Phosphatidylinositol-4-OH kinase, CPSF: Cleavage and polyadenylation specificity factor, ATP4: P-type cation translocating ATPase, DHODH: Dihydroorotate dehydrogenase, CYTB: Cytochrome B, DXR: 1-
deoxy-D-xylulose-5-phosphate reductoisomerase; SMILES: simplified molecular line entry system.
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Table 3. 3. | Assessment of compound solubility by UV/vis spectroscopy. 
Fil.: filtered; std: standard. 
Ta l  S3. Asse sment of compound s l bility by UV/vis spectroscopy.
280 300 320 340 360 800
DHA fil. 2.351 0.462 0.250 0.179 0.124 0.041
DHA std. 2.314 0.456 0.244 0.173 0.120 0.042
Chloroquine fil. 2.637 1.170 2.155 2.075 0.203 0.042
Chloroquine std. 2.747 1.331 2.562 2.178 0.204 0.041
Piperaquine fil. 2.322 0.473 0.269 0.189 0.129 0.041
Piperaquine std. 2.694 0.822 0.646 0.555 0.462 0.304
MMV007181 fil. 2.346 0.470 0.259 0.194 0.139 0.042
MMV007181 std. 2.677 0.754 0.534 0.551 0.508 0.131
MMV000442 fil. 2.517 0.606 0.380 0.310 0.248 0.086
MMV000442 std. 2.754 0.898 0.711 0.660 0.619 0.274
MMV006455 fil. 2.810 0.904 0.336 0.186 0.130 0.041
MMV006455 std. 2.826 0.928 0.329 0.175 0.120 0.041
Fil.: filtered; std: standard.




≥ 100 µM  and ≤ 500 µM
≥ 100 µM  and ≤ 500 µM














Herein we report the results of P. falciparum asexual blood stage susceptibility assays 
that compared the susceptibility of early rings, late rings, early trophozoites, late 
trophozoites and schizonts, for a set of 36 clinical and experimental antimalarials. These 
studies, which exposed each tightly-synchronized stage for 8 h and assessed growth 
stage at the same 60 h timepoint (Fig. 3.1A), extend earlier experimental designs that 
assessed activity on a subset of stages or did not include wash-offs to restrict exposure 
to each stage 349,350. Since compounds are washed out after each exposure moment and 
parasites are allowed to continue to grow in absence of compound until the end of the 
assay, the stage specificity assay quantifies the cytotoxic (killing) effect of compounds. 
The IC508h values are therefore in essence stage-specific half-maximal lethal doses (LD50) 
351. This contrasts with the IC5072h values that are determined in assays that expose
parasites continuously to compounds and measure the cytostatic (growth inhibitory) effect 
of compounds. Our results were combined with metabolomic profiling of the cellular 
pathway perturbations caused by these compounds, as an exploratory approach to 
identify common or unique profiles among the tested antimalarials. Classification of 
compounds according to the timing of their peak activity revealed a remarkable variety of 
profiles among both clinical and the experimental compounds (Fig. 3.6). As examples, 
the inhibitors DSM265 and atovaquone (which target DHODH and CytBC1 respectively) 
showed activity against late trophozoites only, and the PI4K inhibitor KAI407 showed 
activity against only schizonts, in good agreement with earlier studies 61,352,353 (Fig. 3.1; 
Fig. 3.5; Table 3.1). 
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Compounds with different chemical scaffolds that are known to target the same or related 
pathways showed similar stage specificity and metabolic profiles. This was especially 
apparent for atovaquone and DSM265 that act on related mitochondrial processes (Fig. 
3.5A). These agents also shared similar killing dynamics, with a monophasic survival 
curve for the highly sensitive late trophozoites and biphasic curves for early trophozoites 
and schizonts (Fig. 3.5B). Of note, when parasite survival was assessed using only the 
SYBR Green signal, and not the Mitotracker signal, we observed the same killing 
dynamics for atovaquone and DSM265. This likely reflects a dual purpose of the 
mitochondria of maintaining its membrane potential through the mitochondrial electron 
transport chain, required for the production of ATP, and enabling pyrimidine biosynthesis 
through DHODH (Fig. 3.5A). Inhibition of DHODH by DSM265 will not only affect 
pyrimidine biosynthesis but also the recycling of ubiquinone that is crucial for the parasite 
to maintain its mitochondrial membrane potential. Likewise, inhibition of CytB by 
atovaquone will not only directly affect the mitochondrial membrane potential, but also the 
recycling of ubiquinone and therefore the function of DHODH. DHODH and CytB are thus 
two distinct drug targets that are functionally linked. In accordance, DSM265 and 
atovaquone show the same stage specificity profile. Pyrimidines are most needed in late 
trophozoites when DNA synthesis peaks, allowing the production of daughter merozoites 
during schizogony 354. Without pyrimidines, late trophozoites would not be able to develop 
into functional schizonts, resulting in a low IC508h and a smooth monophasic killing curve 
in late trophozoites (Fig. 3.5B). In early trophozoites and schizonts, the dependency on 
pyrimidines is lower but a functional mitochondrial membrane potential would still appear 
to be vital for the many ongoing biological processes, leading to a biphasic response in 
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which the first shift relates to pyrimidine biosynthesis and a second shift relates to the 
mitochondrial membrane potential. Early and late rings showed a monophasic response 
with high IC508h values, reflecting a parasite growth phase when pyrimidine biosynthesis 
and mitochondrial activity appear to be minimal. Atovaquone inhibition through membrane 
potential disruption was relatively ineffective in our 8 h exposure model, illustrating the 
need for longer compound exposure for mitochondrial electron transport chain inhibitors 
352,355. Importantly, incomplete killing by atovaquone and DSM265 was observed in all 
stages, matching previous data from recrudescence-based assays that showed 
atovaquone to be a slow and incomplete killer 332,356.  
 
Of note, the late trophozoite stage specificity profiles for ATQ and DSM265 are consistent 
with the timing of expression of their targets: cytb expression peaks during the late 
trophozoite stage, whereas maximal expression of dhodh spans early to late trophozoite 
stages 357. The same holds true for KAE609 that targets PfATP4: transcription of pfatp4 
peaks at the early trophozoite stage 357, consistent with KAE609 being inactive against 
rings yet active against early trophozoites and later stages. Interestingly, pi4k, which 
encodes the target of KAI407, is transcribed at fairly stable levels without showing a clear 
peak at any stage 357. The schizont-specific activity profile of KAI407 may be determined 
by the availability of substrates that interact at this stage with PI4K. 
 
These assays also differentiated the mode of action of chloroquine, piperaquine, and 
mefloquine, which share a core 4-aminoquinoline ring structure. Piperaquine essentially 
consists of two molecules of chloroquine connected by a central linker. Chloroquine and 
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piperaquine are generally thought to act at the highly metabolically active trophozoite 
stage by inhibiting the biomineralization of free heme, released during hemoglobin 
digestion, into hemozoin, thereby causing a buildup of toxic free heme or heme-drug 
adducts 41. Both chloroquine and piperaquine showed a similar stage specificity profile 
when the error margin is taken into account, and exerted potent growth inhibition in early 
ring stages. This would suggest that hemoglobin catabolism begins even in early rings, 
prior to the formation of the digestive vacuole inside which the bulk of hemozoin is 
generated. This inference is supported by a previous report 347 and studies that detected 
hemoglobin uptake 358 and activity of falcipains (required for hemoglobin digestion 359) in 
very early rings. Notably, early rings showed a flatter slope of the dose-dependent curve 
than late rings and trophozoites, indicating different growth inhibitory dynamics (Fig. 3.1, 
Fig. 3.2). Metabolic perturbation profiles, nonetheless, revealed a strikingly different 
profile for chloroquine and piperaquine (Fig. 3.7).  Chloroquine induced various 
perturbations that were not observed under piperaquine pressure, such as >2-fold 
increased levels of dAMP, dUTP, cytidine, xanthosine and N-acetyl-lysine, decreased p-
hydroxybenzoate levels, and decreased peptide levels that are characteristic for 
hemoglobin catabolism inhibition. Some of these metabolic changes in chloroquine-
exposed parasites, such as the increased dAMP levels, caused chloroquine to 
metabolically cluster with the PfATP4 inhibitor KAE609 and other compounds that cause 
an overall disturbance in cellular homeostasis. This clustering, however, is based on 
rather modest changes and should be interpreted with caution. Piperaquine metabolically 
clustered with other compounds that induced an overall low differential fold change (Fig. 
3.7). The only notable changes were >2-fold decreased levels of dCDP, dTMP, guanosine 
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and guanine. This suggests that piperaquine might have an additional mode of action 
beyond inhibition of hemozoin formation that perturbs purine and pyrimidine metabolism. 
 
Mefloquine, an arylamino alcohol that also shares a quinoline ring, was earlier reported 
to inhibit hemozoin formation in parasites at a lower level than chloroquine 93, possibly 
because of reduced mefloquine accumulation in the digestive vacuole. Earlier studies 
examining mefloquine and its relationship to the primary resistance determinant PfMDR1 
(located on the membrane of the digestive vacuole) suggested that mefloquine acts 
primarily outside the digestive vacuole 297. The difference in mode of action between 
mefloquine and chloroquine is also reflected in their stage specificity and metabolomics 
profiles, with mefloquine showing peak activity only in trophozoites and clustering 
separately from other compounds affecting hemoglobin catabolism (Fig. 3.7). These data 
further support the notion that the target of mefloquine is presumably located outside of 
the digestive vacuole, affecting the parasite in ways that could not be detected by our 
metabolomics study. 
 
The clinical antimalarial lumefantrine displayed peak activity during both rings and 
trophozoites, similar to chloroquine and piperaquine but different from the trophozoite-
only peak activity of mefloquine. Metabolically, lumefantrine induced minor peptide 
increases and clustered with GNF-Pf-5660 that is known to affect hemoglobin uptake 
without directly targeting hemozoin formation 271. The different stage specificity and 
metabolic profiles between lumefantrine and mefloquine suggest distinct mode of actions, 
despite PfMDR1 being a determinant of low-level resistance to both 183.  
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Methylene blue is known to act as a redox cycler and is used clinically to treat 
methemoglobinemia via its reduction of Fe3+ to Fe2+ 360. Methylene blue also binds 
hematin (a precursor of hemozoin crystals) at low micromolar concentrations in vitro 360. 
Our finding of similar stage-specificity and metabolomic profiles between methylene blue 
and piperaquine suggest that both could impact heme detoxification and hemozoin 
formation, albeit via different mechanisms. Methylene blue potentially causes a reduction 
of Fe3+ whereas piperaquine is presumed to bind Fe3+-heme and prevent its incorporation 
into chemically inert hemozoin 206. Methylene blue, in contrast to piperaquine, is also 
potent against mature gametocytes that are not thought to degrade hemoglobin 334, 
implying an additional mode of action for methylene blue that might affect additional redox 
cycling agents such as NADPH levels 240. 
Interestingly, ferroquine and naphthoquine, which are both chloroquine derivatives that 
are currently part of artemisinin-based combination therapies under clinical trials 361,362, 
shared a unique stage-specificity profile showing peak activity during early rings and a 
gradual increase of IC508h values through to schizonts (Fig. 3.2). Ferroquine has 
hemozoin inhibitory activity similar to chloroquine and has been shown to induce the 
formation of hydroxyl radicals via the Fenton reaction, leading to lipid peroxidation and 
exacerbating oxidative stress in the parasite 363-365. This additional mode of action might 
contribute to the unique stage-specific profile of ferroquine action. The mode of action of 
naphthoquine is less understood. Even though parasites exposed to naphthoquine and 
ferroquine did not reveal major changes in the levels of detected metabolites thus causing 
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them to cluster in the low fold change metabolic group (Fig. 3.7), their shared and 
distinctive stage-specificity profiles suggest a common target or pathway. 
Compounds with peak activity during ring stages are highly desired. In our assays, 
naphthoquine, ferroquine and WLL-vs showed peak activity specifically during ring 
stages, whereas chloroquine, piperaquine, methylene blue, dihydroartemisinin, 
lumefantrine, GNF-Pf-5660, MMV022224 and MMV668311 showed peak activity in rings 
and trophozoites. This diversity among ring-active compounds suggests the presence of 
multiple druggable processes in rings, despite this stage being considered less 
metabolically active 260 than trophozoites. One such process involves the proteasome, 
since the ring-active compound WLL-vs specifically binds to and inhibits the β2 and β5 
subunits of the P. falciparum 26S proteasome 269,270. Other processes that appear to 
begin early in rings include hemoglobin endocytosis and catabolism 271,358,359.  
We note that WLL-vs, included in our study, is a covalent binder of the P. falciparum 26S 
proteasome inhibitor, meaning that wash-out protocols would have little effect on its 
irreversible mode of action. Previous studies on Plasmodium have shown that mRNA 
transcripts are produced in a “just-in-time” fashion, i.e. when they are needed for the 
parasite’s development 357. This would suggest that the chances of falsely detecting early 
stage activity are minimal. However, a lingering effect after drug wash-out could 
theoretically result in overestimating compound activity during later stages. For this 
reason, we have included five different time points at which compound exposure was 
started, followed by drug wash-outs, in order to minimize compound carry over. This 
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approach was validated with our WLL-vs data, which showed lower IC508h values in rings 
compared to trophozoites and schizonts (Fig. 3.2).  
 
An established high-priority mode of action is inhibition of mitochondrial functions, 
targeting either DHODH (DSM265) or CytBC1 (atovaquone) 366 (Fig. 3.5A). Both, 
however, yield resistance at low inocula, which in patients translates into an increased 
risk of treatment failure using these classes of inhibitors 367,368. The experimental 
compounds MMV000787, MMV021735 and MMV030666 showed peak activity in late 
trophozoites, albeit with incomplete killing, and shared the same distinct metabolic profile 
of increased dihydroorotate and N-carbamoyl-L-aspartate levels and decreased orotidine 
5-P levels (Fig. 3.7) that is characteristic for DHODH and CytBC1 inhibition 260. 
Interestingly, selections with these former compounds failed to yield resistant parasites, 
even at high inocula of 5×108 parasites. They also did not show the biphasic curves 
observed for atovaquone and DSM265. These data raise the possibility that inhibition of 
mitochondrial pathways might be achievable through mode of actions that are distinct 
from DHODH and CytBC1 and that are less prone to resistance acquisition. In addition to 
the metabolic signature of mitochondrial inhibition, MMV030666 also induced decreased 
peptide levels, causing it to metabolically cluster with compounds inhibiting hemoglobin 
catabolism (Fig. 3.7). However, MMV030666 still maintained a late trophozoite stage-
specific activity profile similar to that of DSM265 and atovaquone but distinct from the 
overall trophozoite or ring plus trophozoite peak activity profiles usually observed for the 
majority of compounds with a hemoglobin catabolism metabolic signature (Fig. 3.4, Fig. 
3.5, Fig. 3.7). Cell morphological analysis of MMV030666-exposed parasites (Fig. 3.11) 
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identified late trophozoites as the most sensitive intra-erythrocytic stage, consistent with 
mitochondrial inhibition, but also showed a bloated digestive vacuole that is characteristic 
for inhibitors of Hb catabolism 201. 
Most hits that clustered within the hemoglobin catabolism group, characterized by 
decreased peptide levels 260, showed peak activity in trophozoites (MMV027496, 
MMV019555, MMV000248, MMV006455, MMV007181 and MMV000442). The exception 
was GNF-Pf-5660 271, lumefantrine and MMV665794 that showed peak activity against 
rings and trophozoites. This observation, plus additional metabolic changes induced by 
MMV019555, highlights the potential diversity in mode of actions among compounds 
showing hemoglobin catabolism perturbation.  
Among all compounds tested, MMV022224 was unique both in its metabolomic fingerprint 
and its stage specificity. Exposure to MMV022224 caused increased peptide levels and 
only this compound showed activity exclusively in rings and trophozoites but not in 
schizonts. Peptide accumulation may suggest a metabolic disruption further downstream 
in the hemoglobin catabolism pathway, possibly of an aminopeptidase or transporter. 
These unique profiles highlight MMV022224 as an attractive hit from a discovery and 
development perspective. 
It is important to note that the metabolomics experiments in this study were exploratory 
in nature, involving one to two biological replicates to screen for known and novel 
candidate mode of actions within a large set of compounds. Once compounds are 
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selected and prioritized for further discovery or development studies, these metabolomics 
data should be complemented with targeted in-depth follow-up studies to validate 
candidate targets and mode of actions as demonstrated recently for a new class of 
pantothenamides 369. 
 
The asexual blood stage susceptibility profiles of compounds may also help determine 
whether a protein is a target or solely a resistance mechanism. Resistance selections 
with MMV675939, MMV665939 and MMV020746 all identified single nucleotide 
polymorphisms or copy number variations in the ABC transporter I family member 1, also 
known as ABCI3 (PF3D7_0319700) 233. MMV675939 was most active on early and late 
trophozoites with IC508h values that were only 2-fold higher than the IC5072h value, while 
MMV020746 and MMV665939 showed IC508h values that were >28-fold higher than the 
IC5072h (Table 3.1). This contrast between the timing of peak activity for MMV675939 and 
the two other compounds suggests that they have different mode of actions and that 
ABCI3 is solely a resistance mediator and not the target.  
 
Asexual blood stage susceptibility profiling may also help prioritize screening hits. 
Compounds with potent IC508h values across all stages are of particular interest for further 
development as such activity profiles might compensate for a faster clearance or other 
pharmacokinetic-related issues that reduce in vivo exposure time. Dihydroartemisinin and 
piperaquine, two first-line antimalarial drugs, showed activity on all stages with IC508h 
values at the most susceptible stages that were within 2-fold of their IC5072h values (Table 
3.1). Chloroquine, mefloquine and lumefantrine showed larger IC508h over IC5072h ratios, 
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but with IC508h values still <300 nM (Table 3.1). Based on these parameters, ferroquine, 
WLL-vs, and GNF-PF-5660 represent promising antimalarial scaffolds. WLL-vs is of 
particular interest given its selectivity for the parasite proteasome and the fact that 
resistance is rare and low-grade 269,270,370.  Ferroquine has shown promising efficacy in 
phase II trials 361 and our assays indicated a unique ring-active profile that underscores 
its potential. With GNF-Pf-5660, chemical derivatization efforts are underway to improve 
its partial in vivo efficacy, established in rodent malaria models 271. 
Compounds that show IC508h values orders of magnitude larger than IC5072h values are 
potentially of less interest as these may have multiple mode of actions throughout intra-
erythrocytic development and/or require longer exposures to achieve full killing. In 
addition, such a profile indicates that the short exposures usually applied for 
metabolomics will likely yield a less informative response. None of the current clinical or 
advanced candidate antimalarials showed this profile, suggesting that this is indeed a 
good de-prioritization criterion for further development. Examples of experimental 
compounds with such an unfavorable profile in our dataset were MMV022478 and 
MMV019017 (Fig. 3.4), and MMV665939 and MMV020746 that showed IC508h values > 
10 μΜ at all stages (data not shown) (Table 3.1). 
MMV000442, MMV006455, MMV007181 and MMV665971 showed a peculiar profile in 
early and late ring stages, with initial growth inhibition at lower compound concentrations 
that reverses to less inhibition at higher concentrations (Fig. 3.3, Fig. 3.4). Solubility 
assays with MMV0004442, MMV006455 and MMV665791 indicated that these 
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compounds have an aqueous solubility >100 μΜ, indicating that these survival curves are 
not due to solubility issues. This phenomenon has been observed in other chemical series 
and can at times be overcome through lead optimization 311. Despite their undesirable 
dose-response curves, these compounds might still prove valuable as starting points for 
drug discovery efforts.  
 
The asexual blood stage specificity profiles can also inform the selection of partner drugs 
for combination therapies. Ideally, combinations would target all different asexual blood 
stages. As an example, schizont-specific compounds could be partnered with compounds 
that target rings and trophozoites. These profiles can also be used to devise strategies to 
delay the emergence of resistance. For example, the late trophozoite-active compound 
DSM265 could be combined with another compound with a broader activity profile 
including late trophozoite in order to delay the emergence of DSM265 resistance 367.  
 
In summary, integrating investigations into antimalarial stage-specific mode of actions 
including metabolic perturbations into drug discovery and development programs should 
benefit ongoing efforts to develop new medicines to counter the spread of antimalarial 
multidrug resistance, as part of the mission to eliminate this disease. 
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Fig. 3. 8. | Structures of the tested antimalarials, part 1. References on mode of action can 






























































































































































































Fig. 3. 9. | Structures of the tested antimalarials, part 2. References on mode of action can 



























































































































































Fig. 3. 10. | Overall activity profile of compounds.  
Overall activity is defined as the stages with IC508h values <1 μM. Fosmidomycin, MMV000787, MMV019017, MMV020746, 
MMV022478 and MMV665939 are not depicted, as all stages showed IC508h values >1 μM. MMV006455, MMV000442, 
MMV007181 and MMV665971 are omitted from panel A due to incomplete killing at individual stages. DHA: 
dihydroartemisinin; CQ: chloroquine; PPQ: piperaquine; LMF: lumefantrine; MQ: mefloquine; MB: methylene blue; FQ: 
ferroquine; NQ: naphthoquine; ATQ: atovaquone. 
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Fig. 3. 11. | Microscopical studies confirm the stage specificity profiles of MMV030666 and 
MMV022224, using ATQ and CQ as controls.  
Synchronized parasites were exposed to 3× their lowest IC508h at the indicated life stages, 
and were assessed at the end of each exposure. ATQ: atovaquone, CQ: chloroquine. 
No drug
control
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4.1. Abstract 
Widespread Plasmodium falciparum resistance to first-line antimalarials underscores the 
vital need to develop compounds with novel modes of action and identify new druggable 
targets. Here, we profiled five compounds that potently inhibit P. falciparum asexual blood 
stages. Resistance selection studies with three carboxamide-containing compounds, 
confirmed by gene editing and conditional knockdowns, identified point mutations in the 
parasite transporter ABCI3 as the primary mediator of resistance. Selection studies with 
imidazopyridine or quinoline-carboxamide compounds also yielded changes in ABCI3, 
this time through gene amplification. The mode of action of the imidazopyridine was 
attributed to inhibition of heme detoxification, as evidenced by cellular accumulation and 
heme fractionation assays. For the copy number variation-selecting compounds, we 
found that resistance, manifesting as a biphasic concentration-response curve, could 
independently be mediated by mutations in the chloroquine resistance transporter PfCRT. 
These studies reveal the interconnectedness of P. falciparum transporters in overcoming 
drug pressure in different parasite strains. 
4.2. Introduction 
An estimated 1.5 billion malaria cases and 7.6 million deaths have been averted since 
2000 as a result of chemotherapy, vector control, diagnosis and access to treatment 2. 
Despite this extraordinary success, 229 million new cases and 409,000 deaths were 
reported in 2019 alone 2, underscoring the difficult path to malaria eradication. The onset 
of wide-spread antimalarial parasite resistance, dating back to quinine resistance in 1910 
and chloroquine (CQ) resistance in the 1950s 41, has been a major obstacle in malaria 
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drug discovery and development efforts and has continuously compromised the important 
role played by chemotherapy in saving lives. Recently, P. falciparum resistance to first-
line Artemisinin-based Combination Therapies (ACTs) has been spreading across 
Southeast Asia and is now threatening sub-Saharan Africa 371-373. This makes it 
imperative that we identify new druggable targets in malaria parasites using compounds 
that have novel modes of antiplasmodial action. 
 
The Malaria Drug Accelerator (MalDA) consortium is a target-guided drug discovery 
platform that applies in vitro blood stage, liver stage and gametocyte screening of 
compounds to identify novel assayable targets 233,343,374. Similar whole-cell screens have 
been used to identify antiplasmodial compounds with sub-micromolar potencies by other 
groups 234-236,342-345 but the lack of target identification has stalled the development of 
many of these compounds into candidates for clinical application 346. We describe here a 
series of experiments including in vitro resistance selections and CRISPR/Cas9 genetic 
validation, drug susceptibility, conditional knock-down (cKD), drug cellular accumulation, 
protein localization and heme fractionation assays to characterize culture-adapted P. 
falciparum resistance to five chemically distinct compounds studied by MalDA. These 
data highlight an important role for the ATP-binding cassette (ABC) transporter ABCI3 





4.3.1. In vitro selection studies on Plasmodium falciparum asexual blood stage 
parasites select for ABCI3 point mutations or gene amplifications.  
We identified possible P. falciparum resistance mechanisms to five chemically distinct 
compounds (Fig 4.1) by performing in vitro single-step resistance selections 375. 107-109 
wild-type cloned 3D7-A10 or Dd2-B2 parasites were exposed to 3× the half maximal growth 
inhibitory concentrations (IC50) of each compound, tested in triplicate. Resistance was 
obtained for all five compounds and clones were recovered by limiting dilution. Whole-
genome sequencing results of these clones segregated the compounds into two distinct 
categories: A) those that generated copy number variations (CNVs) (compounds 1 and 2); 
and B) those that generated single nucleotide polymorphisms (SNPs) (compounds 3, 4 and 
5) in ABCI3 (Fig 4.1). Specifically, compound 3 generated resistant parasites harboring
either the ABCI3 Y2079C or R2180P mutations, compound 4 the L690I or R2180G 
mutations, and compound 5 the F689C or S696Y mutations (Fig 4.2A).  
The CNV clones selected using compounds 1 and 2 all had three copies of ABCI3, 
compared to a single copy in the parental 3D7-A10 line, and generated biphasic dose-
response curves against both compounds. These biphasic curves yielded two IC50 values, 
termed IC50 shift 1 and shift 2. The IC50 shift 1 and 2 for the CNV line against compound 1 
was 106±8 nM and 1249±79 nM respectively relative to the parental IC50 of 47±0.8 nM 
(Table 4.1). For compound 2, IC50 shifts 1 and 2 were 265±34 nM and 4054±69, 
respectively, compared to the parental IC50 of 281±19 nM. The Y2079C and R2180P SNPs 
that were generated from 3D7-A10 parasite selections with compound 3 resulted in a ~3× 
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shift in IC50 (2746±89 nM and 3029±141 nM respectively, compared to the parental value 
of 1012±64 nM). For compound 4, the ABCI3 L690I and R2180G mutants were ~9-16× 
resistant to the compound (2300±217 nM and 1268±55 nM respectively compared to the 
3D7-A10 parental value of 140±14 nM). Selections using compound 5 were performed on 
a Dd2-B2 background, yielding ABCI3 F689C and S696Y mutations that caused a ~11-
180× increase in IC50, i.e. 89±4 nM and 1433±24 nM compared to the parental Dd2-B2 IC50 
of 8.0±0.9 nM (Table 4.2).    
To test the causal role of ABCI3 SNPs in P. falciparum resistance to these compounds, we 
developed a CRISPR/Cas9 gene editing strategy to edit the L690I mutation into wild-type 
3D7-A10 parasites (Fig 4.2B). Results with the edited (ed.) line (ABCI3 L690I ed.) confirmed 
similar levels of resistance to the selection compound 4 as observed with the drug-
pressured line (ABCI3 L690I) (20-fold vs 22-fold IC50 increases relative to the parent for edited 
vs selected mutants; Fig 4.2C; Table 4.3). Additionally, this mutation conferred a modest 
(2- to 2.3-fold) level of cross-resistance to another SNP-selecting compound 3 (that 
selected for Y2079C and R2180P). The L690I mutants showed no significant difference in 
susceptibility to the CNV-selecting compound 1 (Fig 4.2C; Table 4.3).  
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Fig. 4. 1. | Chemical structures of MMV compounds used in this study.  
Compounds 1 (MMV675939) and 2 (MMV084864) selected for CNVs in ABCI3 whereas 
3 (MMV665939), 4 (MMV020746) and 5 (MMV1634566) selected for SNPs in this gene. 
1 is a 2,6-disubstituted imidazopyridine (2-(3-(trifluoromethyl)phenyl)-6-N-(5-(trifluoro-
methyl)pyridin-2-yl)-1H-imidazo[4,5-c]pyridine); 2 is a quinoline tetrazole carboxamide 
(N-quinolin-3-yl-3-tetrazol-1-yl-benzamide); 3 is a  thiophene carboxamide (N-cyclohexyl-
3-[(4-fluoro-benzoyl)amino]-2-thiophenecarboxamide); 4 is an 8-aminoquinoline pyridine 



















































































































Fig. 4. 2. | ABCI3 L690I mutation confers resistance to compounds 3 and 4. 
(A) Topology of ABCI3 protein based on the TMHMM, InterPro and Uniprot structural
algorithms. SNP-selecting compounds (3-5) generated the mutations indicated in red,
whereas CNV-selecting compounds are boxed. (B) The ABCI3 L690I point mutation was
introduced into parental 3D7-A10 parasites using a two-plasmid CRISPR/Cas9 approach
with the nearby double stranded break site indicated with a thunderbolt. Transfected
parasites were selected using blasticidin-S deaminase (BSD). gRNA: guide RNA;
yDHODH: yeast dihydroorotate dehydrogenase; UTR: untranslated region. (C) Parasites
Cas9-edited to express the ABCI3 L690I mutation (ABCI3 L690I ed.) phenocopied the gain
of resistance observed in 4-pressured parasites harboring this same mutation (ABCI3
L690I). L690I conferred cross resistance to 3 but not the CNV-selecting compound 1. Bar
graphs indicate mean±SEM IC50 values of 72 h dose-response assays with asynchronous




Table 4. 1. | Plasmodium falciparum asexual blood stage IC50 data in nM for the tested antimalarials. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates); () the IC50 and SEM of the 
second shift of the biphasic curve. * Selections with compound 5 were run on a Dd2-B2 parental background (IC50 = 8nM). 
P values were determined by comparison between the variant lines and parental 3D7-A10 using Mann-Whitney U tests. 
Antimalarials Mean IC50 SEM N
Mean 
IC50
SEM N P  value
Mean 
IC50
SEM N P  value
Mean 
IC50
SEM N P  value
Mean 
IC50
SEM N P  value
Mean 
IC50
SEM N P  value




(<0.0001) 48.0 0.8 14 0.71 58.0 2.0 14 0.0001 56.0 2.0 5 0.0062 45.0 1.0 7 0.23




(0.0095) 252 13.0 6 0.24 275 12.0 6 0.94 260 14.0 6 0.48 208 11.0 6 0.0043
3 1012 64.0 11 2890 246 5 0.0005 2746 89.0 15 <0.0001 3029 141 15 <0.0001 2784 196 8 <0.0001 2511 225 8 <0.0001
4 140 14.0 10 500 47.0 15 <0.0001 1241 34.0 8 <0.0001 1918 61.0 7 0.0001 1268 55.0 4 0.002 2300 217 5 0.0007
5* 2.0 0.1 10 25.0 0.9 11 <0.0001 8.0 0.7 6 0.0002 29.0 1.7 6 0.0002 21.0 1.0 6 0.0002 2.0 0.3 9 0.36
6 16.0 2.0 11 32.0 3.0 15 0.0001 20.0 1.0 10 0.11 25.0 1.0 10 0.0015 23.0 1.0 8 0.01 17.0 0.7 8 0.54
Dihydroartemisinin 0.4 0.1 6 0.3 0.0 6 0.13 0.4 0.1 6 0.39 0.6 0.1 6 0.24 0.4 0.1 6 0.59 0.4 0.1 6 0.31
Chloroquine 5.0 0.5 4 4.9 0.4 5 0.91 5.1 0.6 5 0.90 6.4 0.6 6 0.17 4.8 0.3 5 0.56 5.3 0.4 5 0.73
Piperaquine 8.5 0.6 5 8.0 1.1 5 0.84 9.5 1.2 5 0.31 10.0 1.6 5 0.55 8.7 1.0 5 0.42 8.2 0.9 5 0.84
md-amodiaquine 10.6 0.2 6 6.6 0.8 6 0.002 7.6 0.9 6 0.04 11.3 0.4 5 0.25 11.7 1.4 4 >0.9999 10.7 0.5 5 >0.9999
Quinine 13.9 0.7 6 11.5 0.7 4 0.11 12.8 0.8 5 0.33 16.1 0.7 6 0.06 12.2 0.8 4 0.11 12.1 0.7 4 0.19
Lumefantrine 0.8 0.2 4 1.4 0.3 4 0.34 1.1 0.2 4 0.49 1.4 0.2 5 0.11 0.8 0.3 5 0.90 0.9 0.3 5 0.90
Mefloquine 4.2 0.6 5 4.0 0.5 5 0.84 4.6 0.6 6 0.66 5.7 0.7 6 0.18 5.6 0.7 5 0.22 5.2 0.5 5 0.31
ABCI3 Y2079CABCI3 3 copies3D7-A10 ABCI3 L690IABCI3 R2180GABCI3 R2180P
14
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Table 4. 2. | Plasmodium falciparum asexual blood stage IC50 data in nM for the tested antiplasmodial compounds. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates); () the IC50 and SEM of the 
second shift of the biphasic curve. * Selections with compound 5 were run on a Dd2-B2 parental background.  P values 
were determined by comparison between the variant lines and parental Dd2-B2 using Mann-Whitney U tests. -- not 
determined. 
Antimalarials Mean IC50 SEM N Mean IC50 SEM N P  value Mean IC50 SEM N P  value
1 27.0(1404) 3.0(343) 4 30.0 3.0 6 -- 34.0 2.0 6 --
2 265(3542) 14.0(465) 5 257 26.0 7 -- 279 26.0 7 --
3 1546 95.0 7 956 112 7 0.0041 >5 mM 4 0.0061
4 246 20.0 7 36.0 4.0 7 0.0006 >10 mM 4 0.0061
5* 8.0 0.9 6 89.0 4.0 6 0.0022 1433 24.0 7 0.0012
Table S1A-2 (related to Fig. 3). Plasmodium falciparum asexual blood stage IC50 data in nM for the tested
ntiplasmodial compounds.
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates); () the IC50 and SEM of
the second shift of the biphasic curve. * Selections with compound 5 were run on a Dd2-B2 parental background. P 
values were determined by comparison between the variant lines and parental Dd2-B2 using Mann-Whitney U tests. -
- not t r i ed.
Dd2-B2 ABCI3 F689C ed. ABCI3 S696Y ed.
14
3 
Table 4. 3. | Plasmodium falciparum asexual blood stage IC50 data in nM for compounds 1, 3 and 4 against 3D7-A10 parent, 
drug-selected, and gene-edited L690I parasite lines. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates). ABCI3 L690I: P. falciparum line 
generated from selections with compound 4. ABCI3 L690I ed.: P. falciparum line generated by introducing the ABCI3 L690I 
mutation into parental 3D7-A10 using CRISPR/Cas9. P values were determined by comparison between the variant lines 
and parental 3D7-A10 using Mann-Whitney U tests. 
Compounds Mean IC50 SEM N Mean IC50 SEM N P  value Mean IC50 SEM N P  value
1 23.0 2.6 6 16.0 2.4 4 0.11 16.0 0.8 4 0.11
3 1548 161 4 3616 299 4 0.03 3327 436 4 0.03
4 188 30.0 4 4168 286 4 0.03 3805 585 4 0.03
3D7-A10 ABCI3 L690I ABCI3 L690I ed.
144 
We also validated the ABCI3 F689C and S696Y mutations by introducing them into parental 
Dd2-B2 parasites using a separate “all in one” CRISPR/Cas9 strategy (Fig. 4.3). The edited 
(ABCI3 F689C ed. and ABCI3 S696Y ed.) and original drug-selected lines (ABCI3 F689C and ABCI3 
S696Y) displayed similar gains of resistance to compound 5 (11-fold vs 12-fold increase in 
IC50 for F689C selected vs edited clones, and 179-fold vs 203-fold IC50 increase for the 
S696Y selected vs edited clones, respectively; Fig. 4.3; Table 4.4). These data confirm 
that the L690I, F689C and S696Y mutations in ABCI3 are drivers of parasite resistance to 
































































Fig. 4. 3. | ABCI3 F689C and S696Y mutations are the drivers of parasite resistance to 
compound 5.  
(A) CRISPR/Cas9 strategy to introduce ABCI3 point mutations into the wild-type Dd2-B2
parasite line. The plasmid contains a human dihydrofolate reductase (hDHFR) selectable
marker and a sequence encoding the guide RNA (gRNA), expressed from a PcDT and a
U6 promoter, respectively. (B) F689C- and S696Y-edited parasites have comparable levels
of resistance to compound 5 as do the selected clones. pBS: BlueScript plasmid; Hrp2:
histidine-rich protein 2; Hsp86: Heat shock protein 86; SpCoCas9: Streptococcus
pyogenes-Plasmodium falciparum codon-optimized Cas9; CAM: Calmodulin; PcDT:
Plasmodium chabaudi dihydrofolate reductase-thymidylate synthase;  UTR: Untranslated
region. Mean ± SEM; N³4,n=2. Mann-Whitney U tests compared the edited and selected





Table 4. 4. | Plasmodium falciparum asexual blood stage IC50 data in nM for compound 5 against Dd2-B2 parent, selected and 
edited ABCI3 F689C and S696Y cell lines respectively. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates). ABCI3 F689C/ ABCI3 S696Y: P. 
falciparum lines generated from selections with compound 5. ABCI3 F689C ed./ ABCI3 S696Y ed.: P. falciparum lines generated 
by introducing ABCI3 F689C and S696Y mutations into parental Dd2-B2 using CRISPR/Cas9. P values were determined 
by comparing the shift in IC50 between the variant lines and parental Dd2-B2 using Mann-Whitney U tests. 
Compound Mean IC50
SEM N Mean IC50
SEM N P  value Mean IC50
SEM N P  value Mean IC50
SEM N P  value Mean IC50
SEM N P  value
5 8.0 0.9 6 89.0 4.0 6 0.0022 94.0 10.0 6 0.0022 1433 24.0 7 0.0006 1626 56.0 7 0.0012




We conducted 72 h susceptibility assays using asynchronous 3D7-A10 or Dd2-B2 parental 
lines and their corresponding drug-resistant clones to investigate levels of resistance 
conferred by CNVs of ABCI3 to the SNP-selecting compounds and vice versa. Results from 
these experiments showed that CNVs of ABCI3 not only conferred parasite resistance to 
the CNV-selecting compounds 1 and 2 but also to the three SNP-selecting compounds (~3-
fold increase in IC50 for compound 3, ~3.6-fold for compound 4 and ~12.5-fold for compound 
5; Table 4.1). In addition, the 3D7-A10-based CNV clone with three copies of ABCI3 and 
the Dd2-B2 parental line displayed biphasic dose-response curves when tested against 
compounds 1 and 2 (Fig. 4.4A, C).  
 
We observed that the effect of mutations in ABCI3 was compound-specific and sometimes 
sensitized parasites to the SNP-selecting compounds. For example, ABCI3 F689C 
mutation conferred parasite sensitivity to both compounds 3 and 4 (~2× and 7× decrease 
in IC50 respectively) despite conferring parasite resistance to compound 5 (~11× increase 
in IC50; Fig. 4.4C; Table 4.2). With the exception of the L690I mutation that does not confer 
parasite resistance to compound 5, the other profiled mutations in ABCI3 (Y2079C, 
R2180P, R2180G and S696Y) conferred parasite resistance to the three SNP-selecting 
compounds (Fig. 4.4B-C; Table 4.2). However, none of the profiled SNPs in ABCI3 
conferred resistance to the two CNV-selecting compounds 1 and 2 (Fig. 4.4A, C; Table 
4.2). Interestingly, the L690I mutant parasites (selected with compound 4) showed no shift 
in susceptibility to compound 5 even though that compound selected for an adjacent ABCI3 
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Fig. 4. 4. | CNVs of ABCI3 confer resistance across all tested chemotypes while SNPs 
confer compound-specific resistance or hypersensitization.  
(A) ABCI3 amplification in 3D7-A10 parasites mediates a biphasic gain of resistance to 1
and 2, whose activities are unaffected by SNPs in this gene. (B) ABCI3 CNVs and most
selected SNPs confer resistance in 3D7-A10 parasites to the three SNP-selecting
compounds 3-5. The L690I mutation, however, does not impact the potency of compound
5. (C) The F689C and S696Y ABCI3 SNPs edited into Dd2 parasites eliminate the biphasic
dose-response observed with 1 and 2 tested against the Dd2 parent. These mutations
afford compound-specific gains of resistance or hypersensitization to the SNP-selecting
compounds 3-5. Mean ± SEM IC50 values and dose-dependent inhibitions are shown in the
bar graphs and dose response curves respectively and were calculated from 72 h assays
with asynchronous parasites. N³5, n=2; **p < 0.01; ***p < 0.001; ****p < 0.0001. Mann-
Whitney U tests compared resistant lines to their respective parent (3D7-A10 or Dd2-B2).
CNVs of ABCI3 only conferred ~2-fold increase in IC50 for compound 6, which closely 
resembles the CNV-selecting compound 1, when compared to parental 3D7-A10 values 
(Fig. 4.5B, 4.6; Table 4.1). In contrast, the ABCI3 CNV line had a ~2× to 27× (shift 1 and 
2 respectively) increase in IC50 compared to the parental line when tested with compound 
1 (Table 4.1). 3D7-A10 selection studies with compound 6 did not yield resistance, despite 
using the same conditions as with 1, indicating a reduced resistance liability with 6.  In a 
separate assay, neither SNPs nor CNVs of ABCI3 conferred resistance to a panel of seven 
clinical antimalarials (dihydroartemisinin, CQ, piperaquine, monodesethyl-amodiaquine, 
quinine, lumefantrine and mefloquine) (Fig. 4.5A, 4.6; Table 4.1).  
Together, these data suggest that ABCI3 constitutes a resistance pathway that is distinct 
from that of existing first-line drugs and the tested ABCI3 SNP and CNV-selecting 
compounds might have different molecular targets. In addition, data from the SNP 
150 
susceptibility assays and the cross-resistance results with compound 6 provide evidence 







































































































































































































Fig. 4. 5. | Genetic modifications of ABCI3 do not confer cross resistance to first-line 
antimalarials or to a compound that is structurally similar to compound 1.  
(A) Dose-response assays of ABCI3 CNV and SNP lines showed no cross-resistance
against a panel of clinical antimalarials. Mean ± SEM; N≥4, n=2. Mann-Whitney U tests vs.
3D7-A10. (B) Compound 6 is structurally similar to the CNV-selecting compound 1 but
displays a different dose response profile. The activity of compound 6 was explored with
asynchronous ABCI3 edited and selected lines in 72 h dose-response assays (top graphs).
The knockdown of ABCI3 showed minimal increase in sensitivity to compound 6 (bottom-
right graph) in a 56 h assay. The concentration of anhydrotetracycline (aTc) had no effect
on the growth of NF54 control line (bottom-left graph). Mean ± SEM; N≥2, n=2. Mann-
Whitney U tests compared the different parasite variants to 3D7-A10, and medium or no
ABCI3 (3 nM and 0 nM aTc, respectively) to wild-type ABCI3 expression (50nM aTc).
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Fig. 4. 6. | Chemical structure of first-line antimalarials and MMV compound 6.  
Compound 6 is identical to compound 1 apart from the absence of  a –CF3 group in the 
pyridyl ring. 
4.3.2. Evidence for ABCI3 SNP-selecting compounds targeting ABCI3.  
To further explore the different interactions between ABCI3 and SNP- or CNV-selecting 
compounds, we engineered a conditional knockdown (cKD) parasite line in which ABCI3 
expression levels were regulated via the TetR-DOZI system 321,322 (Fig. 4.8A). In this 
system, translation of ABCI3 protein occurs in the presence of anhydrotetracycline (aTc), 
























































parasites in the presence of 50 nM aTc. Medium and low ABCI3 expression levels were 
achieved by culturing the parasites in 3 nM and 0 nM aTc respectively. In the absence of 
aTc, ABCI3 cKD parasite growth was reduced by ~33% compared to control after the first 
cell cycle and by ~92% after the second cycle (72 h and 120 h respectively; Fig. 4.7A). 
We used this system to test possible compound inhibition of ABCI3 by conducting 56 h 
drug susceptibility assays with CQ as a negative control (Fig. 4.7B-G; Table 4.5). 
Compound-target interactions were determined by comparing the IC50 of compounds 
against wild-type versus ABCI3 cKDs parasites. We observed an aTc-dependent 
increase in parasite sensitivity to the two CNV-selecting compounds 1 and 2, with 2-3× 
hypersensitivity at 0 nM aTc (Fig. 4.7C-D; Table 4.5). In contrast, under the same 
conditions we observed a 7-11× increase in sensitivity to the three SNP-selecting 
compounds 3, 4 and 5 (Fig. 4.7E-G; Table 4.5). cKD parasites were ~2-fold more 
sensitive to compound 6 in the absence of aTc (Fig. 4.5B; Table 4.5). Wild-type parasite 
susceptibility to the tested compounds was not aTc-dependent (Fig. 4.8). The observed 
increase in cKD sensitivity to the SNP-selecting compounds suggests a stronger 
inhibitory interaction with ABCI3 that is distinct from that of the CNV-selecting 
compounds.  
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Fig. 4. 7. | Validation of SNP-selecting compound inhibition of ABCI3 using conditional 
knockdown assays.  
(A) Down-regulation of ABCI3 (cKD), caused by removing aTc from the culture, reduced
parasite viability by ~33% and 92% after one and two complete replication cycles,
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and was used as a negative control. (C-D) ABCI3 cKD lines are only 2 to 3-fold sensitized 
to compounds 1 and 2. (E-G) In the absence of aTc, cKD parasites are ~7 to 11-fold 
sensitized to SNP-selecting compounds 3, 4 and 5, suggesting direct inhibition of ABCI3 
as a target. Bar graphs and growth curves indicate mean ± SEM IC50 values of 56 h dose-
response assays with highly synchronized ring-stage parasites. N, n = 5, 2; *p<0.05, 
**p<0.01, ***p<0.001. Mann-Whitney U tests compared parasites with partially or fully 
downregulated levels of ABCI3 (achieved with 3 nM and 0 nM aTc, respectively), to 
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Fig. 4. 8. | Regulation of ABCI3 expression using a conditional knock-down line. 
(A) The pSN054 plasmid was used to transfect NF54pCRISPR parasites to generate a
conditional knockdown ABCI3 transgenic line. (B) The concentration of aTc had no effect
on the growth of NF54 control parasites tested in 56 h assays against the compounds





Table 4. 5. | Plasmodium falciparum asexual blood stage IC50 data in nM for ABCI3-linked antiplasmodial inhibitors when 
tested in the presence or absence of aTc in a conditional knockdown cell line. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates).  P values were determined by 
comparing the IC50s of parasites grown under 3 and 0 nM aTc with those grown at 50 nM,  using Mann-Whitney U tests. 
Antimalarials Mean IC50 SEM N Mean IC50 SEM N P  value Mean IC50 SEM N P  value
Chloroquine 6.4 0.2 4 6.4 0.1 3 >0.9999 6.0 0.4 4 0.69
1 60.2 12.0 7 28.7 4.6 8 0.04 19.4 3.4 7 0.0023
2 236 13.5 8 160 6.2 7 0.0003 128 8.7 8 0.0002
3 804 35.2 7 153 4.2 8 0.0003 74.9 9.6 7 0.0006
4 117 5.5 8 24.5 0.9 7 0.0003 14.1 0.3 8 0.0002
5 10.0 2.1 7 2.4 0.6 7 0.0012 1.4 0.4 8 0.0003
6 28.3 5.4 7 18.0 2.6 8 0.28 12.9 2.7 7 0.03
50 nM aTc 3 nM aTc 0 nM aTc
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4.3.3. CNV-selecting compound 1 accumulates to high levels in parasites.  
We used the parasite inoculum effect on antiplasmodial potency 376 to assess the cellular 
accumulation of one CNV and two SNP-selecting compounds: 1, 3 and 4. The CNV-
selecting compound 1 displayed an inoculum-dependent IC50 profile similar to that of CQ 
against parental 3D7-A10 and L690I edited cell lines (Fig. 4.9A-B). In contrast, the ABCI3 
CNV line had a markedly different profile against 1, suggesting a difference in this 
compound’s cellular accumulation in the presence of three copies of ABCI3 (Fig. 4.9B). We 
extrapolated the linear relationship between the inoculum size and the measured IC50 for 
CQ and 1 to determine the absolute IC50, which was then used to calculate the cellular 
accumulation ratio (CAR) (Fig. 4.9C) 324. CAR results predicted that CQ accumulated ~1-
2× more in 3D7-A10 and the L690I mutant compared to the CNV line with three copies of 
ABCI3, whereas compound 1 was predicted to accumulate ~30× more in 3D7-A10 
compared to the CNV line. Compound 1 accumulation in the L690I mutant line was 
estimated to be ~2× less compared to parent 3D7-A10 (Fig. 4.9C; Table 4.6). Compounds 
3 and 4 did not display an inoculum-dependent concentration response (Fig. 4.10). These 
findings suggest that ABCI3 gene amplification might confer resistance to the CNV-
selecting compounds by reducing their concentrations at their site(s) of antiplasmodial 
action. The lack of cellular accumulation for the SNP-selecting compounds suggests that 
they might kill parasites through modes of action that differ from those of CNV-selecting 
compounds.       
160 
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Fig. 4. 9. | ABCI3 amplification confers resistance to 1 by potentially effluxing this 
compound away from its site of action.  
(A) CQ displays an inoculum effect with a parasitemia-dependent dose-response curve
unaffected by amplification or point mutation in ABCI3. Growth was determined 48 h after
initiating drug treatment of highly synchronized ring-stage parasites. (B) Parental 3D7-A10
and ABCI3 L690I ed. parasites also display a parasitemia-dependent dose-response to
compound 1. A reduced inoculum effect was observed with the ABCI3 CNV line treated with
1. (C) The ABCI3 CNV parasite line displays ~30× lower cellular accumulation ratio for
compound 1 compared to parental 3D7-A10. CQ was used as a positive control. Mean ±
SEM; N, n = 5, 2; **p<0.01. Mann-Whitney U tests vs. 3D7-A10. (D) ABCI3 foci localize to
punctate structures in the parasite cytosol and occasionally with the nucleus and the ER.
ABCI3 Flag-tagged parasites were stained with DAPI (nucleus, blue) and antibodies
specific to Flag (green), PfCRT (DV membrane, red) and BIP (ER, magenta). Scale bars:
2μm. (E) Immuno-EM image of an HA-tagged ABCI3 trophozoite stained with anti-HA
antibodies, revealing staining in the cytosol, nucleus, nuclear membrane and ER.
Arrowheads highlight organelles of interest. C, cytosol; ER: endoplasmic reticulum; N:
nucleus; NM: nuclear membrane; Hz: hemozoin crystals. Scale bar: 500 nm.
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Fig. 4. 10. | ABCI3 mutations and amplifications do not show parasitemia-dependent dose 
responses against SNP-selecting compounds.  
Compounds 3 and 4 had similar dose-response across all the three tested lines regardless 
of the starting parasite inoculum size. The absolute IC50 could therefore not be calculated 
from extrapolating the linear relationship between starting inoculum size and the measured 










































































































































Table 4. 6. | Cellular accumulation ratio of chloroquine and compound 1 in Plasmodium falciparum asexual blood stage 
parasites. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates).  P values were determined by 
comparing accumulation levels between the variant lines and parental 3D7-A10, using Mann-Whitney U tests. 
Antimalarials Mean IC50 SEM N Mean IC50 SEM N P  value Mean IC50 SEM N P  value
Chloroquine 36553 2385 6 17658 414 6 0.0022 28916 729 6 0.0043
1 59915 2678 6 2082 426 6 0.0022 25744 1288 6 0.0022
3D7-A10 ABCI3 3 copies ABCI3 L690I ed.
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4.3.4. ABCI3 shows broad localization to multiple intraparasitic compartments.  
We interrogated the subcellular localization of ABCI3 by performing immunofluorescence 
and immuno-electron microscopy (IEM) assays on tagged ABCI3 parasite lines 193 using 
3×HA- or 3×Flag-tagged lines, respectively. We used CRISPR/Cas9 to generate 
recombinant 3D7-A10 parasite lines that expressed either a 3×Flag or a 3×HA tag at the C-
terminal end of the endogenous ABCI3 locus (3D7-A10WT-ABCI3-3×Flag or 3D7-A10WT-
ABCI3-3×HA; Fig. 4.9D, E). 
Immunofluorescence assays (IFA) using an antibody against the Flag tag localized ABCI3 
to foci on or around the nucleus as well as in the parasite cytosol (Fig. 4.9D, 4.11A). No 
evident co-localization was observed with the PfCRT digestive vacuole (DV) marker 377, the 
endoplasmic reticulum (ER) marker binding immunoglobulin protein (Bip) 378 or the cis-Golgi 
marker ER lumen protein retaining receptor (ERD2) 379 (Fig. 4.9D, 4.11A). We observed 
minimal association with the vesicular transport markers Rab5B and Rab7 380 (Fig. 4.11A). 
These Rab proteins are thought to contribute in part to endocytosis of host Hb to the DV 
193,358,381. IEM analysis of at least eight parasites cultured independently in triplicate (31 total 
images) localized ABCI3 49% of the time to the cytosol and 24% to the nucleus and nuclear 
membrane. Other sites of localization included the DV (8%), the plasma membrane (6%), 
and the ER and intracellular vesicles (13%) (Fig. 4.9E, 4.11B, 4.12; Table 4.7). Parallel 
processing of untagged parasites revealed no staining with these same labeling conditions. 
This broad intracellular distribution of ABCI3 mirrors an earlier report of mCherry-3×Myc 
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Fig. 4. 11. | ABCI3 foci localize to vesicles and various cellular organelles. 
(A) In the fluorescent image, ABCI3 Flag-tagged parasites were stained with anti-Flag
(green), DAPI (nuclear, blue), anti-PfCRT (DV membrane, red), anti-ERD2 (cis-golgi), or
anti-Rab5B or anti-Rab7 (markers of vesicular transport) antibodies. The plasmid used to
generate the tagged lines is illustrated. Scale bars: 2 μm. (B) Immuno-EM images of HA-
tagged ABCI3 parasites stained with anti-HA antibodies. ER, endoplasmic reticulum; N,
nucleus; NM, nuclear membrane; Hz, hemozoin crystals (digestive vacuole); V, vacuole;






























































Fig. 4. 12. | (preceding page and this page). Representative immuno-EM images of 3×HA-


















































Table 4. 7. | Transmission electron microscopy image scoring of Plasmodium falciparum 
asexual blood stage parasite subcellular localization of anti-HA stained ABCI3-3×HA.   
Results were collated from parasites obtained on three separate occasions for electron 
microscopy processing and imaging. ND: not determined. 
222 79 2 0 4 1 1 0 5 13
222 81 2 ND 1 ND 2 1 6 12
222 82 0 ND 1 0 2 0 1 4
222 83 1 0 1 0 4 0 3 9
222 85 3 ND 0 5 2 0 15 26
222 86 0 0 1 2 0 1 10 15
222 88 1 ND 0 0 2 7 6 17
222 89 1 2 2 0 5 0 4 15
222 90 0 3 0 0 5 3 2 13
222 91 1 3 0 1 0 2 5 13
223 95 0 ND 0 ND 2 1 6 9
223 96 0 ND 2 ND 3 0 8 13
223 97 0 ND 0 ND 2 1 4 7
223 99 1 ND 0 1 2 0 8 12
223 100 0 ND 2 0 4 1 3 10
223 102 1 0 3 1 4 1 8 18
223 104 2 2 0 ND 2 0 5 11
223 106 3 1 1 2 5 2 9 23
226 64 0 ND 0 0 0 0 3 3
226 65 0 0 0 0 1 3 7 11
226 66 0 2 1 0 3 0 4 11
226 68 0 0 2 3 3 1 11 20
226 70 0 ND 5 0 2 0 16 23
226 72 1 1 0 0 1 0 14 18
226 73 2 0 1 0 0 0 1 5
226 74 0 1 1 0 3 1 2 8
226 75 0 ND 0 0 0 1 8 9
226 77 1 0 0 1 2 0 4 8
226 78 0 7 3 4 1 1 2 19
226 79 1 ND 0 0 1 1 10 13
226 80 2 0 2 0 1 4 6 15
25 22 33 21 65 32 196 403
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4.3.5. CNV-selecting compound 1 inhibits intracellular hemozoin formation.  
Given the evidence of its maximal activity against trophozoites 189, partial  ABCI3 
localization to the DV, and the recent demonstration of inhibition of hemozoin (Hz) formation 
by an imidazopyridine scaffold 383, we examined the potential of compound 1 to inhibit 
hemozoin (Hz) formation in P. falciparum. As a surrogate for inhibition of heme 
detoxification in the parasite, we first tested the ability of this compound to inhibit the 
conversion of hematin to β-hematin (βH), the synthetic equivalent of Hz, in a pyridine-based 
detergent-mediated assay designed to simulate the DV milieu 384. Results showed that 
compound 1 inhibited βH formation (with a mean±SEM IC50 of 29±2.2 µM), similar to the 
two positive control aminoquinolines CQ and amodiaquine (mean±SEM IC50s: 20±1.2 µM 
and 9±1.3 µM, respectively; Fig. 4.13J; Table 4.9). In contrast, SNP-selecting compounds 
3-5 failed to block βH formation (IC50: >500 µM), similar to the negative controls
pyrimethamine (an antifolate) and doxycycline (a protein synthesis inhibitor; Fig. 4.13J; 
Table 4.9).  
To further test whether compound 1 could target intracellular heme detoxification, we 
performed a cellular heme fractionation assay to test concentration-dependent effects of 
the compound on the three heme species: hemoglobin (Hb), free heme (i.e. the labile form 
liberated by Hb proteolysis), and Hz 93,326. In this experiment, synchronized early ring-stage 
parasites were incubated with increasing drug concentrations, and the levels of the various 
heme species were quantified both as proportions of total heme extracted and as absolute 
amounts of heme iron (Fe) per cell (Table 4.8). These amounts were calculated from total 
amounts of Fe obtained using a heme standard curve. Exposure of parasites to incremental 
171 
concentrations of compound 1 led to concentration-dependent increases in the proportions 
of free heme and a corresponding decrease in Hz compared to untreated controls (Fig. 
4.13E-F). This profile was statistically significant at 2-4× IC50 concentrations and was also 
observed when the absolute amount of heme per cell, rather than proportions, was 
analyzed. The mean±SEM amount of free heme present in the untreated control was 
2.7±0.3 femtogram (fg) of heme Fe per cell while the amount present at 4×IC50 of compound 
1 was 6.4±0.3 fg (Table 4.8). This mean 2.4-fold increase in toxic free heme directly 
corresponded to a significant decrease in Hz at the equivalent IC50 concentration (Fig. 
4.13F) and was directly proportional to inhibition of  parasite growth (Fig. 4.13K). 
Expectedly, a similar effect was observed upon treating parasites with CQ, a known 4-
aminoquinoline inhibitor of the heme detoxification process in the parasite DV (Fig. 4.13B-
C, K). There was no concentration-related association between the amounts of free heme 
and Hz in parasites incubated with compounds 3-5 or pyrimethamine, although the amount 
of Hz Fe appeared to decrease at higher concentrations (Fig. 4.13H-I, 4.14; Table 4.8). 
These decreases, however, did not directly correspond to significant perturbations to free 
heme Fe levels or correspond to parasite death (Fig. 4.14J-L) and might reflect a stress 
phenotype from inhibition of other unrelated target(s). Treatment with compounds 3 and 4 
caused significant increases in Hb levels, with a lesser impact on levels of free heme and 
Hz, suggesting potential activity of these compounds upstream in the Hb import pathway 
(Fig. 4.14A, D, G; Table 4.8). 
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Fig. 4. 13. | Parasites treated with compound 1 display a heme fractionation profile similar 
to CQ.  
(A-C) Heme fractionation profile of CQ-treated NF54 parasites showing an increase in 
free heme and a decrease in Hz, as determined 32 h post drug exposure. (D-F) 
Compound 1 caused a concentration-dependent accumulation of free heme and 
reduction in Hz levels. (G-I) Pyrimethamine treatment did not interfere with heme or Hz 
accumulation. (J) Concentration-dependent inhibition of β-hematin formation by 
compounds 1, 3-5 and four clinical antimalarial controls (N=3 independent experiments, 
Fig. 6
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data shown as means±SEM). (K) Concentration-dependent inhibition of parasite growth 
obtained with chloroquine or compound 1 mirrored increasing levels of free heme, with 
these IC50 values intersecting. This result provides evidence that for 1 the inhibition of Hz 
formation is a primary cause of parasite growth inhibition. Percent levels of heme species 
are represented on the left y-axis while absolute heme amounts determined from a heme 
standard curve and measured in femtogram per cell are represented on the right y-axis. 
Statistical comparisons of the drug-treated lines to their untreated controls were 
performed using two-tailed Student's tests (with Welch correction). *p<0.05; **p<0.01; 
***p<0.001. 
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Fig. 4. 14. | Parasites treated with compounds 3-5 do not display a heme fractionation 
profile similar to CQ.  
(A-I) Treatment of parasites with compounds 3-5 did not interfere with heme or Hz 
accumulation. (J-l) Concentration-dependent inhibition of parasite growth obtained with 
compounds 3-5 was independent of free heme levels. 
Fig. S7






















































































































































































































































































































Table 4. 8. | Mean±SEM amount of hemoglobin, free heme and hemozoin in drug-treated 
parasites represented as percent proportion or absolute amount of heme iron per cell in 
fg/cell. 
Mean±SEM amount of hemoglobin, free heme and hemozoin represented as percent and 
fg/cell. The amounts of heme in different parasite lines were determined by the heme 
Hemoglobin Free heme Hemozoin Hemoglobin Free heme Hemozoin
Compound Drug concentration
% Heme species Heme Fe (fg/cell)
No drug control 1.08 ± 0.11 6.12 ± 0.34 92.79 ± 0.31 0.80 ± 0.09 4.49 ± 0.14 68.30 ± 1.79
0.5×IC50 (6 nM) 0.65 ± 0.14 6.72 ± 0.40 92.62 ± 0.32 0.47 ± 0.10 4.78 ± 0.19 66.04 ± 2.95
1.0×IC50 (12 nM) 0.65 ± 0.08* 7.63 ± 0.42 91.71 ± 0.38 0.47 ± 0.05* 5.48 ± 0.24* 65.91 ± 2.22
2.0×IC50 (24 nM) 1.12 ± 0.02 11.09 ± 0.35*** 87.79 ± 0.35** 0.70 ± 0.01 6.92 ± 0.14** 54.83 ± 1.45*
3.0×IC50 (36 nM) 1.82 ± 0.03* 10.23 ± 0.28***87.95 ± 0.24*** 1.20 ± 0.06* 6.78 ± 0.31** 58.30 ± 2.51*
4.0×IC50 (48 nM) 0.78 ± 0.10 12.23 ± 0.41***86.99 ± 0.32*** 0.46 ± 0.06* 7.17 ± 0.27** 51.05 ± 1.15**
No drug control 2.12 ± 0.11 5.85 ± 0.28 92.04 ± 0.48 1.43 ± 0.13 3.94 ± 0.18 62.11 ± 0.54
0.5×IC50 (12.5 nM) 2.56 ± 0.14 5.53 ± 0.20 91.91 ± 0.29 1.61 ± 0.12 3.51 ± 0.21 58.13 ± 1.54
1.0×IC50 (25 nM) 2.61 ± 0.08 5.51 ± 0.21 91.88 ± 0.29 1.64 ± 0.16 3.58 ± 0.19 59.77 ± 3.21
2.0×IC50 (50 nM) 2.48 ± 0.14 5.47 ± 0.13 92.05 ± 0.26 1.57 ± 0.09 3.47 ± 0.13 58.27 ± 1.26*
3.0×IC50 (75 nM) 3.15 ± 0.12** 5.76 ± 0.13 91.09 ± 0.11 1.89 ± 0.11* 3.46 ± 0.11 54.62 ± 1.02**
4.0×IC50 (100 nM) 2.76 ± 0.08 5.53 ± 0.22 91.71 ± 0.27 1.72 ± 0.14 3.40 ± 0.13 56.49 ± 1.56*
No drug control 3.12 ± 0.36 4.76 ± 0.50 92.12 ± 0.72 1.80 ± 0.21 2.73 ± 0.29 53.09 ± 0.32
0.5×IC50 (24 nM) 3.81 ± 0.67 4.98 ± 0.43 91.21 ± 0.81 1.87 ± 0.37 2.84 ± 0.33 51.65 ± 0.74
1.0×IC50 (48 nM) 3.73 ± 0.48 5.45 ± 0.21 90.82 ± 0.54 1.84 ± 0.07 3.02 ± 0.21 50.28 ± 3.01
2.0×IC50 (96 nM) 3.48 ± 0.46 8.24 ± 0.31** 88.28 ± 0.45* 1.98 ± 0.28 4.67 ± 0.11* 50.18 ± 1.81
3.0×IC50 (144 nM) 3.71 ± 0.52 10.41 ± 0.18** 85.87 ± 0.64** 1.97 ± 0.31 5.48 ± 0.18** 45.17 ± 0.76***
4.0×IC50 (192 nM) 4.97 ± 0.83 13.32 ± 0.29***81.71 ± 0.62*** 2.83 ± 0.33 6.40 ± 0.29*** 39.28 ± 1.55**
No drug control 0.78 ± 0.09 6.55 ± 0.25 92.67 ± 0.27 0.53 ± 0.05 4.42 ± 0.07 62.83 ± 3.52
0.5×IC50 (385 nM) 2.24 ± 0.24* 5.77 ± 1.27 92.00 ± 1.13 1.24 ± 0.06*** 3.41 ± 0.98 52.01 ± 5.63
1.0×IC50 (770 nM) 3.07 ± 0.17*** 6.55 ± 0.52 89.75 ± 0.68* 1.74 ± 0.06*** 3.06 ± 0.04*** 42.47 ± 3.47*
2.0×IC50 (1540 nM) 4.09 ± 0.48* 6.22 ± 0.62 89.69 ± 0.88 1.97 ± 0.14** 3.02 ± 0.32* 44.52 ± 6.56
3.0×IC50 (2310 nM)4.57 ± 0.40** 6.16 ± 0.21 89.27 ± 0.34** 2.69 ± 0.31* 3.60 ± 0.07** 52.27 ± 1.42
4.0×IC50 (3080 nM)3.79 ± 0.20** 6.21 ± 1.17 90.0 ± 1.24 1.47 ± 0.08*** 2.42 ± 0.51 35.27 ± 3.72**
No drug control 0.95 ± 0.03 6.94 ± 0.44 92.11 ± 0.46 0.67 ± 0.05 4.92 ± 0.54 64.91 ± 2.97
0.5×IC50 (65 nM) 2.38 ± 0.07*** 9.00 ± 0.22* 88.62 ± 0.14* 1.32 ± 0.05*** 5.03 ± 0.44 49.34 ± 3.13*
1.0×IC50 (130 nM) 2.66 ± 0.07*** 6.91 ± 0.80 90.43 ± 0.78 1.36 ± 0.03** 3.53 ± 0.41 46.21 ± 0.37*
2.0×IC50 (260 nM) 1.89 ± 0.03*** 5.70 ± 0.79 92.42 ± 0.82 0.90 ± 0.04* 2.74 ± 0.46* 44.10 ± 0.82*
3.0×IC50 (390 nM) 2.12 ± 0.05*** 7.60 ± 1.37 90.28 ± 1.35 1.01 ± 0.05* 3.62 ± 0.67 42.89 ± 1.14**
4.0×IC50 (520 nM) 1.54 ± 0.04*** 6.16 ± 0.63 92.29 ± 0.61 0.66 ± 0.01 2.65 ± 0.32* 39.60 ± 0.59*
No drug control 1.36 ± 0.07 8.84 ± 0.47 89.80 ± 0.50 0.91 ± 0.04 5.87 ± 0.29 59.68 ± 0.57
0.5×IC50 (2.5 nM) 1.89 ± 0.14* 8.50 ± 0.42 89.61 ± 0.56 1.07 ± 0.01 4.82 ± 0.06 51.16 ± 3.26
1.0×IC50 (5 nM) 1.23 ± 0.07 8.29 ± 0.71 90.48 ± 0.77 0.78 ± 0.02 5.22 ± 0.22 57.60 ± 4.04
2.0×IC50 (10 nM) 2.05 ± 0.22 8.26 ± 0.24 89.69 ± 0.46 1.35 ± 0.03** 5.50 ± 0.34 60.09 ± 5.64
3.0×IC50 (15 nM) 1.56 ± 0.12 9.29 ± 0.44 89.15 ± 0.55 0.94 ± 0.07 5.58 ± 0.25 53.59 ± 0.76**
















fractionation assay (see methods). Parasites were treated with increasing concentrations 
of chloroquine, pyrimethamine and compounds 1,3-5 at different multiples of their IC50 
values and hemoglobin, free heme and hemozoin amounts measured 30 h later. N, 
n=1,>3. Statistical comparisons of the drug-treated lines to their untreated controls were 
performed using two-tailed Student's tests (with Welch correction). *p<0.05; **p<0.01; 
***p<0.001. 
Table 4. 9. | In vitro !-hematin inhibition assay IC50 data in µM 
for the tested antimalarials. 
SEM: standard error of the mean; N: number of biological 
repeats (with technical duplicates). 2 was not tested because 
of lack of compound. 
Antimalarials Mean IC50 SEM N
1 29.3 2.2 3
3 >500 >500 3
4 >500 >500 3
5 >500 >500 3
Chloroquine 20.0 1.2 3
Amodiaquine 9.4 1.3 3
Pyrimethamine >500 >500 3
Doxycycline >500 >500 3
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4.3.6. Mutant PfCRT modulates parasite susceptibility to inhibitors that select for 
CNVs in ABCI3.  
In light of the evidence that part of the mode of action of 1 and 2 involves inhibition of Hz 
formation and heme detoxification, we next assessed whether PfCRT could affect their 
activity, as mutations in this DV transporter can protect parasites against Hz formation 
inhibitors such as CQ. These assays used recombinant Dd2 parasites expressing either 
the mutant Dd2 PfCRT isoform that mediates CQ resistance, or the wild-type CQ-sensitive 
3D7 isoform (Dd2 Dd2 and Dd2 3D7, respectively). Dose-response assays with the control 
drug CQ showed the expected 9-fold higher IC50 and IC90 values in Dd2 Dd2 parasites, 
compared with isogenic Dd2 3D7 parasites (expressing the Dd2 and 3D7 pfcrt alleles, 
respectively) (Fig. 4.15A; Table 4.10). Intriguingly, these isogenic lines implicated Dd2 
PfCRT as a mediator of reduced parasite susceptibility to all five inhibitors linked to ABCI3 
(Fig. 4.15B-F; Table 4.10).  
In the case of the two CNV-selecting compounds 1 and 2, we observed biphasic curves in 
Dd2 Dd2 parasites, contrasting with a monophasic curve in Dd2 3D7. IC50 values with both 
lines were similar but Dd2 Dd2 parasites showed substantially higher (14-26 fold) IC90 values 
(Fig. 4.15B-C; Table 4.10). In contrast, the SNP-selecting compounds 3, 4 and 5 showed 
monophasic curves in both lines with ~2-3× IC50 and IC90 increases in Dd2 Dd2 parasites 
compared with Dd2 3D7 (Fig. 4.15D-F; Table 4.10). This is similar to the fold IC50 increase 
obtained via mutation in ABCI3 for compound 3 but much lower than the mutant ABCI3-
mediated gain of resistance to compounds 4 and 5 (Table 4.1, 4.2). Assays with isogenic 
parasite lines expressing 1 or 2 copies of pfmdr1, which like pfcrt encodes a DV-resident 
178 
multidrug resistance transporter, showed no effect on the antiplasmodial potency of any 
ABCI3-associated inhibitor (Fig. 4.16; Table 4.11).  
 Fig. 7






























































































































































































































Fig. 4. 15. | Mutant PfCRT in Dd2 parasites plays a role in susceptibility to ABCI3-associated 
compounds in Dd2 parasites.  
(A) CQ resistance is conferred by the Dd2 PfCRT isoform (M74I/ N75E/ K76T/ A220S/
Q271E/ N326S/ I356T/ R371I), showing a ~9-fold IC50 increase relative to isogenic gene-
edited Dd2 parasites expressing the 3D7 wild-type PfCRT isoform. (B-C) The mutated
PfCRT isoform confers resistance and generates biphasic dose-response curves to
compounds 1 and 2. (D-F) Dd2 Dd2 PfCRT isoform confers modest (~2×) resistance to
SNP-selecting compounds 3, 4 and 5. Mean ± SEM; N, n = 4, 2; *p < 0.05. Mann-Whitney
U tests compared Dd2 Dd2 to Dd2 3D7.
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Fig. 4. 16. | PfMDR1 amplifications do not affect parasite susceptibility to ABCI3-associated 
compounds.  
Isogenic parasite lines expressing 1 (KD1) or 2 (FCB) copies of pfmdr1 were equally 
susceptible to all five ABCI3-associated inhibitors. Mefloquine and lumefantrine were 




































































































































































































































Table 4. 10. | Plasmodium falciparum asexual blood stage IC50 data in nM for the tested antimalarials 
against PfCRT isoforms. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates); () the IC50 
and SEM of the second shift of the biphasic curve. P values were determined by comparing IC50 shift of 
the Dd2 Dd2 parasite lines compared to Dd2 3D7 using Mann-Whitney U tests. 
Antimalarials Mean IC50 SEM N Mean IC50 SEM N P  value
Chloroquine 11.0 2.2 4 101 12 4 0.0286
1 47.0 6.7 4 29.0(1234) 5.8(162) 4 0.1143 (0.0286)
2 203 24.0 4 236(2780) 23.0(504) 4 0.3429 (0.0286)
3 563 18.0 4 1268 58.0 4 0.0286
4 100 4.9 4 236 23.0 4 0.0286
5 2.2 0.2 4 4.9 0.4 4 0.0286
Dd2 3D7 Dd2 Dd2
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Table 4. 11. | Plasmodium falciparum asexual blood stage IC50 data in nM for the 
tested antiplasmodial compounds against PfMDR1 isoforms. 
--: not determined 
Antimalarials Mean IC50 SEM N
Mean 
IC50
SEM N P  value
1 74.12 20.6 3 84.86 30.9 3 --
2 278.4 34.9 4 270 33.1 4 0.6857
3 1361 109 5 1760 111 5 0.0556
4 233.5 10.1 5 324.8 22.4 5 0.0079
5 8.592 1.96 4 12.93 2.94 4 0.2
Mefloquine 6.549 1 4 4.416 0.91 4 0.2






Our data identify ABCI3 as a pleiotropic modulator of P. falciparum asexual blood stage 
parasite susceptibility to a range of antiplasmodial chemotypes represented by compounds 
1-5, with resistance associated with ABCI3 amplifications or point mutations. Intriguingly, 
this member of the P. falciparum ATP-binding cassette transporters appears to be broadly 
distributed within the parasite, mostly to punctate structures in the cytosol, with additional 
staining of the nucleus, nuclear membrane, DV, and plasma membrane. In vitro resistance 
selection assays using 1 and 2 generated parasites with three copies of abci3 that conferred 
varying levels of resistance to all five compounds. In contrast, selections with 3-5 generated 
SNPs in abci3 that did not alter parasite susceptibility to either of the CNV-selecting 
compounds. None of these SNPs: Y2079C and R2180P (compound 3), L690I and R2180G 
(4), and F689C and S696Y (5), have been observed in parasite genome data sets (reported 
in malariagen.net and plasmoDB.org) from field isolates, suggesting that these compounds 
have modes of action unrelated to antimalarials in clinical use.  
 
We confirmed that ABCI3 L690I, F689C and S696Y were the primary drivers of parasite 
resistance to compounds 4 and 5 using CRISPR/Cas9 gene editing. Cross-resistance 
studies showed that unlike CNVs, these mutations sometimes conferred no resistance or 
even hypersensitized parasites to other SNP-selecting compounds. The L690I and F689C 
mutations, while adjacent, produced distinct phenotypes when profiled against the three 
SNP-selecting compounds. L690I, selected with compound 4, conferred resistance to both 
this compound and 3 but not 5. In contrast, F689C, selected with 5, only conferred 
resistance to this agent but sensitized parasites to both 3 and 4. Strikingly, S696Y, located 
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in the same transmembrane 5 helix as residues 689 and 690, conferred high levels of 
resistance (³180-fold) to all three SNP-selecting compounds. These data provide evidence 
that ABCI3 SNP-mediated drug resistance is compound specific and suggest that this 
transporter interacts differently with the SNP and CNV-selecting compounds. These results 
also suggest that like the CNVs, some ABCI3 mutations can confer resistance to a broad 
set of chemotypes. 
To explore differences in cellular accumulation between compounds and the impact of 
genetic changes in ABCI3, we assayed compounds 1 (CNV), 3 (Y2079C and R2180P) and 
4 (L690I and R2180G) in parental 3D7-A10, ABCI3 3 copies and ABCI3 L690I ed. parasites using 
an inoculum effect assay 376. These assays extrapolated linear relationships between the 
IC50 and the parasite inoculum size to quantify the cellular drug accumulation ratio (CAR), 
defined as the ratio of the amount of drug in a parasitized red blood cell versus the amount 
in a similar volume of medium 324,325,376,385. Results showed that the CNV-selecting 
compound 1 accumulated ~30× and ~2× less in the ABCI3 CNV line and in the L690I mutant 
line respectively, relative to the 3D7-A10 parent. The difference in CQ accumulation 
between the three lines was only ~2-fold. No cellular accumulation was observed for the 
two SNP-selecting compounds 3 and 4. The decreased cellular accumulation of 1 in the 
ABCI3 3 copies line suggests that ABCI3 might potentially mediate parasite resistance to this 
compound 1 by effluxing it from its primary site of action.  
Based on results from our cellular accumulation experiments that hinted at different 
targets/modes of action for the SNP and CNV-selecting compounds, and the ABCI3 
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localization assays that showed partial DV localization, we tested the ability of select 
compounds to inhibit biomineralization of heme to Hz as a potential mode of action. 
Compound 1 appeared to interfere with the heme detoxification pathway in a CQ-like 
pattern, leading to the accumulation of free heme and a corresponding decrease in Hz 
levels consistent with recent observations of similar effect by 2,4-disubstituted 
imidazopyridine series 383. In contrast, none of the tested ABCI3 SNP-selecting compounds 
showed any activity on the heme-Hz detoxification pathway, pointing to alternative modes 
of action. These findings corroborate the βH inhibition results and flag inhibition of heme 
detoxification by compound 1 as it’s likely mode of action. Recent studies have reported 
that the Plasmodium cGMP-dependent kinase, PfPKG, might be a potential target for 
imidazopyridine-based derivatives 386. However, our observation of optimal compound 1 
activity against trophozoites 189 does not collaborate with the ring and schizont peak 
expression of PfPKG, making the latter an unlikely target and further supporting Hz 
inhibition as the mode of action model of this compound. We also observed that compound 
1 had no effect on Hb levels, suggesting that it does not target endocytosis of this host 
factor. 
Our observation of an unusual biphasic dose-response curves with compounds 1 and 2, 
tested in growth inhibition assays against the 3D7-based ABCI3 CNV parasite line 
(selected with 1) and the non-drug-pressured Dd2-B2 line, recalls the biphasic responses 
to piperaquine (PPQ) seen in PPQ-resistant parasites 201,292,387. These biphasic 
relationships have been attributed to either the presence of multiple parasite stages that 




concentration-dependent off-target activity (that can sometimes be overcome with subtle 
chemical changes), or concentration-dependent activation of drug efflux mechanisms 
207,311,388,389.  
 
For 1 and 2, we also identified mutant PfCRT as a contributor to susceptibility in Dd2 
parasites. Growth inhibition assays with these compounds and isogenic Dd2 Dd2 (CQ-
resistant) and Dd2 3D7 (CQ-sensitive) lines 310 revealed biphasic dose-response curves in 
the former line, as opposed to the monophasic profile obtained with Dd2 3D7. This shift to 
a biphasic curve in the edited pfcrt-mutant line mirrors the observation with non-edited 
Dd2, suggesting that mutant pfcrt is the major driver of this biphasic response in Dd2 
parasites (that harbor a sole copy of abci3), as opposed to 3D7 that shows a classic 
monophasic curve. Of note, pfcrt-edited Dd2 Dd2 differs from Dd2 3D7 by 8 amino acid 
substitutions in this transporter (M74I/ N75E/ K76T/ A220S/ Q271E/ N326S/ I356T/ 
R371I), which collectively mediate resistance via a gain of CQ transport 377,390,391. These 
data suggest that the biphasic gain of resistance observed with Dd2 PfCRT might reflect 
its ability to transport 1 and 2. A similar biphasic dose-response profile was earlier 
observed with the PfCRT variants Dd2+F145I and Dd2+T93S that confer PPQ resistance, 
also via a gain of transport 202,377.  
 
Both CQ and PPQ accumulate by up to several thousand fold in drug-sensitive parasites, 
driven presumably by their gain of protonation (to PPQ4+ or CQ2+) in the highly acidic DV 
and their binding to Hz, combined with the absence of an appropriately mutated PfCRT 
transporter that can efflux them back into the parasite cytosol 207,377,392. Our studies 
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revealed even higher levels of compound 1 accumulation in drug-sensitive 3D7 parasites 
compared with CQ, and 1 and 2 both harbor multiple sites for protonation. Conceivably, 
these two ABCI3 CNV-selecting compounds might act primarily in the DV, with the CQ-
resistant Dd2 PfCRT isoform able to efflux them out of the vacuole into the parasite 
cytosol. This proposed mode of action is consistent with our observation that compound 
1 inhibited Hz formation and parasite growth at equivalent IC50 values.  
Selection studies with 1 and 2 in initially fully-sensitive 3D7 parasites revealed a different 
path to resistance. This line harbors wild-type PfCRT that transports less CQ than the 
Dd2 isoform and presumably also transports little or no compounds 1 and 2. Selection 
with these compounds resulted in ABCI3 amplification, which we hypothesize results in 
their lack of accumulation in the DV. Indeed, we observed significantly less cellular 
accumulation of 1 in 3D7 parasites that had acquired 3 copies of abci3. This transporter 
was observed mostly in the parasite cytosol, presumably associated with membrane-
bound structures, and to only a minor extent with the parasite DV. These data suggest 
that multicopy ABCI3 might be able to efflux compound out of the parasite or perhaps, as 
a result of increased levels on the DV, might enable efflux from this site of drug action. 
Interestingly, abci3 amplification in 3D7 parasites created a biphasic dose-response 
curve, phenocopying the dose-response obtained via mutant PfCRT in Dd2 parasites. To 
our knowledge, this is the first instance where the resistance determinant to a particular 





Our studies point to a separate mode of action of compounds 3-5 compared with 1 and 
2, based on their differences in dose response, cellular accumulation, heme fractionation, 
and genetic changes causing resistance. These results collectively suggest that 3-5 act 
outside the DV. Intriguingly, Dd2 mutants resistant to 5 (harboring the ABCI3 mutations 
F689C or S696Y) lost their biphasic dose-response with the heme-inhibiting compounds 
1 and 2, providing evidence that these SNPs reversed mutant PfCRT-mediated 
resistance. Results with our ABCI3 cKD lines (generated in NF54, the parent of 3D7) were 
informative in showing that reduced levels of ABCI3 caused increased parasite sensitivity 
to all five tested compounds. This susceptibility profile, however, differed markedly 
between the SNP (3, 4 and 5)- and CNV (1 and 2)-selecting compounds. While the cKD 
parasites were ~7-11-fold more sensitive to 3-5 in the absence of aTc, they were only ~2 
to 3-fold more sensitive to 1 and 2. We conjecture that ABCI3 itself might therefore be a 
target of 3-5. This distinction between the modes of action between the SNP- and CNV-
selecting compounds is consistent with our recent observations of differences in their 
timing of action, with 1 showing a peak of activity in trophozoites (the stage of maximal 
heme detoxification) versus 3 and 4 that showed cumulative activity across all stages 189. 
We note that ABCI3 was also observed in proteomic studies to be abundant throughout 
all asexual blood stages 393. For compounds 3-5, Dd2 PfCRT caused a minor (2-fold) 
increase in the IC50. These data suggest an intricate connection between PfCRT and 
ABCI3 in dictating parasite susceptibility to these compounds. We note that both 
transporters are apparently essential for asexual blood stage parasite growth, as 
previously demonstrated for PCfRT and evidenced herein with our cKD studies showing 
a loss of growth upon depletion of ABCI3 382,394,395. In contrast, we found no evidence for 
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a role of pfmdr1 amplification, which can modulate parasite susceptibility to the first-line 
drugs lumefantrine and mefloquine and which like pfcrt encodes a DV-resident transporter 
207.  
ABCI3 belongs to the AAA+ superfamily of ATPases that are found in all kingdoms of 
living organisms, where they participate in diverse cellular processes including membrane 
fusion, proteolysis and DNA replication. Other potential functions for members of this 
superfamily include protein folding and unfolding, assembly or disassembly of protein 
complexes, protein transport and degradation, replication, recombination, repair and 
transcription 396,397. The diffuse localization of ABCI3 suggests that in P. falciparum, the 
endogenous functions of this protein involve some of these essential processes in 
parasites. However, more research, including solving the structure of the protein and 
solute and drug transport assays, is required to narrow down the list of potential 
endogenous functions of ABCI3 in intra-erythrocytic P. falciparum parasites and to better 
understand how this function is coopted through amplification or point mutations to 
mediate antiplasmodial drug resistance.  
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The emergence and spread of Plasmodium falciparum resistance to first line antimalarials 
creates an imperative to identify and develop novel potent chemotypes. Here we report the 
identification of MMV688533, an acylguanidine discovered using an orthology-based 
screen that displays fast parasite clearance in vitro and is not cross-resistant with known 
antimalarials. In a P. falciparum SCID mouse model, MMV688533 displays a long-lasting 
pharmacokinetic profile and excellent safety. Selection studies revealed a very low 
propensity for resistance, with modest loss of potency mediated via point mutations in 
PfACG1 and PfEHD. These proteins are implicated in intracellular trafficking, lipid utilization 
and endocytosis, suggesting interference with these pathways as a novel mode of action. 
This declared preclinical candidate offers the potential for a single low-dose cure in patients.  
 
5.2. Introduction 
Worldwide, malaria mortality and incidence were estimated to decrease by 60% and 37% 
respectively from 2000 to 2015. This positive trend came to an end in 2016, with cases and 
deaths plateauing and 229 million cases and 409,000 deaths estimated in 2019 2. P. 
falciparum parasite resistance to first-line Artemisinin-based Combination Therapies 
(ACTs) continues to be on the rise in Southeast Asia and now threatens Africa 371-373. 
Despite extensive worldwide efforts, malaria drug discovery and development efforts have 
encountered major obstacles to identifying new agents with novel modes of antiplasmodial 





To address these barriers, we applied a novel drug discovery approach leveraging research 
and development programs on human diseases at Sanofi. While classic approaches rely 
on the identification of compounds that are both potent and specific against Plasmodium 
parasites, our strategy first identified Plasmodium-active compounds from a library of 
chemical matter with known activity against human targets selected from discovery 
programs through to Phase III clinical trials. Compounds active against P. falciparum 
asexual blood-stage parasites were then chemically optimized to increase antiplasmodial 
specificity and reduce host toxicity. Our approach led to the identification of several highly 
potent new chemical series, including the acylguanidines ultimately exemplified by 
MMV688533. This molecule was shown to act via a novel mode of action that only allowed 
P. falciparum parasites to acquire low-grade resistance under drug pressure.  
 
5.3. Results 
5.3.1. Identification of acylguanidines as a potent antiplasmodial chemical series 
with promising physicochemical properties. 
A bioinformatics-mediated analysis of Sanofi drug discovery programs led to the selection 
of 450 compounds active against one of 33 human targets for which putative orthologs were 
found in P. falciparum, Trypanosoma brucei, Trypanosoma cruzi, and/or Leishamania 
donovani. We also included 350 compounds active against any one of 28 Sanofi high-
priority human targets. Screening of these 800 compounds against cultured P. falciparum 
asexual blood stage parasites identified 120 compounds whose half-maximal growth 
inhibition concentration (IC50) was ≤1 mM, corresponding to a 15% hit rate. As a 
comparison, classical random screening approaches have earlier yielded 0.35-0.68% hit 
194 
rates 234-236, highlighting the benefit of our drug discovery strategy. We then applied hit 
selection criteria including suitable physicochemical properties 
(https://www.mmv.org/research-development/information-scientists) and IC50 values <1 
mM against a panel of drug-sensitive or -resistant P. falciparum strains, and screened an 
additional set of 800 analogs of preferred hits to expand Structure-Activity Relationships 
(SAR) 398. This work yielded six chemical scaffolds for medicinal chemistry optimization. 
Here we describe the acylguanidine series, which includes the initial hit MMV668603 that 
was exquisitely potent against P. falciparum NF54 asexual blood stages, with an IC50 of 1.7 
nM. This hit originated from the dimerization of a compound chemically related to 
Cariporide, an inhibitor of human Na+/H+ exchanger isoform 1 (NHE1) that has anticancer 
and cardioprotective properties 399,400. A hit to lead optimization program, including SAR 
studies, led to the intermediate compound MMV669851 and the eventual preclinical 
candidate MMV688533 (Fig. 5.1A). Compared to MMV668603, the candidate MMV688533 
does not contain a diazo moiety, shows improved solubility (from <10 µg/mL to >1,000 
µg/mL at pH 1) and intestinal permeability, and retains potent antiplasmodial activity (Fig. 
5.1A; Tables 5.1, 5.2).  
5.3.2. MMV688533 displayed fast parasite killing rate and high potency against P. 
falciparum and P. vivax strains in vitro and ex vivo. 
MMV688533 was highly potent against multiple P. falciparum strains, with IC50 values in 
the low nanomolar range and no evidence of reduced potency against parasite lines 
resistant to antimalarials currently in the clinic or in development (Table 5.3). These data 




MMV688533 also showed excellent ex vivo activity against asexual blood stage parasites 
from fresh P. falciparum isolates from Ugandan patients (median IC50 = 1.3 nM, range 
0.02 – 6.3 nM, N=143). In Papua Indonesia, where both P. falciparum and P. vivax are 
endemic, MMV688533 remained potent in ex vivo assays, with similar IC50 values against 
both parasite species (medians of 18.9 and 12.0 nM respectively; Table 5.4). 
MMV688533 was as potent if not more so than either chloroquine or piperaquine against 
P. falciparum and P. vivax clinical field isolates (Table 5.4). 
 
MMV688533 displayed a fast-killing profile in the parasite reduction rate (PRR) assay 332, 
as demonstrated by a log10 PRR of nearly 5, corresponding to a decrease of parasitemia 
by nearly 5 orders of magnitude during a single 48 h intra-erythrocytic developmental cycle 
(Fig. 5.1B). This profile is similar to dihydroartemisinin, the active metabolite of artemisinins 
that constitute the fastest-acting class of antimalarials available to date 182. This compound 
displayed very rapid parasite killing when tested over the range of 1-30× IC50 (Fig. 5.1C), 
as well as very low cytotoxicity (Table 5.5).  
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Fig. 5. 1. | The preclinical antimalarial candidate MMV688533 has a fast rate of 
antiplasmodial activity that offers single-dose cure of P. falciparum infection in a 
humanized mouse model.  
(A) Structural representation showing the optimization of the acylguanidine series from the initial
hit MMV668603 and the lead MMV669851 to the candidate MMV688533. (B) Mean ± SD values
of viable P. falciparum parasites determined daily for 5 days after in vitro with MMV688533 at 10×
the IC50. Dihydroartemisinin, Chloroquine, pyrimethamine and atovaquone were included as
reference antimalarial drugs. (C) Mean ± SD values of P. falciparum viability determined daily for
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(D) Compound efficacy was assessed by measuring the initial clearance and time of
recrudescence of P. falciparum in the peripheral blood of humanized mice administered single
doses of MMV688533 ranging from 0.5 mg/kg to 75 mg/kg (two mice per dose). DHA (50 mg/kg)
and vehicles were included as controls. (E) Concentration of MMV688533 in serial blood samples
obtained after administering different doses to P. falciparum-infected humanized mice assayed in
(D). LOQ: Limit Of Quantification.
5.3.3. MMV688533 displayed fast and potent in vivo efficacy and favorable in vitro 
ADME and in vivo PK properties. 
MMV688533 was highly efficacious in the NOD-SCID IL2Rγnull mouse model of P. 
falciparum asexual blood-stage infection 333, with a single oral dose of 5 mg/kg resulting in 
a rapid reduction in parasitemia to below the limit of detection within 48 h, followed by 
recrudescence to 1% by day 18. By comparison, vehicle-treated mice attained a lethal 
parasitemia of 8-10% by day 5 (Fig. 5.1D). These data predicted an ED90 of 2 mg/kg, 
corresponding to the single dose required to reduce parasitemia by >90% by day 7 
compared to vehicle-treated mice (Table 5.6). Four consecutive daily doses of 0.9 mg/kg 
produced >90% reduction in parasitemia by day 7 (data not shown). Importantly, one dose 
of at least 5 mg/kg MMV688533 cleared parasites as rapidly as 50 mg/kg dihydroartemisinin 
(Fig. 5.1D). Pharmacokinetic-pharmacodynamic (PK/PD) modeling predicted an in vivo 
minimal parasiticidal concentration of 20.3 ng/mL (Table 5.7).  
PK studies indicated a low plasma clearance (CL) in mice, rats and dogs (Table 5.8). When 
tested on purified cytochrome P450 enzymes, MMV688533 did not show high inhibitory 
potency (Table 5.9).  MMV688533 also displayed a moderate to high volume of distribution 




(3.2 h in mice, 50.7 h in dogs) (Table 5.10; Table 5.14). The oral bioavailability of 
MMV688533 was >70% in rodent species (Table 5.10). Human CL and Vss parameters 
calculated from rat and dog allometry were predicted to be inferior to 5% of the hepatic 
blood flow using two methods (see Methods section) and 5.0 L for a 70 kg patient, 
respectively. The predicted half-life of MMV688533 in humans was greater than 100 h 
(Table 5.16).  
 
We then predicted the efficacious single dose in humans based on: (i) the minimal 
parasiticidal concentration derived from PK/PD modeling of the Pf NOD-SCID data (Tables 
5.6; 5.7); (ii) the Kkill derived from in vitro PRR studies (Fig. 5.1B); (iii) the PK in mouse, rat 
and dog used in allometric scaling (Tables 5.10-15); and (iv) a biopharmaceutical model 
(GastroPlus). This latter model predicted that at least 50% of a 500 mg dose was absorbed 
when administered in fed conditions. A 100 mg dose is absorbed up to 70% in fasted 
conditions while at this dose, the food effect is less than 30% (data not shown). Using these 
parameters, a single oral administration of 30 mg MMV688533 in humans was predicted to 
maintain its concentration above the minimal parasiticidal concentration over a period of 96 
h, which covers two P. falciparum erythrocytic replication cycles, and to reduce parasitemia 
by at least 6 logs when a conservative in vitro log PRR value was capped at 3.  Similarly, a 
dose of 24 mg was predicted to reduce parasitemia when the in vitro log PRR value of 5 
was used. A single-dose treatment with 66 mg of MMV688533 was predicted to reduce 




5.3.4. MMV688533 revealed a favorable tolerability profile. 
In silico toxicity predictions did not raise any safety alerts other than a moderate phototoxic 
risk (Table 5.17), which proved minimal when tested in MMV688533-treated BALB/c 3T3 
mouse fibroblasts exposed to UV light. Genotoxicity testing with MMV688533, including 
preliminary Ames and micronucleus assay were negative. Profiled on a receptor/enzyme 
panel, MMV688533 displayed micromolar affinity for calcium and chloride channels as well 
as for benzodiazepine and dopamine receptors (Table 5.18). Considering its similarity with 
cariporide, cardiovascular parameters were assessed in detail. MMV688533 had a modest 
effect on the hERG channel with an IC50 of 30 µM (data not shown) and 4.6 µM when 
measured by automatic and manual Patch-Clamp (Table 5.19), respectively. Inhibition 
studies with Nav1.5 and Cav1.1 ion channels yielded IC50 values of 14 µM and 2.1 µM,
respectively (Table 5.19). When tested in the Pukinje fiber assay, MMV688533 induced 
mild effects that were not suggestive of a torsadogenic profile. However, because of the 
limited solubility of the compound in the conditions of this study, a full cardio-safety in vitro 
evaluation at higher concentrations was not possible. Therefore, in vivo studies were 
conducted to better assess potential cardiovascular safety risks. Continuous intravenous 
administration of MMV688533 (at 10, 20 and 30 mg/kg) to anesthetized guinea pigs did not 
affect blood pressure, heart rate, the ECG RR or QT intervals, or the QRS complex (data 
not shown). In summary, in silico, in vitro and in vivo safety studies with MMV688533 did 
not raise any measurable cardiotoxicity alerts. 
Preliminary safety was assessed in rats and dogs via oral treatment and drug exposure 




Sprague-Dawley rats, no clinically apparent changes were observed at 12.5, 25 and 50 
mg/kg dose levels. 12.5 mg/kg/day exposure was considered the No-Observed Effect Level 
(NOEL) in this study due to an increase of liver biomarkers and microscopic changes (foamy 
macrophages, microscopic changes) at the two highest doses. In a non-GLP 2-week toxicity 
study in beagle dogs, (0.5 and 1 mg/kg/day once daily and 2 mg/kg/day every other day), 
only minimal transient changes of no safety concern were detected. In conclusion, the no-
observed-adverse-effect level (NOAEL) was declared at 1 mg/kg and the corresponding 
cumulated exposure over 14 days was 14-fold higher than that predicted for a 30 mg single 
dose in humans (Table 5.22). Such a predicted safety margin was judged promising enough 
to progress MMV688533 to more detailed regulatory preclinical studies before first-in-
human clinical trials. 
 
5.3.5. MMV688533 is maximally potent against P. falciparum rings and early 
trophozoite stages. 
To assess the timing of MMV688533 action, we employed an in vitro asexual blood stage 
susceptibility assay that measures compound activity against early and late rings, early and 
late trophozoites, and schizonts 189. The assay was validated by the stage-specific 
susceptibility profiles of dihydroartemisinin, chloroquine and the PI4K inhibitor KAI407 61, 
which showed the expected peak activities on early rings, rings and trophozoites, and 
schizonts, respectively 189. MMV688533 and dihydroartemisinin shared a similar activity 
profile, with early rings to early trophozoites being the most susceptible, whereas schizonts 






Fig. 5. 2. | MMV688533 antiplasmodial activity is unrelated to existing antimalarials and 
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(A) In vitro asexual blood stage susceptibility assay showing MMV688533 activity in early and late
rings, early and late trophozoites, and schizonts. IC50 values are shown as means ± SEM (N>3, n
= 2). (B) Mean ± SEM IC50 values of selected (sel.) (533-CL1, 533-CL2 and 533-CL4), edited (ed.)
(PfACG1G98V, PfACG1W286R, PfEHDD218Y) lines and the sel. ed. line 533-CL1EHD-D218Y compared to
the 3D7-A10 parental line. N>6, n = 2; **P <0.01, ***P <0.0005; ns: not significant. (C) Western
blot data showing effective reduction in PfACG1 and PfEHD protein levels upon removal of aTc,
as detected using antibodies specific to the 2×HA tag added to the C-terminus of each protein.
Parasite survival was measured by quantifying expression of the integrated RLuc cassette (Fig.
5.3), in the presence (50 nM) or absence of aTc. Data represent the mean of three biological
replicates and are normalized to a fully inhibitory concentration of chloroquine (200 nM). (D) Dose-
response curves for MMV688533 against PfACG1 and PfEHD conditional knockdown (ckD)
parasites expressing wild-type or substantially reduced levels of each protein upon culturing with
500 nM aTc or no aTc, respectively. (E) G98V and W286R mutations in PfACG1 and a
combination of both G98V in PfACG1 and D218Y in PfEHD in sel. ed. 533-CL1EHD-D218Y did not
confer cross-resistance to a panel of known antimalarial drugs compared to the 3D7-A10 parent.
Mean ± SEM; N>3, n = 2. (F) Fluorescence microscopy images of fixed NF543×HA-EHDattB-ACG1-
eGFP parasites either stained with anti-GFP (green) antibodies or anti-HA (magenta) antibodies.
Nuclei were stained with DAPI (blue). Scale bars: 2 µm. (G) Fluorescence microscopy image of
fixed and doubly stained NF543×HA-EHDattB-ACG1-eGFP parasites using anti-GFP (green) and
anti-HA (magenta) antibodies. Nuclei were stained with DAPI (blue). Scale bars: 2 µm. (H-L)
Fluorescence microscopy images and 3D reconstructions of fixed NF543×HA-EHDattB-ACG1-eGFP
parasites co-stained with antibodies to anti-GFP (green) and (H) anti-PfCRT antibodies, (I)
LipidTOX neutral lipid stain, (J) anti-PDI, (K) anti-ERD2 or (L) anti-Rab5A (red) antibodies. Nuclei
were stained with DAPI (blue). Scale bars: 2 µm. (M-Q) Fluorescence microscopy images and 3D
reconstructions of fixed NF543×HA-EHDattB-ACG1-eGFP parasites co-stained with antibodies to anti-
HA (magenta) and (M) anti-PFCRT antibodies, (N) LipidTOX neutral lipid stain, (O) anti-PDI, (P)





5.3.6. Ramping selections with P. falciparum asexual blood stage parasites yield 
low-grade resistance to MMV688533. 
To identify possible resistance mechanisms to MMV688533, we performed single-step in 
vitro resistance selections by exposing triplicate flasks of 2×109 wild-type Dd2-B2 parasites 
to 3×IC50 of MMV688533. These single-step selections did not yield resistant parasites after 
60 days, suggesting a low propensity for resistance development for this compound. This 
was further confirmed in ramping selections, which entailed gradually increasing the drug 
pressure from 1 to 11× IC50 on triplicate flasks of 2×108 3D7-A10 parasites each over a six-
month period. This selection yielded only very low-grade resistance, with a 2 to 5-fold IC50 
increase in each of the three drug-pressured lines (Fig. 5.2B; Table 5.23). Whole-genome 
sequencing (WGS) of four resistant clones obtained from across the three pressured lines 
identified single nucleotide polymorphisms (SNPs) in five genes: a conserved Plasmodium 
protein of unknown function (PF3D7_0910300); an EH domain-containing protein (EHD; 
PF3D7_0304200); a conserved Plasmodium protein of unknown function 
(PF3D7_0510100); a putative RNA pseudouridylate synthase (PF3D7_0511500); and the 
putative ATP synthase (C/AC39) subunit (PF3D7_1464700) (Table 5.23; 5.24).  
 
Of significance, all four clones (sel. 533-CL1 – CL4, named after the last three digits of the 
selecting compound MMV688533 followed by the clone name), carried G98V (clones sel. 
533-CL1 and sel. 533-CL4), W286R (clone sel. 533-CL2) or T92* stop codon (clone sel. 
533-CL3) mutations in PF3D7_0910300, suggesting a key role for this protein in conferring 
resistance to MMV688533. PF3D7_0910300, which we herein have named Plasmodium 
falciparum acylguanidine 1 (PfACG1) after the chemical series that generated MMV688533, 
204 
is a conserved Plasmodium protein of unknown function. Clone sel. 533-CL4, which also 
has a D218Y mutation in gene PF3D7_0304200 (PfEHD), displayed the highest level of 
resistance to MMV688533 (4.6-fold IC50 shift) (Fig. 5.2B; Table 5.23). This points to an 
additional role for PfEHD in enhancing parasite resistance to the compound. Based on 
these observations, the presence of PfACG1 mutations in all the selected clones and the 
boost in resistance conveyed by an additional PfEHD D218Y mutation in sel. 533-CL4, we 
hypothesized that these two proteins, out of the five proteins identified using WGS, play a 
crucial role in mediating resistance to MMV688533.  
To test this hypothesis, we introduced the G98V and W286R mutations in PfACG1 and the 
D218Y mutation in PfEHD individually into wild-type 3D7-A10 parasites using a 
CRISPR/Cas9 gene-editing strategy. This yielded the edited lines ed. 3D7 ACG1G98V, ed. 
3D7 ACG1W286R and ed. 3D7 EHDD218Y lines respectively. The G98V mutation in the ed. 
3D7 ACG1G98V line conferred comparable levels of resistance to the corresponding selected 
clone sel. 533-CL1, whereas the W286R mutation in ed. 3D7 ACG1W286R line only 
contributed around half of the resistance observed in sel. 533-CL2 (Fig. 5.2B; Table 5.23). 
The D218Y mutation in PfEHD alone was insufficient to confer resistance. To test whether 
SNPs in PfACG1 are needed to obtain higher grade resistance to MMV688533 we 
introduced the D218Y mutation into the background of the clone sel. 533-CL1, using a 
CRISPR/Cas9 strategy. This clone harbors the G98V mutation in PfACG1. The resulting 
sel. ed. 533-CL1EHD-D218Y line showed a 6.2-fold shift in IC50 compared to wild-type 
parasites, comparable to the 4.6-fold shift in clone sel. 533-CL4. These results provide 
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evidence that the D218Y mutation in PfEHD enhances resistance to MMV688533 only 
when the G98V mutation is already present in PfACG1.  
5.3.7. Conditional knockdown of the resistance determinants PfACG1 and PfEHD 
does not affect in vitro parasite growth. 
To further explore the role of PfACG1 and PfEHD, we engineered conditional knockdown 
parasite lines in which we could regulate protein expression levels via the TetR-DOZI 
system 322. Normal protein levels were maintained by culturing parasites in the presence of 
anhydrotetracycline (aTc) (Fig. 5.3). Western blot analysis of these lines, which harbored a 
C-terminal 2×HA epitope tag fused to each gene product, confirmed the expression of
PfACG1 and PfEHD in the presence of aTc (Fig. 5.2C; Fig. 5.3B). aTc withdrawal resulted 
in the loss of protein expression, confirming efficient knockdown of the proteins. Despite 
the significant knockdown observed from the Western blots, assessment of growth over two 
replicative cycles revealed that PfACG1 and PfEHD parasite lines, maintained in the 
absence of aTc, were able to progress through the intra-erythrocytic stage life cycle similar 
to controls, suggesting that loss of function of both proteins does not affect viability under 
normal culture conditions (Fig. 5.2C). To test for ex vivo compound-target interactions, we 
determined the IC50 of MMV688533 against wild-type versus knockdown conditions of 
PfACG1 and PfEHD. Similar to an unrelated control line, knockdown of PfACG1 and PfEHD 
did not result in differential susceptibility to MMV688533 (Fig. 5.2D), pointing to a non-
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Fig. 5. 3. | Conditional knockdown (cKD) strategy for PfACG1 and PfEHD. 
(A) Schematic representation of the generation of PfACG1 and PfEHD cKD lines. (B)
Western blot-based assessment of PfACG1 and PfEHD translational regulation via the
TetR-DOZI-RNA aptamer module. The expected mass of the PfACG1-2×HA and EHD-
2×HA proteins are 55.7 kDa and 66.4 kDa, respectively. Results show maintenance of
protein expression in the presence of aTc, contrasting with undetectable levels of either
protein upon removal of aTc. GAPDH was used as a loading control.
5.3.8. MMV688533-resistant parasites do not show cross resistance to current 
antimalarials. 
To test whether resistance to MMV688533 might impact the efficacy of clinical antimalarials, 
we tested the 3D7 ACG1G98V and 3D7 ACG1W286R edited lines as well as the high-grade 
resistant clone sel. ed. 533-CL1EHD-D218Y for cross-resistance against a diverse panel of 
eleven known antimalarials. This study employed 72 h asexual blood stage parasite 
susceptibility assays across a range of drug concentrations (Fig. 5.2E, 5.4; Table 5.25). 
Neither the individual G98V and W286R mutations in PfACG1 nor the multiple SNPs in sel. 
ed.  533-CL1EHD-D218Y conferred cross-resistance to these drugs, implying that MMV688533 
has a novel mode of action against P. falciparum. 
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5.3.9. PfACG1 and PfEHD localize primarily to distinct intracellular parasite 
vesicles. 
To interrogate the subcellular localization of PfACG1 and PfEHD we performed 
immunofluorescence studies with a variety of cellular co-markers. We generated a doubly 
tagged recombinant NF54attB parasite line expressing a 3×HA tag at the C-terminus of the 
PfEHD endogenous locus as well as a stably-integrated transgenic copy of PfACG1 that 
was C-terminally tagged with eGFP (NF543×HA-EHDattB-ACG1-eGFP) (Fig 5.5).  
PfACG1-eGFP mainly localized to foci around the digestive vacuole (DV) of the parasite 
with residual labeling observed around the parasite nucleus (Fig. 5.2F; Fig. 5.6, 5.7). 
PfEHD likewise appeared in foci that localized mostly to the parasite periphery as well as 
close to the DV; other foci were also other observed, although to a lesser extent, throughout 
the parasite cytoplasm (Fig. 5.2F; Fig. 5.8, 5.9). Co-labeling using anti-HA and anti-GFP 
antibodies to assess co-localization of PfACG1 with PfEHD showed no overlap between 
the two fluorophores (Fig. 5.2G).  
Since most of the eGFP signal for the PfACG1-fusion protein was observed adjacent to the 
DV we performed co-stains using antibodies directed to PfCRT, PfMDR1 or Plasmepsin II, 
which are known to localize to the DV (Fig. 5.2H; Fig. 5.6A-B, 5.7B-C). This confirmed 
proximity to the DV, but only showed infrequent, seemingly random overlap between 
PfACG1 and either of the DV transmembrane proteins PfCRT and PfMDR1. To investigate 
whether PfACG1 could overlap with neutral lipid bodies, which are often localized adjacent 
to the parasite DV 401, we carried out co-stains using LipidTOX and Nile Red (Fig. 5.2I; Fig. 
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5.6C-F, 5.7D-G). Although not all eGFP positive foci exclusively overlapped with these lipid 
bodies we observed very frequent juxtaposition. These observations point to the possibility 
that PfACG1 partially associates with lipid storage bodies localized close to the DV. Despite 
our detection of an eGFP signal close to the nucleus, no overlap was detected when co-
staining for the parasite endoplasmic reticulum (ER) using antibodies specific for PDI 
(protein disulfide isomerase; Fig. 5.2J; Fig. 5.7H-I). Instead, the eGFP signal showed some 
overlap with antibodies to ERD2 and PMT (phosphoethanolamine N-methyltransferase), 
which represent markers for the cis- and trans-Golgi 378,379, respectively (Fig. 5.2K; Fig. 
5.6G-J, 5.7J-K). To test whether PfACG1 localized to Rab-positive vesicles that are known 
mediators of vesicular traffic, we co-stained with Rab5A, 5B and Rab7 antibodies. We only 
observed infrequent overlap, similarly to co-stains performed with antibodies against K13, 
a marker for hemoglobin endocytosis 193,402 (Fig. 5.2L; Fig. 5.6K-N, 5.7L-O). Along these 
lines no colocalization was observed for PfACG1 and coronin, a protein involved in F-actin 
organization that has recently been associated with in vitro resistance of early ring stages 
to artemisinins 403 (Fig. 5.6O).  Lastly, we assessed co-localization to the parasite 
mitochondrion using MitoTracker Deep Red, as well as to the apicoplast as visualized with 
anti-ACP antibodies. No overlap was observed between PfACG1-eGFP and those 
organelles (Fig. 5.6P,Q). 
Similar to our observations with PfACG1, we detected PfEHD-positive foci that were close 
to the DV but did not co-localize with PfCRT (Fig. 5.2M; Fig. 5.9B-C). Co-stains using 
LipidTOX occasionally co-localized some of the HA-labeled PfEHD vesicles with neutral 
lipid bodies (Fig. 5.2N; Fig. 5.8A-B, 5.9D). To investigate PfEHD association with the 
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parasite ER as well as the Golgi apparatus we used anti-PDI antibodies or anti-ERD2 and 
anti-PMT antibodies respectively. Frequent proximity and partial overlap were observed 
between PfEHD positive foci and the ER-resident markers PDI and BIP, whereas the Golgi 
stains revealed no obvious association between PfEHD and this organelle (Fig. 5.2O-P; 
Fig. 5.8C-F, 5.9E-H). In mammalian cells, EH domain (EHD)-containing proteins, serving 
as protein interaction platforms, are known to primarily function as key regulators in 
endocytosis 404. To explore whether PfEHD could play a similar role in protein and lipid 
trafficking processes in parasites we performed immunofluorescence (IFA) studies using 
antibodies to coronin and Rab proteins. We found that PfEHD vesicles that localized close 
to the parasite membrane frequently overlapped with coronin, hinting at a possible 
interaction between the two proteins (Fig. 5.2Q; Fig. 5.8G-J, 5.9I-J). Immunofluorescence 
assays carried out with the panel of Rab antibodies (anti-Rab5A, 5B, 5C, Rab7 and 
Rab11A) as well as antibodies to K13 revealed some juxtaposition of Rab-positive vesicles 
and K13-positive foci with PfEHD (Fig. 5.8K-P, 5.9K). In contrast, when assessing potential 
PfEHD association with the apicoplast using anti-ACP antibodies, we did not observe 





Fig. 5. 5. | Genetic manipulation strategies for PfACG1 and PfEHD.  
(A) CRISPR/Cas9 strategy to edit SNPs into the endogenous pfacg1 locus. Cas9 was 
derived from Streptococcus pyogenes and codon optimized for P. falciparum; transcription 
was regulated from a P. falciparum calmodulin promoter. The plasmid also contains a 
hDHFR selectable marker under the PcDT promoter and a sequence encoding the guide 
RNA (gRNA) under a U6 promoter. The pfacg1 donor has >300bp of homology flanking the 
mutation of interest (G96V or W286R). (B) attB´attP based strategy to integrate pfacg1-
eGFP as a transgene into the cg6 locus of NF54attB parasites. pfacg1-eGFP and the BSD 
selectable marker are transcribed from a calmodulin and a PcDT promoter, respectively. (C) 
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CRISPR/Cas9 strategy to introduce a 3×HA into the 3’ end of the endogenous pfehd locus 
in NF54attB parasites expressing the pfacg1-eGFP transgene. The plasmid also contains a 
hDHFR selectable marker and a sequence encoding the guide RNA (gRNA), under a PcDT 
and a U6 promoter, respectively. The donor fragment has two regions of pfehd homology 
flanking the 3×HA tag. attL: attB left junction segment; attR: attB right junction segment. 
BSD: Blasticidin-S deaminase; CAM: Calmodulin; eGFP: enhanced Green Fluorescent 
Protein; gRNA: guide RNA. hDHFR: human dihydrofolate reductase; Hrp2: histidine-rich 
protein 2; Int: Mycobacteriophage Bxb1 serine integrase; Neo: Neomycin; pBS: BlueScript 
plasmid; Hsp86: Heat shock protein 86; PcDT: Plasmodium chabaudi dihydrofolate 
reductase-thymidylate synthase; pfacg1: Plasmodium falciparum acylguanidine 1 gene; 
pfehd: Plasmodium falciparum Eps15 homology domain containing gene; SpCoCas9: 
Streptococcus pyogenes-Plasmodium falciparum codon-optimized Cas9; UTR: 
Untranslated region. 
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Fig. 5. 6. | Fluorescence microscopy images of fixed and labeled NF543×HA-EHDattB-ACG1-
eGFP parasites.  
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PfACG1 was detected using antibodies specific to eGFP. Costaining used (A) anti-PfMDR1 
antibodies that label the digestive vacuole membrane 405,406; (B) anti-plasmepsin II 
antibodies that label the digestive vacuole lumen 407; (C, D) LipidTOX neutral lipid stain that 
stains lipid bodies 408; (E, F) Nile Red that also stains lipid bodies 409; (G, H) anti-ERD2 
antibodies that label the cis-golgi 379; (I, J) anti-PMT that labels phosphoethanolamine N-
methyltransferase present in trans-Golgi structures 378; (K-M) anti-Rab5A, anti-Rab5B and 
anti-Rab7 that labels vesicles 193; (N) anti-K13 that labels the ER, vesicles and cytostomes 
193; (O) anti-coronin antibodies that stain compartments with F-actin 410; (P) MitoTracker Red 
that labels mitochondria; or (Q) anti-ACP antibodies that label the acyl carrier protein present 
in the  apicoplast 411. Nuclei were stained with DAPI (blue). Scale bars: 2 µm. 
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Fig. 5. 7. | Fluorescence microscopy images of fixed and labeled NF54pCRISPRTetR-DOZI-
ACG1-2×HA parasites.  
PfACG1 was detected using antibodies specific to HA (green). Costaining used (A) anti-HA 
stain; (B-C) anti-PfCRT antibodies that label the digestive vacuole membrane 377; (D-G) 
LipidTOX neutral lipid stain; (H-I) anti-PDI; (J-K) anti-ERD2; (L-0) anti-Rab5B. Nuclei were 

































Fig. 5. 8. | Fluorescence microscopy images of fixed and labeled NF543×HA-EHDattB-ACG1-
eGFP parasites.  
PfEHD was detected using antibodies specific to HA (magenta). Costaining used (A, B) 
LipidTOX neutral lipid stain; (C, D) anti-PDI that labels the plasmodial protein disulfide 
isomerase that is localized in the ER 412; (E) anti-ERD2; (F) anti-PMT; (G-J) anti-coronin; 
(K-0) anti-Rab5A, anti-Rab5B, anti-Rab5C, anti-Rab7 and anti-Rab11A that label vesicles 
involved in trafficking 413,414; (P) anti-K13; or (Q) anti-ACP antibodies (cyan). Nuclei were 
stained with DAPI (blue). Scale bars: 2 µm. 
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Fig. 5. 9. | Fluorescence microscopy images of fixed and labeled NF54pCRISPRTetR-DOZI-
EHD-2×HA parasites.  
PfEHD was detected using antibodies specific to HA (magenta). Costaining used (A) anti-
HA stain; (B-C) anti-PfCRT; (D) LipidTOX neutral lipid stain; (E-G) anti-PDI; (H) Bip 
antibodies that stain the ER 415; (I-J) anti-coronin; (K) anti-Rab5B. Nuclei were stained with 



























Here, we report an exquisitely potent antimalarial, MMV688533, discovered among Sanofi 
compounds active on defined human targets and that were assayed for potency against P. 
falciparum asexual blood stage parasites. Our screen of 800 compounds yielded a high hit 
rate, with 120 showing submicromolar antiplasmodial activity. Physicochemical analysis 
identified acylguanidines as the most promising series, with subsequent structure analysis 
relationship (SAR)-based lead optimization yielding MMV688533. Parasite reduction ratio 
assays revealed exceptionally fast killing, with MMV688533 reducing the parasite load by 
>3 log within 24 h after drug addition, similar to dihydroartemisinin and considerably faster
than the comparator first-line drugs chloroquine and pyrimethamine. MMV688533 also 
displayed minimal toxicity against mammalian cells, slow clearance, and a long half-life 
predicted at 100 h in humans.  Single-dose efficacy in the P. falciparum-infected SCID 
mouse model was excellent, with parasite clearance and delayed recrudescence observed 
at doses as low as 5 mg/kg. These data highlight the therapeutic potential of this novel class 
of antimalarials.  
Whole-cell screens for antimalarials have in recent years yielded multiple potent 
antimalarials that despite their promise have encountered parasite resistance at 
frequencies and levels that pose an important concern for their further development as 
curative drugs 41. For example, inhibitors of the drug targets PfATP4 or PfeEF2 can select 
for resistance from as a few as 106-107 parasites, with SNPs causing IC50 increases of up 
to several hundred-fold 251,264,416; unpublished results). In contrast, using these same 
selection procedures 417, MMV688533 yielded no resistance when used to pressure even 
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large parasite inocula (6×109). Low-grade resistance could only be achieved using a 
ramping method of gradually increasing drug concentrations over a 6-month period. 
Parasite clones from these selections showed 2- to 5-fold higher IC50 values against 
MMV688533. Whole-genome sequencing identified two distinct point mutations or a stop 
codon in the PfACG1 gene in all clones assayed from three independent selections. Upon 
gene editing, both point mutations afforded only a 2-fold IC50 increase. One clone also 
harbored a point mutation in PfEHD, which upon editing into a PfACG1 mutant line resulted 
in a 6-fold higher IC50 relative to the drug-sensitive 3D7 line. Other editing results showed 
that this PfEHD mutation on its own was insufficient to mediate parasite resistance. We 
note that three other genes were observed to each harbor a single non-synonymous 
mutation. These mutations occurred separately in only one of the three flasks and may be 
attributable to stochastic events that arise naturally at low frequency during extended in 
vitro culture 418,419. 
PfACG1 and PfEHD are both considered to be dispensable for P. falciparum asexual blood 
stage in vitro growth 395, consistent with our cKD data in which no significant growth 
inhibition occurred despite virtually complete protein knockdown (Fig. 5.2C). PfACG1, 
previously annotated as conserved protein of unknown function, is only conserved among 
Apicomplexan parasites of the genus Plasmodium, with minimal (~ 20%) amino acid identity 
to Cryptotosporidium andersoni and C. muris. Protein sequence analysis shows a signal 
peptide at the N-terminus and a single transmembrane domain at the C-terminal end. Little 
else is known about this protein. PfEHD contains a highly-conserved Eps15 homology 
domain (EHD) involved in protein-protein interactions and found in proteins that play a key 
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role in endocytosis 404. PfEHD has previously been linked to vesicular trafficking in P. 
falciparum parasites 420.  
PfACG1 and PfEHD did not co-localize in our immunofluorescence assays. Nonetheless, 
PfACG1 co-localized with the neutral lipid markers LipidTOX and Nile Red, as well as the 
Golgi markers ERD2 that mediates protein retention in the ER and PMT that plays a critical 
role in phosphatidylcholine synthesis, suggesting its role in vesicular trafficking or storage 
of lipids. In contrast, PfEHD showed some co-localization with the ER markers ERD2 and 
PDI as well as the actin-binding protein coronin. PfEHD has previously been shown to be 
an interacting partner of AP-2µ, an adapter protein that is essential for endocytosis and 
intracellular trafficking 421. Taken together, these data suggest that PfACG1 and PfEHD 
might be involved in related intracellular trafficking pathway(s) acted upon by MMV688533, 
which would be consistent with our observation that mutations in both proteins contributed 
to higher-grade resistance to this compound. These results, along with lack of chemical-
genetic interaction observed using the cKD lines (Fig. 5.2C), suggest that neither of these 
two proteins is the actual target of MMV688533 and function instead as resistance 
mediators. Finally, these data suggest that the MMV688533 mode of action involves 
inhibition of vesicular trafficking and/or lipid storage pathways.  
In conclusion, we report the novel acylguanidine MMV688533 with favorable fast-acting and 
long-lasting pharmacokinetic/pharmacodynamic properties. Drug selection studies showed 
that parasites could only acquire low-grade resistance with large inocula, and no cross-




These data suggest a novel mode of action for MMV688533, which appears to involve lipid-
associated intracellular trafficking of essential components. The promising preclinical 
therapeutic margin and very low single doses predicted to be efficacious in humans should 
significantly improve compliance and enable a low cost of goods. Further safety and 
pharmacological preclinical evaluations are currently ongoing to support the initiation of 
human clinical trials.  
22
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Table 5. 1. | MMV688533 chemical formula and calculated /experimental properties of malonate salt. 
* Technical limit of the Syrius T3 apparatus. tPSA: Topological polar surface area (the sum of the surface of all polar
atoms, primarily oxygen and nitrogen including hydrogen atoms). Compounds with tPSA >140 Å suffer from poor cell
permeability. pKa: Dissociation constant. LogP: Partition coefficient. LogD: Distribution coefficient. LogP is expressed as
a log10 of the concentration ratio between non-aqueous organic (n-octanol) and aqueous (pH-buffered water). Ideally,
compounds should possess a LogP value not greater than 5 (otherwise too lipophilic, thereby creating solubility issues).


















C27 H19 F6 N5 O6 (free base: C24 H15 F6 N5 O2)
623.47 g/mol (free base: 519.41 g/mol)
2.4 (base) /5.8 (base)
0
195.03 (free base: 120.43)
7
180°C
All batches synthetized so far are under the same crystalline form 
(anhydrous form)
3.79
3.93 / No value (> 3)*
22
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Table 5. 2. | MMV688533 (malonate salt) solubilization profile against time. 
The equilibrium solubility of MMV688533 malonate salt in buffered solutions (room temperature) and physiological relevant 
aqueous buffers (37°C) is pH dependent. Good solubility was observed in acidic conditions and poor solubility under more 
neutral conditions. Because the solubility of malonate salt is difficult to assess in some media due to its conversion into the 
free base form 2 (hydrated form of free base), we determined the concentration of solubilized compound as a function of 
time. LOQ: Limit Of Quantification. Low solubility is < 10 µg/mL; moderate solubility is between 10 µg/mL and 1000 µg/mL; 
high solubility is > 1000 µg/mL. 
 MMV688533
Time (hours) 0.25 0.5 1 2 4 24 Medium
Supernatant 
(24h)
pH 1.0 (0.1N HCl) 1750 2480 2870 2670 3770 4780 1.1 1.1 Malonate form1 ≥ 4.7 mg/ml
pH 3.0  2.8 5.4 6.5 7.6 7.2 14.2 2.8 2.9 Malonate form1 ≥ 14 µg/ml
pH 4.5  1.6 2.1 2.72 3 2.8 0.96 4.3 4.3 Malonate form1 ≤ 3 µg/ml
pH 7.4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 7.4 6.5 Base form 2 ≤ 3 µg/ml
Water 1 2 4.3 7.6 10 14.4 N/A 3.1 Malonate form1




Gastric fed state 11 12 14 15 18 27 3.1 3.1 Malonate form1
∼
 27 µg/ml
Fasted state simulated 
intestinal fluid
107 154 15 11 13 20 6.7 4.7 Base form2 ≥ 150 µg/ml
Fed state simulated 
intestinal fluid
3980 3540 1760 1990 2180 150 5 4.8 Base form2 ≥ 3.9 mg/ml
Predicted solubility 
of malonate saltRoom temperature
37°C
X-Ray diffraction





Table 5. 3. | MMV688533 in vitro IC50 (nM) of culture-adapted lab and field P. falciparum isolates. 
MMV688533 potency on chloroquine-sensitive (NF54, 3D7) and chloroquine-resistant (K1, Dd2) parasites, as determined 
from dose-response assays and IC50 analyses, was below 10 nM. This compound showed no cross-resistance with other 
known antimalarials as determined using a diverse panel of  lab-adapted field isolates: HB3, 7G8, TM90C2B, D6, V1/S, 
FCB and Cam3.1. No cross resistance was observed with Dd2 mutant parasites selected for resistance to DDD107498, 
fosmidomycin, MMV390048, GNF156, DSM265 or ELQ300 and which acquired resistance via amino acid substitutions or 
copy number variation (CNV) in eEF2, PFDXR, PFPI4K, PFACRL, PFDHODH and PFCYTB respectively. HCl: Hydrochloric 
acid; *SYBR Green assay; PFEF2: P. falciparum translation elongation factor 2; PFDXR: P. falciparum 1-deoxy-D-xylulose-
5-phosphate reductoisomerase; PFPI4K: P. falciparum phosphatidylinositol 4-kinase; PFCARL: P. falciparum cyclic amine
resistance locus; PFDHODH: P. falciparum dihydroorotate dehydrogenase; PFCYTB: P. falciparum cytochrome b.
HCl 9.0 8.6 7.3 7.8 2.5 5.5 4.1 4.4 7.1 8.5 - 7.5 8.7 7.2 7.3 - -
Malonate  16 31* - - - - 15 - - - 16 - - 15 - 21 18













Table 5. 4. | MMV688533 activity against Plasmodium parasite lines and field isolates. 
In vitro activity against Plasmodium culture-adapted lines or field isolates was calculated from dose-response curves and is 
shown as median or mean half-maximal growth inhibition concentrations (IC50 values) in nM. For the laboratory lines, 
numbers of independent repeats are shown in brackets. 3D7 and FC27 are chloroquine-sensitive whereas Dd2 and K1 are 
chloroquine-resistant. Potency of the other antimalarials was compared to MMV688533 using a Wilcoxon rank sum test. 






















MMV688533 1.9 (4) 3.0 (4) 9.7 (2) 19 (2) 1.3 (143; 0.02 - 6.3) 18.9 (15; 5.3-39.2) 12.0 (6; 5.4-19.9)
Chloroquine 11 (11) 347 (10) 10.9 (2) 100.3 (2) 17*** (143; 2.1 - 346) 64.8*** (15; 38.3-283) 36.4* (6; 11.6-114)
Piperaquine 4.4 (11) 7.9 (10) 25.8 (2) 111.2 (2) 5.1*** (140; 0.3 - 26) 60.8*** (15; 17.6-130) 46.6* (6; 15.0-135)
Mefloquine 4.8 (11) 6.6 (10) 37.2 (2) 8 (2) 8.3*** (120; 0.5 - 24) 10.0 (15; 4.9-41.9) 11.2 (6; 8.1-20.7)







Table 5. 5. | MMV688533 in vitro cytotoxicity IC50 (µM) on 
human cell lines and rat hepatocytes. 
MMV688533 showed a selectivity of >1,000 against the three 
designated cell lines tested. There was also no swelling or 
depolarization on rat liver-isolated mitochondria at 62.5 µM. 
HCl: Hydrochloric acid; HL60: Human leukemia cell line; 
HepG2: Human liver carcinoma cells; w/o: without; BSA: 
Bovine Serum Albumin. 
Salt HL60 HepG2 Rat hepatocytes 
HCl 13.1 > 15.6 15.0 (18.0 w/o BSA)
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Table 5. 6. | Summary of efficacy parameters from the P. falciparum-infected human 
red blood cell SCID mouse model study performed in recrudescence mode. 
Effective dose 90% (ED90) and area under the curve 90% (AUCED90) are defined 
as the dose in mg/kg and the estimated average daily exposure, respectively, that 
reduce parasitemia by 90%  on day 7 post-infection as compared to vehicle-
treated mice. In this assay, this level of reduction implies no net parasite growth 
in blood. AUCPCC and CmaxPCC is defined as the minimum average daily exposure 
(PCC, parasite clearance concentration) and maximal blood concentration (Cmax) 
necessary to achieve maximum parasite clearance from peripheral blood. 
AUCCURE and CmaxCURE are defined as the minimum drug exposure and Cmax in 
blood associated with cure of P. falciparum-infected SCID mice infused with 
human red blood cells. 
Non-standard 1-day ED90 2.0 1.9 - 2.1 mg/kg
Non-standard 1-day AUCED90 3,097 2,335 - 4,484 ng.h/ml
Non-standard 1-day AUCPCC 8,046 3,802 - 12,511 ng.h/ml
Non-standard 1-day CmaxPCC 382 231 - 576 ng/ml
Non-standard 1-day AUCCURE > 193,123 - ng.h/ml
Non-standard 1-day CmaxCURE > 5,506 - ng/ml
Units95% Interval of confidenceMeanParameterAssay
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Table 5. 7. | Minimal parasiticidal concentration of MMV688533 in the P. falciparum infected 
NSG mouse model. 
The minimal parasiticidal concentration (MPC), was determined from the IC90 value of the 
killing curve plotted as a function of the circulating drug concentration and calculated from 
IC50 and the Hill coefficient. The MPC determined from either the IC50 estimate of the final 
PK/PD run or from the median IC50 of its related bootstrap analysis ranged between 14.7 
and 20.2 ng/ml. a [25,75% quantile] for MPC deduced from [25,75% quantile] for IC50. 
EC50 origin EC50 (ng/mL) MPC (EC90) (ng/mL)
Final run #79865 (population estimate) 1.63 14.7
Bootstrap analysis: median [25,75% 
quantile] from n= 504 successful runs
2.25 [1.59;3.44]  20.3 [14.3;30.9]a
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Table 5. 8. | MMV688533 in vitro metabolic clearances in 
microsomes and hepatocytes from different species. 
In vitro metabolic stability studies were performed using liver 
microsomes and cryopreserved hepatocytes of mouse, rat, dog, 
macaque or human origin. Results indicate low metabolic 
clearances in all species. CLint: in vivo intrinsic clearance. Low liver 
microsome CLint values are < 10 µL/min/mg, moderate values are 
between 10 and 50 µL/min/mg, and high values are > 50 
µL/min/mg. Low hepatocyte CLint values are < 4 mL/h/106 cells; 
moderate values are between 4 and 20 mL/h/106 cells; and high 











Table 5. 9. | MMV688533 inhibition of cytochromes P450 (CYP). 
Data shown above were generated with purified CYP enzymes. When tested in 
vitro with human liver microsomes, MMV688533 did not inhibit CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A at concentrations up to 10 μM (data not shown). 
CYP1A2 Phenacetin no inhibition
CYP2B6 Bupropion 56.4 Mixed 12.6
CYP2C8 Amodiaquine 1.6 Mixed 0.8
CYP2C9 Diclofenac 3.3 Mixed 2.4
CYP2C19 S-Mephenytoin 13.7 Mixed 9.0
CYP2D6 Dextromethorphan 10.6 Competitive 4.0
CYP3A4/5 Midazolam 8.2 Mixed 15.3









Table 5. 10. | MMV688533 pharmacokinetic parameters in male Swiss mice and male Sprague Dawley rats after 
intravenous and oral route administration. 
MMV688533 was administered by oral gavage (po, with compound suspended in methylcellulose/Tween 80 
0.6%/0.5% in water) and by IV route as a solution using PEG200/ solutol/ G5% (20/5/75; w/w/v) to male Swiss 
mice (PKS10191-VA) and male Sprague Dawley rats respectively. Compound concentrations were determined by 
LC-MS/MS, with a Limit of Quantification (LOQ) of 2 ng/mL for plasma and 5 ng/mL for blood. (-) below the LOQ. 
In both species, the clearance (CL) is equivalent to the relatively low value of 0.005 µL/min/mg. In rodents, a T1/2 
value (po) > 8h is considered as a long half-life when translated into humans. F (%), percent bioavailability. B/P, 
blood to plasma ratio. ND, not done. 
Intravenous 3 Plasma 6.14 10.3 0.29 1.36 3.2 - - -
Per os 3 Blood 0.86 11.7 - - 4 8 - -
Per os 10 Plasma 2.24 33 - - - 4 96 -
Per os 10 Blood 2.21 30 - - 16 8 - 1.2
Per os 30 Blood 8.13 152 ND ND 26 4 ND ND
Intravenous 3 Blood 5.65 9.5 0.30 2.09 7.5 - -
Per os 10 Blood 1.14 22.8 - - 9.6 4 71
Male Swiss mice
Male Sprague Dawley rats














Table 5. 11. | MMV688533 pharmacokinetic parameters in male Sprague Dawley rats after oral administration. 
MMV688533 malonate salt was administered at 30 and 300 mg/kg by oral gavage (methylcellulose/Tween 80 
0.6%/0.5% in water) to male Sprague Dawley rats. Concentrations were determined using LC-MS/MS, with a limit of 
quantification of 25 ng/ml for blood and 125 ng/g for tissues. At the 30 mg/kg dose level, the highest concentrations 
were reached at 6 h post-dosing and the exposures increased roughly proportionally with dose between 30 and 300 
mg/kg for AUC exposure while Cmax increased sub-proportionally with dose. The quantitative tissue distribution was 
also evaluated in brain, liver, lung, heart and kidney at the 30 mg/kg dose level after oral administration. Broad 
distribution of MMV688533 was observed with tissue/blood concentration ratios above 1 in all tissues except the brain. 
The Tmax ranged mostly between 4 and 24 hours. The highest levels (tissue/blood concentration ratio = 55) were 
observed in lung > liver > kidney > heart > brain. Penetration into brain was significantly lower compared to penetration 
into other tissues. *Tissue:blood AUC ratio.
Malonate Per os 30 Blood 6.0 6 310 310 16 -
Malonate Per os 300 Blood 30 48 2800 2800 38 9.1
Malonate Per os 30 Brain 3.2 4 140 160 24 0.5*
Malonate Per os 30 Liver 246 6 11000 11000 21 35*
Malonate Per os 30 Heart 81 6 3200 3200 19 10*
Malonate Per os 30 Kidney 182 4 7500 7500 16 24*














Table 5. 12. | MMV688533 blood toxicokinetic parameters in male and female Sprague 
Dawley rats. 
MMV688533 maximal blood concentrations (Cmax) were reached in females at 24 h post-
dosing (last sampling time) and in males at 8 h post-dosing on Day 1 at 100 mg/kg. In 
females, MMV688533 Day 4 dose proportionality (Cmax and AUC0-24) over the 25-50 
mg/kg/day dose range increased slightly supra-proportionally and were similar to the 50-
100 mg/kg/day dose range. A 2-fold increase in dose (50 mg/kg/day vs 25 mg/kg/day) led 
to a 3.1-fold increase in Cmax and a 3.4–fold increase in AUC0-24 and a further 2-fold 
increase in dose (100 mg/kg/day vs 50 mg/kg/day) led to a 1.1-fold increase in Cmax and 
a 1.1–fold increase in AUC0-24. In males, a slightly sub-proportional increase was 
observed. MMV688533 exposures increased in proportion over the 50-100 mg/kg/day 
dose range. A 2-fold increase in dose (50 mg/kg/day vs 25 mg/kg/day) led to a 3.0-fold 
increase in Cmax and a 3.3–fold increase in AUC0-24. A further 2-fold increase in dose (100 
mg/kg/day vs 50 mg/kg/day) yielded a 2.3-fold increase in Cmax and a 2.2–fold increase 
in AUC0-24.  At 100 mg/kg/day, MMV688533 mean accumulation ratios (D4/D1) in blood 
were 1.8 for both AUC0-24 and Cmax in females and 2.5 AUC0-24 and 2.4 Cmax in males. 
Based on MMV688533 Cmax and AUC0-24 in blood, no gender effect was observed on Day 
1. On Day 4, exposure in females was slightly higher with a female to male ratio ranging
from 1.7 to 1.8 after dosing with 25 mg/kg/day or 50 mg/kg/day. No gender effect was
observed at 100 mg/kg/day on Day 4, with a female to male ratio of 0.86 to 0.88. -, not
determined. Two rats (one male and one female) were used per dose.
Day 1 Day 4 Day 1 Day 4 Day 1 Day 4
Male 25 Blood - 3.0 - - - 57.6
Male 50 Blood - 8.9 - - - 188
Male 100 Blood 8.6 20.4 8 24 163 413
Female 25 Blood - 5.2 - - - 99.4
Female 50 Blood - 16.0 - - - 335
Female 100 Blood 10.1 17.9 24 24 195 355
Sex




Table 5. 13. | MMV688533 mean biliary and urinary 
excretion parameters in male Sprague Dawley rats. 
Biliary and urinary excretion was evaluated over 24 
h after intravenous administration of 10 mg/kg 
MMV688533 as a solution of 40% Captisol in water 
to dual cannulated (bile duct and duodenum) male 
Sprague Dawley rats. An exploratory LC-MS/MS 
method with a limit of quantification of 1 ng/ml was 
used to quantify urine and bile samples. Data are 
shown as mean ± SD (CV%), from three rats. Low 
biliary and urine excretions were observed with 
around 2% of the administered dose being 
recovered after 24 h. 
Period 
(h) Bile Urine
0-4 1.36 ± 0.28 (12) -
0-8 1.48 ± 0.28 (19) -
0-24 2.05 ± 0.38 (18) 2.22 ± 1.13 (51)
 Excreted drug cumulated over 24 





Table 5. 14. | MMV688533 mean pharmacokinetic parameters in female Beagle dogs after 
intravenous injection. 
MMV688533 was administered to 3 female Beagle dogs via intravenous route as a solution using 
PEG400/Ethanol/Solutol HS15/G5% (20/5/5/75) pH 3.0. Compound concentration was 
determined using LC-MS/MS. The limit of quantification was 5 ng/ml for blood. CL is equivalent 
to 0.011 µL/min/mg and is indicative of low clearance. In humans, compounds with a volume of 
distribution (Vss) < 4 L are expected to be found exclusively in plasma. When Vss is > 40 L, 
compounds are distributed in all tissues of the body and are almost absent in the plasma. 

















Table 5. 15. | Mean blood pharmacokinetic parameters of MMV688533 and its metabolite RA14677213 following a single 
oral administration as capsule or oral solution to pentagastrin-induced male Beagle dogs. 
The pharmacokinetics of MMV688533 and its metabolite RA14677213 were investigated in blood after a single 0.5 
mg/kg dose that was orally administered to male Beagle pentagastrin-induced dogs. The solution formulation was at 
0.25 mg/mL in PEG400/Ethanol/Solutol/G5% (20/5/7.5/67.5). The capsule formulation [MMV688533 /microcrystalline 
cellulose/croscarmellose sodium (5/91.67/3.33)] was followed by 50 ml water. 30 minutes before oral administration, 
the dogs were treated with pentagastrin (intra-muscular injection, 6 μg/kg, 0.25 mL/kg). The gastric pH was measured 
before dosing and was found to be < 3.0. MMV688533 and RA14677213 were quantified using LC-MS/MS with limits 
of quantification of 0.83 ng/ml and 1.0 ng/ml, respectively. Maximal MMV688533 blood concentrations were observed 
between 2-24 h for the capsule and between 2-4 h for the solution. MV688533 exposure observed after oral 
administration as capsule was around 25% lower compared to exposure observed after oral administration as solution. 
For RA14677213, the maximal blood concentrations were observed between 2-4 h for the capsule and between 4-6 
h for the solution. Similar pharmacokinetic profiles were observed between MMV688533 and its metabolite. The 
elimination half-life for both capsule and solution formulations was ~40 h for MMV688533 and ~50 h for its metabolite. 
On average, RA14677213 represented around 22% of parent exposure for both formulations.









(µg.h/mL) Tlast (h) T1/2 (h)
MMV688533 Capsule 89.7 10.7 (2-24) 1.55 4.58 4.85 168 41
MMV688533 Solution 99.6 2.67 (2-4) 1.99 6.09 6.49 168 42.8
RA14677213 Capsule 19.9 3.33 (2-4) 0.36 1.13 1.24 168 51.5
RA14677213 Solution 22 5.33 (4-6) 0.405 1.38 1.54 168 51.6
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Table 5. 16. | MMV688533 predicted 
human parameters. 
Mahmood rules and Fixed exponent 
method of allometric scaling of 
clearance from animal data predicted a 
low to a very low MMV688533 
clearance (3.6 and 1.4 L/h (< 5%) of 
hepatic blood flow) in humans. This 
corresponded to a predicted half-life of 
103 and 277 h respectively. The 
volume of distribution relying on 
allometry method with an exponent of 1 
was predicted to be as high as 5.0L for 
a 70 kg individual. 
Clearance 
(L/h) T1/2 (h) Vdss (L)
Low: 3.6 103 5.0
Very low: 1.4 277 5.0
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Table 5. 17. | MMV688533 in silico prediction of genotoxicity/organ toxicity. 
Knowledge-based approach using the software Derek and QSAR based 
(Leadscope) were used to predict in silico genotoxicity, hepatotoxicity, 
nephrotoxicity, cardiotoxicity and phototoxicity. (* moderate in vitro and low in 
vivo). 
Toxicity Derek Leadscope Internal toxicity results
Mutagenicity No alert No alert No alert
Clastogenicity No alert No alert No alert
Hepatotoxicty No alert Not relevant To be monitored
Nephrotoxicity No alert Not applicable To be monitored
Cardiac toxicity No alert Not applicable To be monitored
Phototoxicity No alert moderate/low risks* No alert
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Table 5. 18. | MMV688533 off-target activities. 
Off target potential pharmacological activities of MMV688533 were assessed in a full 
CEREP profile on 19 enzymes (uptake assays), 88 receptors (binding assays), ion 
channels and amine transporters at 1 µM inhibition activity. The criterion for dose-
response determination was "greater than 60% inhibition of activity or displacement 
of the labeled ligand". MMV688533 was found inactive at 1 µM on a panel of 315 
kinases. Interactions of MMV688533 with receptors – although at very high 
concentrations – carry an alert for central nervous system and cardiovascular effects. 
These alerts have not been confirmed when assessed through in vivo experiments 
and GLP safety pharmacology testing prior to human clinical trials. 
Assay IC50 (µM)
BZD (peripheral) (antagonist radioligand) 0.9
Ca2+ channel (L, dihydropyridine site) (antagonist radioligand) 1.1
Cl- channel (GABA-gated) (antagonist radioligand) 4.3
Dopamine transporter (h) (antagonist radioligand) 9.4
Sigma (non-selective (h) (agonist radioligand) 4.8
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Table 5. 19. | MMV688533 in vitro activity in µM on 
different cardiac ion channels. 
No cardiotoxicity alert was identified with 
MMV688533 from all the evaluated in vitro 
endpoints. 
Channel Conc. (µM)
Potassium channel (hERG) 4.6
Sodium channel (Nav1.5) 14
Calcium channel (Cav1.1) 2.1
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Table 5. 20. | MMV688533 non-compartmental analysis of 
exposure in male Sprague Dawley rats. 
The steady-state AUC0-24h and cumulated AUC in 2-week 
toxicity studies were calculated using a non-compartmental 
analysis. Five animals per dose and sex were used to 
determine the concentration of MMV688533 in whole blood. 
Dose 
(mg/kg)








Table 5. 21. | MMV688533 cumulated exposure over 14 days of treatment in Beagle dogs. 
Cumulated AUC was calculated from 2-week toxicity studies using a population pharmacokinetic model. 






over 15 days 
(mg/kg)
mean mean Male & Female
0.5 once daily 7.5 30,000 27,400 28,700 52,000 32,300 42,200 35,400 (27,400-52,000)
1.0 (QD) 15 76,600 87,700 82,200 67,400 86,000 76,700 79,400 (67,400-87,700)
2.0
once every 2 
days (Q2D) 
14 73,300 76,200 74,800 41,100 69,100 55,100 64,900 (41,100-76,200)
FemaleMale
AUC0-360h individual values from non-parametric 
superposition (ng.h/mL)
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Table 5. 22. | Calculation of MMV688533 safety margin based on cumulative AUC 
over 14 days at the NOAEL dose in rats and dogs. 
For rats the therapeutic index based on the cumulative AUC over 14 days at the 
NOAEL (No Observed Adverse Effect Level) dose of 12.5 mg/kg in rats, as 
compared with the AUC from an estimated single oral dose of 30 mg in humans, 
was estimated to be >20. For dogs the therapeutic index calculated based on the 
cumulative AUC over 14 days at the NOAEL dose of 1 mg/kg in dogs, compared 
with the AUC from an estimated single oral dose of 30 mg in humans, was estimated 
to be 14. Whole blood exposure in humans was predicted based on compound 





Exposure (AUC0-inf, µg.h/mL) 




Rat 12.5 747 5.7 >20
Dog 1.0 79 5.7 13.8
24
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Table 5. 23. | Mutations identified in MMV688533-selected resistant P. falciparum clones and validated using CRISPR/Cas9 
gene editing. 
Four parasite clones (sel. 533-CL1 from flask 1, sel. 533-CL2 and 533-CL3 from flask 2, and sel. 533-CL4 from flask 3) 
were generated from selections (sel.), and named after the last 3 digits of the selecting compound (MMV688533) followed 
by the clone number. These clones were then chosen for whole-genome sequencing. Fold IC50 increases compared to the 
parent 3D7-A10 are indicated below the clone names. P. falciparum ACG1W286R, ACG1G98V and EHDD218Y strains were gene 
edited (ed.) using CRISPR/Cas9 to introduce the designated mutation into 3D7-A10 parasites. The sel. ed. 533-CL1EHD-
D218Y clone was generated by CRISPR/Cas9 editing the EHD D218Y mutation into the selected 533-CL1 clone. wt: wild-
type, *: stop mutation resulting from a deletion-induced frameshift. 
Gene product Gene ID 3.1× IC50 1.7× IC50 2.5× IC50 4.6× IC50 1.8× IC50 1.2× IC50 2.2× IC50 6.2× IC50
Conserved Plasmodium  protein (PfACG1) PF3D7_0910300 W286R W286R T92* G98V G98V wt G98V G98V 
EH domain-containing protein (PfEHD) PF3D7_0304200 wt wt wt D218Y wt D218Y wt D218Y 
Conserved Plasmodium  protein PF3D7_0510100 wt wt wt wt wt wt N1042H N1042H 
RNA pseudouridylate synthase, putative PF3D7_0511500 wt wt K2762E wt wt wt wt wt




















Table 5. 24. | Protein functional pathway relationships.    
GO: Gene Ontology 
Conserved Plasmodium  protein (PfACG1) PF3D7_0910300 Q8I349_PLAF7 - - - -
EH domain-containing protein (PfEHD) PF3D7_0304200 Q9NLB8_PLAF7 vesicle transport heterocyclic compound -
Conserved Plasmodium  protein PF3D7_0510100 Q8I403_PLAF7 - - heterocyclic compound RNA binding
RNA pseudouridylate synthase, putative PF3D7_0511500 Q8I3Z1_PLAF7 - - heterocyclic compound RNA binding
ATP synthase (C/AC39) subunit, putative PF3D7_1464700 Q8IKJ0_PLAF7 - transport heterocyclic compound -
GO_function2Gene product Gene ID Protein ID GO_component GO_process GO_function1
24
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Table 5. 25. | Asexual blood stage IC50 data in nM of MMV688533-resistant parasite lines against common antimalarials. 
SEM: standard error of the mean; N: number of biological repeats (with technical duplicates).  ed., gene edited. sel., 














KAE609 0.7 0.1 3 0.7 0.0 3 0.6 0.02 3 0.7 0.04 3
Dihydroartemisinin 0.8 0.2 3 0.7 0.1 3 0.9 0.1 3 0.7 0.04 3
Lumefantrine 1.5 0.3 3 1.2 0.04 3 1.2 0.02 3 0.9 0.04 3
Chloroquine 5.5 1.0 3 6.2 0.1 3 8.3 1.1 3 9.2 1.5 3
Mefloquine 10.6 0.4 3 9.3 0.1 3 11.0 0.5 3 6.1 0.7 3
Ferroquine 6.5 1.3 3 8.1 0.4 3 11.5 1.9 3 12.1 2.6 3
Piperaquine 14.8 2.6 3 12.6 1.0 3 17.8 1.4 3 15.4 2.1 3
Quinine 24.5 3.7 3 22.2 1.3 3 25.2 2.6 3 15.4 0.8 3
md-amodiaquine 24.1 2.4 3 26.5 1.5 3 30.9 2.2 3 31.2 7.4 3
GNF179 45.7 9.1 3 42.4 7.1 3 55.0 11.2 3 35.1 7.4 3
Fosmidomycin 359 22 3 401 38 3 331 37 3 248 9.7 3
3D7-A10 wild type sel. ed. 533-CL1EHD-D218Yed. 3D7 ACG1W286Red. 3D7 ACG1G98V
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Chapter 6. Concluding Remarks and Future Directions 
6.1. Overview 
The advancement of next generation antimalarials hinges on the identification of new 
Plasmodium drug targets and innovative drug discovery approaches. Presented herein 
are three independent projects that cover both of these areas. The experimental tools 
used in these studies provide a basis for new research avenues into protein-drug 
interactions and compound structure-activity relationships and constitute a foundation on 
which to build on the progress made thus far in the fight against malaria.  
6.2. Chapter 3. Combining stage specificity and metabolomic profiling 
to advance antimalarial drug discovery. 
With the increasing spread of P. falciparum resistance to artemisinins and their partner 
drugs, the development of antimalarials with new mode of actions is more critical than 
ever. High-throughput screens are able to identify potent chemical scaffolds, but not 
knowing their target often hampers their further development. Malaria drug discovery 
pipelines would thus greatly benefit from new assays that interrogate the mode of action 
and activity profile of screening hits. We designed an approach that provides more 
resolution into the different modes of action of clinical and experimental antimalarials by 
identifying the specific moment of asexual blood stage development against which these 
compounds are most active and combining this with a metabolomics assessment of 
pathway perturbations. This identified several stage specificity profiles that correlated well 
with inhibition of particular metabolic pathways. Interestingly, we also identified 
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compounds that act on similar pathways albeit through different targets, based on their 
shared metabolomics profile but differential stage specificity profile. Aside from the insight 
that this approach provided into the tested clinical antimalarials, the results also offered 
a rationale for the prioritization of experimental compounds. As such, we identified several 
hits from the MMV Malaria Box and the Malaria Drug Accelerator consortium with 
promising antimalarial profiles for further development, especially in the context of 
combination therapies. Importantly, this approach can also be adopted for other 
pathogens that undergo multiple differentiation steps within their host.  
As earlier stated, it is important to note that the metabolomics experiments in this study 
were exploratory and involved only one to two biological replicates to screen for known 
and novel candidate mode of actions within a large set of compounds. Further targeted 
and in-depth follow-up experiments should be conducted once compounds are selected 
and prioritized for further discovery or development studies. Moving forward, and given 
the time- and resource-commitment required to generate robust data sets for these 
experiments, compounds should go through additional screenings and only be proposed 
for these assays after meeting set criteria. Benchmarks include but are not limited to 
compound propensity for resistance (minimum inoculum of resistance), speed of kill, 
activity against multiple life cycle stages, and structural and target novelty. These pre-
screenings would inevitably reduce the number of compounds for the asexual blood 
stage-specificity and metabolomics analyses, which would in turn allow for a more robust 
analysis of metabolomic pathways targeted by the said compounds. 
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6.3. Chapter 4. The Plasmodium falciparum ABC transporter ABCI3 
confers parasite strain-dependent pleiotropic antimalarial drug 
resistance.  
The persistent threat of multidrug resistance mediated by P. falciparum transporters 
makes it imperative to identify their interactions with first-line drugs and antiplasmodial 
compounds in the discovery and development pipeline. Here we report on P. falciparum 
ABCI3, an ATP-binding cassette transporter with broad cellular localization that can 
confer antiplasmodial drug resistance through gene amplifications or point mutations. 
Results from in vitro selections, validated through gene editing, conditional knockdown 
and cellular accumulation studies, provide evidence that ABCI3 might be the primary 
target of point mutation-selecting carboxamide-containing compounds 3-5. We also 
observed that the gene amplification-selecting imidazopyridine-containing compound 1 
targets the heme detoxification pathway, supporting the hypothesis that although ABCI3 
is a resistance mediator to both SNP and CNV-generating compounds, the latter have a 
separate mode of action.  
The unusual biphasic dose-response curves observed with compounds 1 and 2 against 
a 3D7-A10-based ABCI3 CNV line and a Dd2-B2 line revealed intriguing insights into 
parasite biology. ABCI3 amplifications in 3D7-A10 resulted in decreased intracellular 
accumulation of compound 1, presumably via drug being effluxed away from its site of 
action. Growth inhibition data for 1 and 2 assayed against isogenic Dd2 Dd2 (CQ-resistant) 
and Dd2 3D7 (CQ-sensitive) lines suggested a different mode of parasite resistance in 
Dd2-B2 parasites with the CQ-resistant Dd2 PfCRT isoform able to confer resistance, 
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also presumably through gain of transport properties resulting from PfCRT mutations. 
Intriguingly, point mutations in ABCI3 neutralized this PfCRT-driven resistance. 
This study highlights unique ways in which P. falciparum is able to evade antiplasmodial 
drug action and underscores the complexity of antimalarial drug discovery efforts. This 
study also identifies ABCI3 as a pleiotropic drug transporter to consider when assessing 
the risk of resistance arising to new antimalarials in the discovery and development 
pipeline.  
Future work on this project should focus on experiments to elucidate the intriguing 
mediation of resistance to compounds 1 and 2 by ABCI3 and PfCRT. An example of one 
such experiment that is already underway involves using recombinant PfCRT (in 
proteoliposomes) to conduct competition transport assays of compounds 1, 4 and 5 and 
known DV-acting 3H-CQ. Based on the Dd2 Dd2 and Dd2 3D7 cross-resistance dataset, we 
hypothesize that mutations in PfCRT confer resistance to compound 1 by effluxing it from 
the DV (proteoliposomes) and that this competes with CQ transport in vitro. It would also 
be interesting to test whether these ABCI3 inhibitors and CQ might show drug-drug 
interactions such as a gain of synergy with certain combinations of these loci.  
A second and equally important set of experiments would be a more detailed co-staining 
of 3’-tagged ABCI3-3×Flag/HA parasite with antibodies against various vesicular makers 
to better establish the membrane structures contributing to the ~50% cytosolic localization 
of ABCI3. Ideally, this set of experiments would also encompass multiple asexual blood 
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stages to show how the location of these vesicles changes throughout this developmental 
cycle. Lastly, solving the structure of ABCI3 using cryo-EM would be an important 
advance in further understanding the structure/function relationship of this protein, which 
would in turn allow for the development of more targeted compounds. Parasites with the 
relevant ABCI3 tags for protein extraction from cultures have already been generated and 
validated.  
6.4. Chapter 5. The antimalarial MMV688533 provides single-dose cures 
with a high barrier to Plasmodium falciparum parasite resistance 
The rise and spread of artemisinin resistance in Southeast Asia has compromised the use 
of some of the first-line ACT therapies, including AS-MQ and more recently DHA-PPQ. The 
threat posed by the spread of this multidrug resistance to Africa has been exacerbated by 
the identification of mutant K13 strains in Rwanda. This necessitates the discovery of novel 
antiplasmodial compounds that may one day replace the artemisinins. Here we present on 
acylguanidines, a novel class of compounds that was discovered using an innovative 
phenotypic screening of the Sanofi chemical library of compounds with known activity on 
human targets. The candidate compound MMV688533 is a potent antimalarial with fast 
antiplasmodial killing kinetics, excellent in vivo activity, and safety and 
pharmacokinetic/ADME standards that allow for advancement to preclinical development. 
In addition, in vitro evolution assays with large parasite inocula using this compound only 
yielded low-grade resistance, and no cross-resistance was observed with established 
antimalarials or advanced preclinical candidates. These findings suggest a novel mode of 
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compound antiplasmodial action involving vesicular trafficking and neutral lipid storage 
pathways.  
Future work on this project should focus on the identification of the actual compound target. 
While PF3D7_0910300, PF3D7_0304200, PF3D7_0510100, PF3D7_0511500 and 
PF3D7_1464700 gene products were implicated as targets from the in vitro evolution 
assays, their polymorphisms only conferred marginal resistance compared to the parental 
line. In addition, cKDs of the putative resistance mediators PF3D7_0910300 and 
PF3D7_0304200 revealed these to be non-essential for parasite in vitro survival. These 
findings imply that the aforementioned gene products are merely resistance mediators and 
not the actual targets of MMV688533. This conclusion has recently been reinforced by 
unpublished data from cellular thermal shift assays (CETSA) performed by our 
collaborators at the University of Dundee, Scotland.   
CETSA is an innovative target identification assay that can be used to assess whether a 
protein binds a drug in in vitro or in vivo experiments by measuring its melting point changes 
in the presence of drug compared to an untreated control 422-424. Protein(s) complexed to a 
ligand (compound) tends to become more resistant against heat-induced unfolding and this 
has been used successfully to screen recombinant proteins against potential inhibitors in a 
thermal shift assays in the past 425. Compounds that alter the melting point of a protein are 
considered binders of the protein under investigation. 
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CETSA experiments using MMV688533 on P. falciparum cell lysate identified several 
putative targets: a hydroxyethylthiazole kinase (PF3D7_1239600); a Plasmodium protein 
of unknown function (PF3D7_0707200); the U6 snRNA-associated Sm-like protein LSm5 
(PF3D7_1443300); the photo-sensitized INA-labelled protein PHIL1 (PF3D7_0109000); the 
40S ribosomal protein S21 (PF3D7_1144000); and an AP2 domain transcription factor 
(AP2-EXP; PF3D7_1466400). Of these, only PF3D7_0707200, PF3D7_1443300 and 
PF3D7_0109000 gene products are essential for parasite survival 395. Of those three, only 
PF3D7_0707200 gene product had a positive melting temperature in the presence of 
MMV688533, making it the most likely target. In addition, the PF3D7_0707200 gene 
product is expressed at the ring stage of parasite development when MMV688533 is most 
active as determined by the stage-specificity assays presented herein 73,393. All these 
positive factors notwithstanding, it is worth noting that the parasite lysates for these CETSA 
experiments were prepared from synchronized late trophozoites and schizonts. As a result, 
more repeats, ideally using lysate from rings, will need to be conducted before any definitive 
conclusions can be made. Conditional knockdown experiments are also scheduled and the 
results from these two datasets will be key to test whether the PF3D7_0707200 gene 
product could be the primary target of MMV688533. 
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